Genetic determinants of ATR inhibitor sensitivity and resistance in Gastric Cancer by Llorca Cardeñosa, Marta Jessica
	
Ph.D. in Medicine 
 
 
Genetic determinants of ATR 
inhibitor sensitivity and 
resistance in Gastric Cancer 
 





















Supervisors:   Prof. Andrés M. Cervantes Ruipérez 
    Dra. Gloria Ribas Despuig 


















The co-Supervisors of the present doctoral Thesis, Dr. Andrés M. Cervantes Ruipérez, 
full professor of Medicine at the Faculty of Medicine of the University of Valencia and 
Dra. Gloria Ribas Despuig, Senior Associate Researcher of the Cancer Functional 
Genomics Group within the Department of Medical Oncology at the Biomedical 
Research Institute-INCLIVA certify that, 
 
 
Marta Jessica Llorca Cardeñosa, graduated in Biology at The University of Valencia, 
Masters in “Molecular Approaches in Biomedical Sciences” at The University of 
Valencia and, funded by the Instituto de Salud Carlos III (Ministerio de Economía y 
Competitividad, FI16/00246), has carried out the present Doctoral Thesis “Genetic 
determinants of ATR inhibitor sensitivity and resistance in Gastric Cancer” and 
that, to their judgement, meets all the necessary requirements in order to qualify for 
the PhD in Medicine for which purpose it will be presented at the University of 
Valencia. The work has been done under their supervision, authorising its presentation 



















Prof. Andrés M. Cervantes Ruipérez  Dra. Gloria Ribas Despuig 
Faculty of Medicine,     Cancer Functional Genomics group 
University of Valencia Biomedical Research Institute 


































“I have not Failed. I have found a thousand ways that won’t work” 







To my supervisors Gloria Ribas and Andres Cervantes for giving me the opportunity 
to join their group when I first started, and supporting me all this time; 
 
 
to my Labo 3 colleagues Maider I., Maria P., Sara O., Maite M. and Pepa C., for all 
the good times we spent together, and for always supporting me and helping me in 
everything I needed; 
 
 
to Irene Chong, for your generosity, positivity, support, and for believing in me when I 
needed it the most; 
 
 
to Chris Lord, for sharing your always bright scientific vision, and for helping me to 
become more resilient and learn how to “roll with the punches”; 
 
 
to my Gene Function colleagues and ICR friends for making special the time I’ve spent 
there, and helping me in the development of this thesis; Specially to Lauren A., Drago 




to María M., Elen B., Katya K., Marta H., Gema P., Barbara G., Elena y David, for 
being my family in London; 
 
 
to my friends Sonia P., and Silvia B. for always being there; 
 
 
to my family, for giving me everything that I have, always supporting me in all ways, 
showing me how to love, and how to live, and for forgiving all my defects; 
 
 
to God, for giving me life every day, and a purpose to live it; 
 
 
















List of abbreviations………………………………………………………………….…5-7 
 
List of tables………………………………………………………………………………...9 
 
List of figures………………………………………………………………………….11-12 
 





 Gastric cancer incidence and mortality………………………………………….19 
 Gastric cancer subtypes (clinical and molecular characterisation)……….19-21 
 Current treatment of gastric cancer…………………………………...……..21-24 
SWI/SNF complex and cancer………………………………………………..24-26 
ARID1A and its significance in gastric cancer………………………………26-28 
DNA damage repair processes in cancer……………………………………28-30 
Double Strand Break repair……………………………………………..…….30-31 
ATR structure…………………………………………………………………...31-34 
Synthetic lethality………………………………………………………………34-35 
ARID1A and DNA damage repair inhibitors…………………………………35-37 
Current clinical use of ATR inhibitors……………………………………...…37-38 
High-Throughput CRISPR/Cas9-based genetic screens to detect mechanisms 
of synthetic lethality …..……………………………………………………….38-39 
Aims and approaches…………………………………………………………..…40 
 
Materials and Methods………………………………………………………….…...41-56 
 Cell lines…………………………………………………………………………….41 
 Microsatellite instability determination…………………………………….....41-42 
 Genomic DNA extraction from cell lines…………………………………………42 
 Polymerase Chain Reaction and gel electroforesis…………………………….42 
 TOPO cloning and sanger sequencing………………………………………42-43 
 Chemicals……………………………………………………………………….43-44 
 Western blotting and antibodies………………………………………………….44 
 Cellular viability assays……………………………………………………………45 
 Cell proliferation experiment………………………………………………………45 
 RNA extraction and Real time-PCR (RT-PCR)……………………………..45-46 
Reverse siRNA transfection Knockdown experiments…………………………46 
In vivo assessment of ATR inhibitor efficacy in gastric cancer Patient-Derived 
Xenografts (PDXs)……………………………………………………………..47-48 
YCC6 VX970 resistant cell lines………………………………………………….48 
Proteomic analysis by mass spectrometry in ATRi...resistant clones……48-49 
Next generation sequencing……………………………………………………...49 
Analysis of cell cycle distribution by FACS………………………………….49-50 
ARID1A CRISPR/Cas9 mutagenesis……………………………………………50 
Positive selection genome-wide CRISPR screen…………………………..50-53 
	 2	




 ATR sensitivity in ARID1A deficient gastric cancer models……………....57-80 
Characterisation of ARID1A status and mutational signature in gastric 
tumour cell lines……………...………………………………………...57-64 
 Sensitivity to ATR inhibition in gastric tumour cell lines……………64-66 
 PARP inhibitor sensitivity in gastric tumour cell lines………………67-68 
Small molecule inhibition to PI3K, HDAC6 and EZH2 in gastric cancer 
tumour cell lines...……………………………………………………...67-71 
ATR and PARP inhibitors combination screens…………………….72-74 
ATR and PI3K inhibitors combination screens……………………...72-76 
Creation of ARID1A isogenic models to assess ARID1A-driven ATR 
inhibition sensitivity…………………………………………………….72-80 
 
In vivo assessment of ATRi efficacy in gastric cancer Patient-Derived 
Xenografts…………………………………………………………………..…..81-91 
 
VX970 positive selection genome-wide CRISPR/Cas9 mutagenesis  
Screen…………………………………………………………………..……..93-107 
 
Creation and characterisation of YCC6 ATR inhibitor resistant clones.109-119 
 
Dense Tiling ATR CRISPRx screen………………………………………121-127 
 
Discussion…………………………………………………………………………..129-148 
 Rationale of this thesis…………………………………………………...………129 
 
Summary of the work presented in this thesis………………………...…129-147 
 ARID1A and ATR are synthetically lethal in vitro and in vivo…..129-132 
In vivo assessment of ATR inhibitors efficacy in gastric cancer 
PDXs………………………………………………………………….133-134 
 ATRi resistance mechanisms in gastric cancer…………….……134-135 
Positive selection genome-wide CRISPR/Cas9  
mutagenesis screen reveals ATR inhibitor resistance-mediating  
genes…………………………………………………………135-143 
ATR inhibitor resistant isogenic cells……………..……….143-145 
Dense tiling ATR CRISPRx screen…………………….….145-147 
  






Appendix (supplementary information)..……………………………………...171-184 
 
Resumen en castellano…………………………………………………………..185-196 
	 3	
List of Abbreviations 
 
5-FU  5-Fluoracil 
ACRG  Asian Cancer Research Group 
ANOVA Analysis Of Variance 
ATCC  American Type Culture Collection 
AUC  Area Under the Curve 
BER  Base Excision Repair 
BID  Twice a day 
C  Celsius 
CAT  Catalytic  
cDNA  Complementary cDNA 
CGC  Cancer Gene Census 
CIN  Chromosomally Instable 
crDNA CRISPR RNA 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 
Ct  Cycle threshold 
CTG  CellTitre Glo 
DE  Drug Effect 
DDR  DNA Damage Response 
DMSO Dymethyl Sulphoxide 
DNA  Deoxyribonucleic Acid 
DSB  Double Strand Break 
dsDNA Double-Stranded DNA 
EBV  Epstein-Barr Virus 
ECF  Epirubicin, Cisplatin, and 5-FU 
EdU  5-ethynyl-2´-deoxyuridine 
EMT  Epithelial-to-Mesenchymal Transition 
FACS  Fluorescence-Activated Cell Sorting   
FDA  Food and Drug Administration 
FFPE  Formalin-Fixed Paraffin Embedded 
FW  Forward  
g  gram 
GC  Gastric Cancer 
gDNA  Genomic DNA 
GEJ  Gastro-Oesophageal Junction 
GERD  Gastroesophageal Reflux Disease 
GFP  Green Fluorescent Protein 
GS  Genomically Stable 
GTP  Guanosine Triphosphate 
gRNA  guide RNA 
HDR  Homology-Directed Repair 
HR  Homologous Recombination 
HPLC  High-Performance Liquid Chromatography 
i  inhibitor(s) 
ICL  Inter-and Intrastrand Crosslink Repair 
ICR  Institute of Cancer Research 
IFN  Interferon 
IHC  Immunohistochemistry 
	 4	
Indel  Short Insertion/Deletion 
IR  Ionizing Radiation  
IRF  Interferon Regulatory Factor 
ISG  Interferon Stimulated Genes 
KCLB  Korean Cell Line Bank 
KDa  Kilo Dalton 
L  Litre 
LOF  Loss of Function 
M  Molar 
m  mili 
MAD  Mean Absolute Deviation 
MAGeCK Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout 
MMR  Missmatch-Repair 
MOI  Multiplicity Of Infection 
MS  Mass Spectrometry 
MSI  Microsatellite Instability 
MSS  Microsatellite Stability 
mRNA messenger RNA 
n  nano 
NER  Nucleotide Excision Repair 
NGS  Next-Generation Sequencing 
NHEJ  Non-Homologous End Joining 
OS  Overall Survival 
PAM  Protospacer Adjacent Motif 
PCR  Polymerase Chain Reaction 
PDX  Patient-Derived Xenograft 
PI  Propidium Iodide 
pptm  parts per ten million 
r2  Spearmans’s rank correlation coefficient 
RFP  Red Fluorescent Protein 
RNA  Ribonucleic Acid 
RNA seq RNA sequencing 
ROS  Reactive Oxygen Species  
RT-PCR Reverse-Transcription Polymerase Chain Reaction 
Rv  Reverse 
sgRNA Single-guide RNA 
SL  Synthetic Lethality 
SF50  Survival Fraction 50% concentration 
siCON Small Interfering ribonucleic acid control (non-targeting0 
SID  Once a day 
siRNA  Short interfering RNA 
SRB  Sulphorhodamine B 
SSB  Single-Strand Breaks 
ssDNA Single-stranded DNA 
T  Time 
TCGA  The Cancer Genome Atlas 
TLS  Trans Lesions Synthesis 
TSG  Tumour Suppressor Gene 
UCSF  University College of San Francisco 
UV  Ultraviolet 
	 5	
v  Version 
VE  Viability Effect 
WHO  World Health Organisation 
WB  Western Blot 
WT  Wyld type 






List of Tables 
 
Table 1. Summary of PCR and Sanger sequencing primers used in this thesis……...43 
 
Table 2. Drugs used in this thesis…………………………………………………….43-44 
 
Table 3. Western blot antibodies used in this thesis……………………………………44 
 
Table 4. Mutation categories identified from Exome sequencing of gastric tumour cell 
lines and HCT 116 ARID1A colorectal isogenic cell line………………………………..59  
 
Table 5. Exome sequencing mutations listed in the Cancer Genome Census found in 
our panel of cell lines……………………………………………………….…………..60-63 
 
Table 6. ARID1A mutations and characteristics identified from exome sequencing of 
gastric tumour cell lines and HCT 116 colorectal ARID1A isogenic pair……………..64 
 
Table 7. Information about the PDX models……………………………………………..82 
 
Table 8. sgRNA detected in the picked resistant colonies from the genome-wide 
CRISPR/Cas9 mutagenesis screen in YCC6 gastric tumour cell line………………..101 
 





List of Figures 
 
Introduction: 
Figure 1. Incidence and mortality of gastric cancer (data extracted from GLOBOCAN 
2018)………………………………………………………………………………………...21 
Figure 2. Molecular classification of gastric cancer…………………………………….22 
Figure 3. SWI/SNF complex………………………………………………………………25 
Figure 4. Frequency of ARID1A mutations amongst cancer types…………………..26 
Figure 5. Mechanisms of DDR……………………………………………………………30 
Figure 6. Mechanisms of DSB Repair……………………………………………………32 
Figure 7. ATR Structure…………………………………………………………………...34 
Figure 8. Synthetic lethality……………………………………………………………….35 
Figure 9. CRISPR/Cas9 mediated gene edition………………………………………..39 
 
Results: 
Figure 1. Characterisation of ARID1A status in GC tumour cell lines…………………65 
Figure 2. Sensitivity to ATR inhibition in ARID1A deficient GC tumour cell lines…….66 
Figure 3. PARP inhibition in GC tumour cell lines……………………………………….68 
Figure 4. PI3K inhibition in GC tumour cell lines………………………………………...70 
Figure 5. HDAC6 and EZH2 inhibition in GC tumour cell lines………………………...71 
Figure 6. ATR and PARP inhibitors combination in GC tumour cell lines………..73-74 
Figure 7. ATR and PI3K inhibitors combination in GC tumour cell lines…………75-76 
Figure 8. Enhanced ATRi sensitivity in SNU 484 ARID1A deficient isogenic GC 
tumour cell lines………………………………………………………………………...78-79 
Figure 9. Sensitivity to ATR inhibition in combination with PARP inhibition in ARID1A 
deficient isogenic GC tumour cell lines…………………………………………………...80 
Figure 10. PDX experimental design…………………………………………………….83 
Figure 11. GC1 ARID1A deficient PDX is highly sensitive to ATR inhibition………..85 
Figure 12. GC2 ARID1A deficient PDX is highly sensitive to ATR inhibition………..86 
Figure 13. GC3 ARID1A deficient PDX is highly sensitive to ATR inhibition………..87 
Figure 14. GC4 ARID1A deficient PDX is highly sensitive to ATR inhibition………..88 
Figure 15. GC5 ARID1A proficient PDX is mildly sensitive to ATR inhibition………..89 
Figure 16. GC6 ARID1A proficient PDX is mildly sensitive to ATR inhibition………..90 
Figure 17. GC7 ARID1A proficient PDX is highly sensitive to ATR inhibition………..91 
Figure 18. Genome-wide SF0 positive selection CRISPR/Cas9 screen workflow...…94 
Figure 19. Preparation of the models, dose optimisation and genome-wide 
CRISPR/Cas9 screen workflow…………………………………………………………..96 
Figure 20. Genome-wide CRISPR/Cas9 screen computational Analysis………….99 
Figure 21. Genome-wide CRISPR/Cas9 YCC6 screen validation pipeline…………100 
Figure 22. Validation CRISPR/Cas9 mini-screen……………………………………..102 
Figure 23. Validation of IRF9 as a candidate for ATRi resistance in IRF1 isogenic  
cells………………………………………………………………………………………...103 
Figure 24. Validation of HUWE1 as a candidate for ATRi resistance in HUWE1 
isogenic cells………………………………………………………………………………105 
Figure 25. Candidate ATRi resistance causing genes identified from GW CRISPR 
screens of 5 cell lines (including data from Wang et al., 2018)………………………..106 
Figure 26. YCC6 ATRi resistant cell experiment design……………………..………110 
Figure 27. Detection of morphological changes in YCC6 ATRi resistant clones…...111 
	 10	
Figure 28. ATRi resistant clones’ data analysis workflow………………...…………..113 
Figure 29. Mass spectrometry transcriptomic data reveals common differentially 
expressed proteins in all YCC6 ATRi resistant clones………………..………………114 
Figure 30. Mass spectrometry transcriptomic data reveals common differentially 
expressed proteins in H1/H2/H3/H4/H6 YCC6 ATRi resistant clones……...………..115 
Figure 31. Mass spectrometry transcriptomic data reveals common differentially 
expressed proteins in H5/M1 YCC6 ATRi resistant clones……………………………118 
Figure 32. Silencing of SMG1 re-sensitises the resistant clones H3 to VX970…….119 
Figure 33. CRISPRx screen workflow………………………………………………….122 
Figure 34. Ion Torrent CRISPRx Sample preparation………………………………..123 
Figure 35. The majority of the ATRi-resistance causing mutations locate in the FAT 




List of appendix tables and figures 
 
Supplementary Table 1. sgRNA and target genes used in the genome-wide screen 
validation experiment……………………………………………………………….171-176 
 
Supplementary Table 2. Table of ATR tiling primers for CRISPRx PCR 1…...174-176 
 
Supplementary Table 3. List of overlapping resistance hits with Z-Score >2 
comparing our YCC6 CRISPR screen results with the TOV21G screen and the 293A, 
HCT 116 and MCF10A cell lines extracted from Wang et al., 2018……………177-181 
 
Supplementary Figure 1. Mass spectrometry transcriptomic data reveals common 
differentially expressed proteins in all YCC6 ATRi resistant clones………….………182 
 
Supplementary Figure 2. Mass spectrometry transcriptomic data reveals common 
differentially expressed proteins in H1/H2/H3/H4/H6 YCC6 ATRi resistant  
Clones……………………………………………………………………………………..183 
 
Supplementary Figure 3. Mass spectrometry transcriptomic data reveals common 











Synthetic lethal approaches in identifying genetic determinants of drug response is a 
powerful method in selecting patents for targeted cancer therapies. Ataxia-
Telangiectasia Mutated (ATM) and Rad3-related protein kinase (ATR) is a valuable 
target to inhibit the DNA damage repair (DDR) pathway, that has been shown to be 
particularly effective in cancer cells harbouring other DDR defects, including truncating 
mutations in ARID1A, found in the 20% of gastric cancer (GC) patients. Although ATR 
inhibitors (ATRi) are emerging as promising cancer therapies, resistance mechanisms 
inevitably arise from these drugs as monotherapy, emphasising the importance of 
identifying genetic determinants of response and resistance to inform drug 
combinations that result in durable clinical responses. 
 
In this thesis, an integrated functional genomics approach was undertaken in order to 
identify genetic determinants to ATRi sensitivity and resistance in GC. First, I show 
that ARID1A defective GCs in vitro and in vivo models exhibit enhanced sensitivity to 
ATRi. Second, I have comprehensively identified and validated genetic determinants 
of ATRi-resistance by undertaking a genome-wide (GW) CRISPR/Cas9 screen and 
created ATRi resistant isogenic models, including CDC25B, HUWE1, CARD10, 
SMG8, SMG9, SMG1, HNRNPF, IRF9, and STAT2. Lastly, I have shown for the first 
time that mutations in the ATR FAT domain cause resistance to ATRi. 
 
These findings inform us about the biological mechanisms of ATRi sensitivity and 
resistance in GC. Furthermore, this data provides the preclinical rationale for 









Gastric cancer (GC) incidence and mortality 
GC is the third leading cause of cancer-related deaths, accountable for over 1,000,000 
new cases in 2018 and an estimated number of 783,000 deaths (1 of every 12 deaths 
worldwide), which makes it the fifth most frequently diagnosed cancer, globally 
(Figure 1). GC is more common in men than in women (1:2) and incidence rates are 
especially high in Eastern Asia (Japan, Korea, Mongolia etc.), South America and 
Eastern Europe. The aetiology of GC is strongly linked to the environment (Kolonel, 
Hankin et al. 1985, Bertuccio, Chatenoud et al. 2009), as Helicobacter pylori (H. pylori) 
infection constitutes the main risk factor for GC (1994, Plummer, Franceschi et al. 
2015). Dietary factors (e.g. high salt content, low fruit intake), Epstein-Barr virus 
infection (EBV), smoking and alcohol consumption are also established risk factors 
(Humans 2012, Cancer Genome Atlas Research 2014, Mayne, Playdon et al. 2016). 
The incidence of GC is related to the location within the stomach; non-cardia GC 
(localised in a more distal region of the stomach) have decreased in prevalence over 
the past years largely due to H. pylori eradication, while GC arising from the cardia 
(gastro-oesophageal junction, GEJ) have increased especially in high-income 
countries. In part, this may be due to its association with obesity, gastroesophageal 
reflux disease (GERD) and a small percentage of Barrett’s oesophageal cases 
(Howson, Hiyama et al. 1986, Ngoan, Mizoue et al. 2002).  
 
Gastric cancer subtypes (clinical and molecular characterisation) 
The vast majority of GC are adenocarcinomas, which have been traditionally classified 
according to histopathological factors, using either Lauren classification, that divides 
GC into diffuse gastric and intestinal subgroups (Lauren 1965), or the world Health 
Organization classification, dividing it in papillary, tubular, mucinous and poorly 
cohesive carcinomas (WHO classification of Tumours of the Digestive System, 2010). 
However, these histological-based classification systems have demonstrated little 
prognostic or clinical utility in terms of treatment stratification (Cervantes, Roda et al. 
2013, Cancer Genome Atlas Research 2014). In contrast, molecular-based 
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classifications aim to identify disease-specific genetic alterations that are potential 




Figure 1. Incidence and mortality of GC (data extracted from GLOBOCAN 2018). The 
incidence of GC (stomach) represents the 5.7% of the incidence of all cancers in the general 
population, being in the 5
th
 position in the ranking with over 1,000,000 new cases reported in 
2018. According to the mortality, GC is the 3
rd
 most common cause of cancer-related deaths, 
responsible of 1 of 12 deaths worldwide. 
 
The implementation of whole genome sequencing and high-throughput techniques in 
cancer research has enabled the development of molecular classifications, including 
the classification published in 2014 by the Cancer Genome Atlas Research Network, 
describing four distinct molecular subgroups (Figure 2). The most frequently occurring 
subgroup, the chromosomally instable GC (CIN, 50%) is characterised by 
chromosomal instability, where gene amplifications are very frequent and involve 
diverse tyrosine kinase receptors or associated pathways (Human Epidermal Growth 
Factor Receptor 2, ERBB2; Epidermal Growth Factor Receptor, EGFR, Epidermal 
Growth Factor Receptor 3, ERBB3; Janus Kinase 2, JAK2; Fibroblast Growth Factor 
Receptor 2, FGFR2; MET Proto-Oncogene, Receptor Tyrosine Kinase, MET; 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit, PIK3C; KRAS 
Proto-Oncogene GTPase, KRAS; and NRAS Proto-Oncogene GTPase, NRAS). The 
microsatellite instability group (MSI, 22% of the cases), is the second most frequent 













































machinery deficiencies, resulting in a very high mutation rate with hotspot mutations 
within genes including ERBB2, EGFR, ERBB3, JAK2, Fibroblast Growth Factor 
Receptor 2 (FGFR), MET, AT-Rich Interactive Domain 1A (ARID1A), 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit  A (PIK3CA) and 
high levels of the Programmed Death-Ligand 1 (PD-L1) expression. Genomically 
stable (GS) GCs, that represent the 20% of the cases are associated with diffuse 
histology according to Lauren’s classification, and show a high frequency of E-
Cadherin (CDH1) mutations (26%) and Ras Homolog Family Member A (RHOA) 
(15%). Finally, the Epstein-Barr virus positive (EBV) related group comprises 9% of 
the cases of GC and these tumours are mainly located in the gastric fundus, showing 
a promoter hypermethylator phenotype and the highest frequency of PIK3CA 
mutations (80%), as well as amplification of JAK2 and PD-L1 genes. A similar 
classification was also determined by the Asian Cancer research group (ACRG), that 
took into account the Tumour Protein P53 (TP53) activity and epithelial-to-
Mesenchymal transition (EMT), thus dividing GC into four groups comprising the 
MSS/EMT, MSI, MSS/TP53WT, MSS/TP53-/- (Cristescu, Lee et al. 2015). These new 
molecular classifications have widened the view of gastric carcinogenesis and have 
focused research in the discovery of genetic actionable targets, that have the potential 
to improve the outcome of patients with GC (Hartgrink, Jansen et al. 2009). 
 
Current treatment of gastric cancer 
Surgical resection of GC is the best curative option, although the risk of relapse 
following resection remains high. For that reason, clinical trials such as MAGIC and 
FLOT4 have reported a benefit from adding perioperative or neoadjuvant 
chemotherapy to patients with operable oesophagogastric cancers, even when 
diagnosed at early stages of the disease (Cunningham, Allum et al. 2006, Al-Batran, 
Hofheinz et al. 2016). More specifically, the MAGIC trial revealed a survival benefit 
from the administration of perioperative epirubicin, cisplatin, and 5-FU (ECF) for 
patients with operable oesophagogastric cancer (Cunningham, Allum et al. 2006). 
Building on this data, the FLOT4 trial showed that the FLOT triplet regimen (oxaliplatin, 
infusional 5-FU, and docetaxel) improves the outcome of patients with localised 
oesophagogastric cancer compared with the ECF triplet (Al-Batran, Hofheinz et al. 





Figure 2. Molecular classification of GC. Comprehensive molecular characterisation of 
gastric adenocarcinoma done by the Cancer Genome Atlas Research in 2014 defined four 
major genomic subtypes of GC: The EBV-infected tumours, tumours presenting microsatellite 
instability (MSI), genomically stable tumours (GS) and chromosomally unstable tumours (CIN) 
(adapted from GC Genome Atlas, 2014).  
 
 
with GC remains poor. Due to the vague presenting symptomatology of GC, the 
majority of the cases are diagnosed at an advanced stage where treatment is mainly 
restricted to platinum based chemotherapy. However, platinum resistance is inevitable 
and new treatment options are required (Cunningham, Oliveira et al. 2008, 
Cunningham, Starling et al. 2008, Okines, Chau et al. 2008, Rao, Starling et al. 2008). 
Many clinical trials using targeted therapies have been undertaken in the last few 
years, but only a modest improvement in OS has been achieved.  Currently, there are 
only three approved targeted treatments in GC. The first targeted therapy in GC that 
was clinically implemented in 2010 was Trastuzumab, a monoclonal antibody targeting 
ERBB2, in ERBB2 amplified cases (HER2-positive). Up to 22 % of gastric 
adenocarcinomas and gastroesophageal tumours show an overexpression in HER2 
(Bang, Van Cutsem et al. 2010, Van Cutsem, Bang et al. 2015). Trastuzumab is given 

























adenocarcinoma in combination with platinum-based chemotherapy. Trastuzumab 
binds to the extracellular domain of the HER2 receptor, inhibiting proliferation of 
tumour cells that overexpress HER2 by preventing the activation cell cycle progression 
pathways and has proved to prolongate survival in HER2-positive patients. However, 
the median OS advantage was observed to be no more than three months, due to the 
development of resistance (ToGA trial) (Bang, Van Cutsem et al. 2010, Croxtall and 
McKeage 2010). The anti-angiogenic, anti-VEGFR2 (Vascular Endotelial Growth 
Factor receptor 2) monoclonal antibody ramucirumab, has also been approved by the 
food and drug administration (FDA) to be used in the second-line setting as 
monotherapy or in combination with paclitaxel, as significant survival benefits in 
patients with advanced GC who had progressed on first-line chemotherapy have been 
observed in the RAINBOW and REGARD trials (Fuchs, Tomasek et al. 2014, Wilke, 
Muro et al. 2014). The last FDA approved targeted therapy in GC consists in the tight-
junction protein Claudin18.2 (CLDN18.2) antibody, IMAB352. Combined with 
chemotherapy, IMAB352 has shown to enhance T-cell infiltration and pro-
inflammatory cytokines (FAST study), increasing OS when used in first-line treatment 
of GC (Lordick, Mariette et al. 2016, Lordick and Terashima 2016).  
 
Additionally, promising phase III trials assessing the effectiveness of immunotherapy 
and immune checkpoint inhibitors in GC are being conducted (Sclafani, Brown et al. 
2016, Kang, Boku et al. 2017, Fuchs, Doi et al. 2018). For example,  pembrolizumab, 
a PD-L1 antibody has been approved by the FDA to be used in third line setting on 
advanced GC and is currently being evaluated in combination with chemotherapy 
(Fuchs, Doi et al. 2018), or nivolumab, a program death 1, PD-1 antibody that has 
been approved for its use in Japan and that is currently being tested in combination 
with an anti-CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) antibody 
(Ipilimumab) in a phase I/II study, showing promising results so far (Kang, Boku et al. 
2017, Janjigian, Bendell et al. 2018).   
 
Despite the extensive efforts and the large number of clinical trials undertaken, 
effective targeted therapies, that can improve the OS in patients with resectable and 
non-resectable GC cancers are still urgently required (reviewed in (Kim, Barzi et al. 
2018). This underlines the importance of; firstly, assessing methods for accurate the 
selection of the candidate population; second, the need of further research into the 
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identification of reliable biomarkers for targeted therapies to be able to predict patients 
who will benefit from treatment, and; lastly exploiting the potential of new treatment 
approaches, such as immunotherapy treatments in monotherapy or combination with 
chemotherapy or other therapies. 
 
SWI/SNF complex and cancer 
The Switch/Sucrose non-fermentable chromatin remodelling complex (SWI/SNF), 
comprises a large protein complex, in charge of the activation of gene expression by 
modulating nucleosomes at gene promoters (Imbalzano, Kwon et al. 1994) (Liu, 
Balliano et al. 2011) and is found widely dysregulated in cancer (Shain and Pollack 
2013). The SWI/SNF complex is capable of unwinding the DNA around histone cores, 
providing access to DNA that regulates transcription, DNA repair and replication, in an 
ATP dependent way (Imbalzano, Kwon et al. 1994, Kwon, Imbalzano et al. 1994). This 
complex has been related to a variety of essential processes in eukaryotic cells, such 
as differentiation, proliferation, DNA repair and tumour suppression (Reisman, Glaros 
et al. 2009). In humans, the SWI/SNF complex can form two different configurations, 
denominated as BAF or polybromo-associated BAF (PBAF). This allows the complex  
to have a broad role of activities, depending on the genetic context (Shain and Pollack 
2013).  
 
SWI/SNF complex includes one of the two mutually exclusive ATPases, SMARCA2 
(BRM) and SMARCA4 (BRG1); and one of the three mutually exclusive functionality-
conferring proteins (i.e. DNA binding, histone binding), ARID1A (BAF250A), ARID1B 
(BAF250B) or PBRM1 (BAF180). Usually, ARID1A and ARID1B are associated with 
BAF complexes, which can work with either BRM, or BRG1 ATPases, while PBRM1, 
together with ARID2 (BAF200) and BRD7 are only found in pBAF complexes, which 
are associated to only BRG1. Additionally, there are some other core and accessory 
subunits that are associated with all versions of the complex (BAF or PBAF), like 
SMARCB1 (BAF47/SNF5), SMARCC1 (BAF155), SMARCC2 (BAF170), SMARCE1 
(BAF57); and SMARCD1 (BAF60A), SMARCD2 (BAF60B), SMARCD3 (BAF60C), 
PHF10 (BAF45A), DPF1 (BAF45B), DPF2 (BAF45D), DPF3 (BAF45C), ACTL6A 
(BAF53A) and ATL6B (BAF53B), respectively (Shain and Pollack 2013) (Figure 3). 
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SWI/SNF mutations are widely spread in several tumour types, occurring, most 
frequently in the subunits with enzymatic activity (SMARCA4 and SMARCA2) or in the 
ones that confer functionality to the complex (ARID1A, ARID1B, ARID1 and PBRM1). 
The fact of SWI/SNF mutations, being described across several units of the complex, 
indicates that the whole functional activity of it might be compromised, even when only 
one of the subunits its mutated, conferring a tumour suppressor role to the complex 
itself (Shain and Pollack 2013). This observation has been described in a 
comprehensive study of protein level variation in colorectal tumour cells, where when 
the downregulation of several proteins, either in the BAF o PBAF configuration of the 
SWI/SNF complex, resulted in the downregulation of other subunits of the complex 
(Roumeliotis, Williams et al. 2017). 
 
From all proteins of the complex, ARID1A (AT-rich interactive domain-containing 1A 
protein), is localised in chromosome 1p36.11, and it constitutes one of the most-
frequently altered proteins across all cancers (Wu, Wang et al. 2014). ARID1A 
encodes for a key DNA binding protein involved in a wide range of cellular processes, 
including gene expression regulation, cell development, differentiation, proliferation, 
apoptosis and DNA repair (Reisman, Glaros et al. 2009, Wu and Roberts 2013, Wu, 
Wang et al. 2014, Wu, Zhang et al. 2016, Sun, Wang et al. 2018).  
 
 
Figure 3. SWI/SNF complex. The SWI/SNF can form two different configurations, 

































ATPases, SMARCA2 (BRM) and SMARCA4 (BRG1); and one of the three mutually exclusive 
functionality-conferring proteins, ARID1A (BAF250A), ARID1B (BAF250B) or PBRM1 
(BAF180). Additionally, the core and accessory subunits are SMARCB1 (BAF47/SNF5), 
SMARCC1 (BAF155), SMARCC2 (BAF170), SMARCE1 (BAF57); and SMARCD1 (BAF60A), 
SMARCD2 (BAF60B), SMARCD3 (BAF60C), PHF10 (BAF45A), DPF1 (BAF45B), DPF2 
(BAF45D), DPF3 (BAF45C), ACTL6A (BAF53A) and ATL6B (BAF53B), respectively.    
 
 
ARID1A and its significance in gastric cancer 
ARID1A is found to be mutated in around the 20% of all cancer cases, being highly 
mutated in ovarian clear cell carcinomas (Jones, Wang et al. 2010) (46-57%), uterine 
endometroid carcinomas (33-49%) (Guan, Mao et al. 2011, Liang, Cheung et al. 2012, 
Cancer Genome Atlas Research, Kandoth et al. 2013), ovarian endometroid 
carcinomas (30%) (Wiegand, Shah et al. 2010), gastric carcinomas (8-27%) (Wang, 
Kan et al. 2011, Jones, Li et al. 2012, Zang, Cutcutache et al. 2012) and oesophageal 
adenocarcinoma (9-19%) (Wang, Nagl et al. 2004, Chong, Cunningham et al. 2013, 
Streppel, Lata et al. 2014), amongst others (Figure 4).  
 
 
Figure 4. Frequency or ARID1A mutations amongst cancer types. ARID1A is one of the 
most frequent altered proteins across all cancers. Figure shows a histogram with the cancer 














































































































ARID1A mutations are mutually exclusive to p53 mutations and are highly prevalent 
in tumours with MSI. This observation has been reported in several histologies, 
including GC (Wang, Kan et al. 2011, Kim, Je et al. 2012, Allo, Bernardini et al. 2014, 
Cancer Genome Atlas Research 2014, Chou, Toon et al. 2014). Furthermore, ARID1A 
has recently been found to physically interact with the mismatch repair (MMR) protein 
MSH2, and it seems that ARID1A is involved in the recruitment of the latter to 
chromatin during replication, contributing to impaired MMR and a mutator phenotype 
in cancer (Shen, Ju et al. 2018). 
 
Additionally, ARID1A loss has been found to frequently coexist with activating 
mutations of PIK3CA (Yamamoto, Tsuda et al. 2012, Zang, Cutcutache et al. 2012, 
Cancer Genome Atlas Research 2014), loss of PTEN expression (Bosse, ter Haar et 
al. 2013), and an increase in the phosphorylation of AKT1 at Ser-473 (Liang, Cheung 
et al. 2012), all events leading to a downstream overactivation of the PI3K/AKT 
pathway. These observations strongly suggest an inter-dependency between ARID1A 
mutations and PI3K/AKT pathway activation, indicating that tumour cells with loss of 
ARID1A expression may be dependent on constitutive activation of the PI3K/AKT-
pathway and therefore may also be synthetically lethal to its inhibition (Samartzis, 
Noske et al. 2013). This could be of considerable clinical relevance since loss of 
ARID1A expression may be predictive for a favourable treatment response to small 
molecule inhibitors of the PI3K/AKT-pathway, which are currently under clinical 
investigation in GC (Samartzis, Gutsche et al. 2014, Zhang, Yan et al. 2016, Lee, Yu 
et al. 2017) 
 
In parallel, studies undertaken in ovarian cancer models have found the ARID1A 
deficiency to be synthetically lethal to the inhibition of the catalytic subunit of polycomb 
repressive complex 2, EZH2 due to its agonistic regulation of PI3K/AKT pathway, 
through the modulation of PIK3IP1 expression (Bitler, Aird et al. 2015). This indicates 
that inhibiting EZH2 methyltransferase activity through the use of EZH2 inhibitors in 
ARID1A-mutated cancers could potentially represent a novel synthetic lethal 
therapeutic strategy (Bitler, Aird et al. 2015). Furthermore, as ARID1A deficiency has 
been linked to an increase in the expression of HDAC6 protein which results on 
apoptotic suppression through the inactivation of p53, HDAC6 has been proposed to 
be an alternative synthetic lethal partner for ARID1A (Bitler, Wu et al. 2017). These 
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affirmations have been extended to the use of pan-HDAC inhibitors, in monotherapy 
or combination with EZH2 inhibitors, following the rationale that ARID1A loss confers 
sensitivity to HDAC inhibitors, due to co-repression of EZH2, supressing the 
expression of EZH2/ARID1A, as well as target tumour suppressor genes such as 
PIK3IP1, thereby inhibiting proliferation and promoting apoptosis in cancer cells 
(Fukumoto, Park et al. 2018). 
 
To the date, other ARID1A described synthetic lethalities resulting from the exposure 
to small molecule inhibitors comprise dasatinib and the ARID1A homolog in the 
SWI/SNF complex, ARID1B. Dasatinib, a multi-target kinase inhibitor was identified in 
a high throughput drug screen performed in 12 Ovarian clear tumour cell lines to 
enhance apoptosis in ARID1A mutant cells in a p21 and RB dependent manner (Miller, 
Brough et al. 2016). In the case of ARID1B, a large cohort of tumour cell lines used to 
discover essential genes, showed a mutually exclusivity of ARID1A and ARID1B, 
where at least one of the copies of ARID1B was necessary for ARID1A deficient cells 
to survive (Cheung, Cowley et al. 2011). This ARID1A-ARID1B synthetic lethality has 
been previously described by other authors, although its clinical utility has not yet been 
exploited (Helming, Wang et al. 2014). 
 
DNA damage repair (DDR) processes in cancer  
Eukaryotic cells have a complex machinery that allows them to maintain the DNA 
integrity through every round of replication. Genomic instability can arise from several 
agents and processes like the ultraviolet radiation, ionizing radiation, reactive oxygen 
species (ROS), environmental agents, and some chemicals and drugs (Lindahl and 
Barnes 2000, Hoeijmakers 2009). The non-efficient repair of these lesions increases 
the risk of mutagenesis in an exponential way, potentially leading to the development 
of tumours (Hoeijmakers 2009). The whole set of pathways involved in the repair of 
DNA lesions is known as the DNA Damage Response (DDR). The DDR machinery 
encompasses a large variety of proteins and pathways, that operate in one way or 
another, depending on the type of damage that needs to be repaired (Lord and 
Ashworth 2012).  
 
The main DDR pathways comprise nucleotide excision repair (NER), the base 
excision repair (BER), the mismatch repair (MMR), the trans lesion synthesis (TLS), 
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the inter-and intrastrand crosslink repair (ICL), DNA single strand break repair and 
DNA double strand break repair (Figure 5). Ultraviolet (UV) light from the sun, reactive 
ROS or numerous chemicals can cause lesions in nucleotides that lead to a distortion 
in the DNA helix. This kind of alterations are repaired by the NER pathway that enables 
unwinding of DNA around the lesion, DNA excision, removal of approximately 30 base 
pairs (bp) around the lesion, reassembling of nucleotides to the gap by the DNA 
polymerase and ligation of DNA strands (Masutani, Sugasawa et al. 1994, Wakasugi, 
Kawashima et al. 2002, Marteijn, Lans et al. 2014). BER enables the correction of 
bases damaged by oxidation, alkylation, deamination and 
depurination/depirimidination. The damaged bases are removed and single 
nucleotides or DNA stretches are cleaved and replaced by a DNA polymerase and a 
DNA ligase (Robertson, Klungland et al. 2009). MMR machinery is responsible for 
correcting the incorporation of inappropriate nucleotides during replication. 
Inactivation of this repair pathway (frequently due to germline mutations or promoter 
hypermethylation of the MLH1, MSH2, MSH6, or PMS2 genes) causes MSI and 
hypermutation in the genome. It has been widely studied and linked to Lynch 
syndrome and colorectal cancer predisposition, although it has also been studied in 
other histologies (Fishel, Lescoe et al. 1993, Leach, Nicolaides et al. 1993, Bak, 
Sakellariou et al. 2014, Cancer Genome Atlas Research 2014). TLS prevents forks 
stalling by bypassing damaged or missing bases, reassuring an efficient completion 
of DNA replication (Chang and Cimprich 2009). To accomplish this, TLS polymerases 
display with a lower fidelity than normal replicative polymerases, increasing the 
mutation frequency, although they only synthetize short stretches of DNA (Sale, 
Lehmann et al. 2012, Sharma, Helchowski et al. 2013). ICL are caused by the 
formation of covalent bonds of proteins or DNA due to the presence of two reactive 
groups in the two adjacent bases on the same strand (intrastrand crosslink) or 
between the two complementary DNA strands (interstrand crosslinks). To remove 
these undesired bonds, proteins involved in the Fanconi Anemia pathways are 
required, as well as homologous repair (HR), NER and TLS pathways (Clauson, 
Scharer et al. 2013). Single strand breaks (SSBs) can arise as a result of ionizing 
radiation or the ROS generation by the cellular metabolism. SSBs are efficiently 
recognized by the poly (ADP) ribose polymerase (PARP). PARP (mainly PARP1) 
binds to the SSB sites and synthetizes PAR-chains that binds to target proteins 
(including itself), activating its catalytic activity and resulting in the initiation of de DNA 
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repair cascade, mainly through the BER pathway. Although PARP1 plays a pivotal 
role in BER, it is also involved in other DDR processes, like the switch from non-
homologous end joining repair to homologous repair at stalled replication forks 
(explained below) (Schultz, Lopez et al. 2003, Hochegger, Dejsuphong et al. 2006, 
Fisher, Hochegger et al. 2007, Bryant, Petermann et al. 2009, Langelier, Planck et al. 
2012). Lastly, double strand break (DSB) repair is essential, as its inefficient reparation 
can lead to mutations and chromosomal rearrangements that can be lethal to cells. 
DSBs can arise as a result of ionizing radiation or from the collapse of replication forks, 
and it can be repaired by several specialised mechanisms. 
 
 
Figure 5. Mechanisms or DDR. Genomic instability can arise from several agents and 
processes like the ultraviolet radiation, ionizing radiation, reactive oxygen species (ROS), 
environmental agents, and some chemicals and drugs. The main DDR pathways include the 
nucleotide excision repair (NER), the base excision repair (BER), the mismatch repair (MMR), 
the trans lesion synthesis (TLS) the inter and intrastrand crosslink repair (ICL), the DNA single 
strand break (SSB) repair and the DNA double strand break (DSB) repair. 
 
 
Double Strand Break repair 
DSBs represent the most lethal type of DNA lesions and it is repaired by two main 
mechanisms; homologue recombination (HR) and non-homologous end joining 
(NHEJ), although alternative-NHEJ and single-strand annealing pathways have also 
been described. HR pathway relies on the intact sister chromatid as a template for 
accurate repair, resulting in faithful replication, and it is relatively error free (Hartlerode 
and Scully 2009, Brandsma and Gent 2012). Briefly, HR is triggered by Mre11-RAD50-

























(ATM) to the DSB, which interacts with CtIP and other exonucleases, that generate a 
single strand DNA (ssDNA) tail (Wyman and Kanaar 2006, Heyer, Ehmsen et al. 2010, 
Stracker and Petrini 2011). Then, the ssDNA is coated by the Replication Protein A 
(RPA) to remove the secondary structures (Sugiyama, Zaitseva et al. 1997), while 
BRCA2 mediates the replacement of RPA by RAD51 to mediate a strand invasion of 
several proteins, including ATM and Rad3-related (ATR) and ATR interacting protein 
(ATRIP), to repair DNA using the correct strand as a template (Williams, Williams et 
al. 2007, Cimprich and Cortez 2008, Pardo, Gomez-Gonzalez et al. 2009). Finally, the 
junctions are resolved resulting in correctly repaired DNA (Pardo, Gomez-Gonzalez et 
al. 2009). Therefore, DNA lesions are detected by sensor proteins, where ATM and 
ATR play a central role, by phosphorylating several mediator proteins (like the cell 
cycle checkpoint kinases 1 and 2, CHK1 and CHK2), that amplify the DDR by 
recruiting several effector substrates (Zhou and Elledge 2000). Both pathways work 
in a orchestrated way and are required for NHEJ, HR, ICL and NER repair pathways, 
as well as for replication fork stability during replication (Ciccia and Elledge 2010) 
(Figure 6A). On the other hand, NHEJ is considered an error-prone pathway, as it 
consists of the ligation of the DNA ends without using the intact sister chromatid 
template (Mahaney, Meek et al. 2009, Brandsma and Gent 2012). NHEJ enables 
binding if Ku70/80 heterodimer to the DSB where it recruits and activates the catalytic 
subunit of the DNA dependent protein kinase (DNA-PK) to mediate the creation of 
compatible ends that can then be ligated (Ciccia and Elledge 2010, Lieber 2010) 
(Figure 6B).  
 
An improved understanding of how DDR contributes to tumourigenesis has informed 
the synthesis of DDR small molecular inhibitors that have had a large impact in the 
clinical practice, based upon the principal of the high–speed replication rate, genomic 
instability and inefficiency of cancer cells to repair DNA damage, making them 
sensitive to these DNA-defect causing drugs that can also be used in combination with 
chemotherapy or radiotherapy. 
 
ATR structure 
ATR is a large protein (2644 amino acids) and a member of the phopho-inositide 3-
kinase related kinases (PIKK) family which is essential for cell viability and embryonic 
development (Brown and Baltimore 2000, Cortez, Guntuku et al. 2001). ATR is in 
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charge of monitoring the progression of replication forks in S phase, maintaining 
genomic stability and promoting a complete and accurate replication of the genome 
by mediating the phosphorylation of a large number of substrates and preventing 
premature mitotic entry (Casper, Nghiem et al. 2002, Cimprich and Cortez 2008, 
McNees, Tejera et al. 2010, Flynn and Zou 2011). Structurally, it contains several 
HEAT (Huntington, Elongation factor 3, Protein phosphatase 2A, and PI3K TOR1) 
repeats, close to the N-terminal, (Ball, Myers et al. 2005, Chen, Zhao et al. 2007, 




Figure 6. Mechanisms of DSB repair. Double strand breaks are mainly repaired through 
homologous repair (HR) or by non-homologous end joining (NHEJ). A. In HR, ATM is mainly 
activated by the MRN complex in a DSB context, resulting in the activation of CHK2 ad p53 
that cause G1 cycle arrest through CDKN1A (p21). Alternatively, single stranded DNA 
(ssDNA) originated in SSB activates ATR, that forms a complex with ATRIP, that 
phosphorylates CHK1, among other targets, causing a G2/M arrest and also S phase 
progression control. B. NHEJ enables binding if Ku70/80 heterodimer to the DSB where it 
recruits and activates the catalytic subunit of the DNA dependent protein kinase (DNA-PK) to 
mediate the creation of compatible ends that can then be ligated. 
 
flanked by FAT (FRAP, ATM, TRRAP) and FATC (FAT-C) domains (Mordes and 





















has been described by some authors, located in between the catalytic and FATC 
domains (residues from 2483 to 2597) (Mordes and Cortez 2008, Mordes, Glick et al. 
2008) (Figure 7). Some regions of the protein have been described to be implicated 
in important protein-protein interactions, such as the heterodimerisation with ATRIP 
(ATR-interacting protein) through its HEAT repeats (Ball, Myers et al. 2005, Chen, 
Zhao et al. 2007); or its activation by its autophosphorylation in the threonine 1989 
(located in the FAT domain) and the FATC/PRD C-terminal domains, mediated by its 
interaction with TopBP1 (Topoisomerase (DNA) II Binding Protein 1) and, to a lower 
extent with ETAA1 (Ewing tumor-associated antigen 1), which are stabilised by its 
heterodimerisation with ATRIP (Mordes and Cortez 2008, Mordes, Glick et al. 2008, 
Liu, Shiotani et al. 2011, Marechal and Zou 2013, Bass, Luzwick et al. 2016, Haahr, 
Hoffmann et al. 2016). Additionally, ATR its known to orchestrate the DDR cascade 
through its binding and phosphorylation to several proteins like CHK1 (Liu, Guntuku 
et al. 2000, Cortez, Guntuku et al. 2001, Ball, Myers et al. 2005, Mordes, Glick et al. 
2008, Bass, Luzwick et al. 2016, Haahr, Hoffmann et al. 2016), although little is known 
about the specific functions of each region of ATR protein in in this complex process. 
Furthermore, due its large size, ATR high-resolution structure has only been partially 
revealed (Rao, Liu et al. 2018).  
 
Mutations in ATR have been associated with Seckel syndrome, a rare condition 
characterised by growth retardation and microcephaly (O'Driscoll, Ruiz-Perez et al. 
2003). Interestingly, deletion of the FATC domain is known to abolish all kinase activity 
of ATR and this is thought to be due the impairment of ATR activation by its interaction 
with TopBP1, as well as a disruption of the adjacent kinase or FAT domain folding 
(Mordes and Cortez 2008, Mordes, Glick et al. 2008). In contrast, mutations in the 
PRD region do not abolish the PIK kinase activity but they cause impairment in kinase 
regulation (Mordes and Cortez 2008, Mordes, Glick et al. 2008). Mutations in the FAT 
domain have been described in an autosomal dominant oropharyngeal cancer 
(p.Gln2144Arg), which caused an inhibition of ATR-dependent responses to DNA 
damage (Tanaka, Weinel et al. 2012). Although FAT domain function has not yet been 
determined, it is possible that it could have a tumour suppressor role as well as 
mediate protein-protein interactions in the same way as other PIKKs (i.e. ATM), as 
looping of the FAT domain results in a direct physical interaction with the kinase 
domain, thereby stabilising the c-terminal end of the protein and being implicated in 
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downstream regulatory activities (Bosotti, Isacchi et al. 2000, Lempiainen and 
Halazonetis 2009).  
 
 
Figure 7. ATR structure. ATR is a phopho-inositide 3-kinase related kinase (PIKK) that 
contains several N-terminal HEAT (Huntington, Elongation factor 3, Protein phosphatase 2A, 
and PI3K TOR1) repeats, and a C-terminal catalytic kinase domain (PI3K/PI4K) (2322aa-
2567aa), flanked by a FAT (FRAP, ATM, TRRAP) (residues 1640-2185) and FATC (FAT-C) 
(residues 2612-2644) domains. An additional PIKK regulatory domain (PRD) has been 
described by some authors, located in between the catalytic and FATC domains (residues 
from 2483 to 2597). 
 
Synthetic lethality (SL) 
The concept of synthetic lethality has been widely used as an approach to target 
genetic deficiencies in tumours and it describes a context where the defect of one 
individual gene is compatible with cell viability, but the perturbation of a combination 
of genes results in cell death (Figure 8) (Brough, Frankum et al. 2011, Ryan, Bajrami 
et al. 2018), providing an approach that can be used to selectively target tumour cells 
(Ashworth and Lord 2018). The first clinical application of SL allowed the use of PARP 
inhibitors (PARPi) for the treatment of breast and ovarian cancers with BRCA1 and 
BRCA2 gene defects (Farmer, McCabe et al. 2005, Tutt, Lord et al. 2005). The recent 
advances in high-throughput screening techniques have enabled the extension of SL 
to other histologies, in order to find new actionable target genes that can specifically 
sensitize cancer cells to drugs that are genotype-specific (Ashworth and Lord 2018). 
Using the concept of SL as an approach to treat cancer is specifically useful in a 
tumour suppressor context (as the case of ARID1A), where the restoration of the 
protein loss is not usually possible, but, the detection of the specific tumour 
dependencies upon that loss can be targeted with a determined treatment, and this 
can constitute an effective alternative.  
HEAT repeats FAT CAT FATC 










Figure 8. Synthetic lethality. SL described a context where the defect of one individual gene 
is compatible with cell viability, but the perturbation of a combination of genes results in cell 
death. 
 
ARID1A and DNA damage repair inhibitors 
One of the multiple roles of ARID1A, and the SWI/SNF complex itself, consists of the 
maintenance of genome integrity. ARID1A is known to participate in the DNA 
decatenation process, facilitating DDR of DSB by its interaction with Topoisomerase 
IIα (TOP2A) during mitosis, which is in charge of decatenating the sister chromatids 
to permit chromosome segregation (Lou, Minter-Dykhouse et al. 2005, Dykhuizen, 
Hargreaves et al. 2013, Williamson, Miller et al. 2016).  ARID1A has been reported to 
be recruited to DSBs through its interaction with ATR, facilitating DSB end processing 
to generate RPA-coated ssDNA, and sustaining ATR activity in response to DSB 
(Shen, Peng et al. 2015). Therefore, loss of ARID1A has been linked to an impaired 
checkpoint activation and a sensitization of cells to several DSB-inducing agents like 
PARPi and ATRi (Bitler, Aird et al. 2015, Bitler, Fatkhutdinov et al. 2015, Shen, Peng 
et al. 2015, Bitler, Aird et al. 2016, Williamson, Miller et al. 2016, Bitler, Wu et al. 2017, 
Jones, Fleuren et al. 2017, Fukumoto, Park et al. 2018). 
 
Although ARID1A is currently not being used as a biomarker in any on-going clinical 
trial, recent studies have demonstrated its clinical importance and suggested that 










inhibitors including ATR, PARP, HDAC, EZH2 and PI3K inhibitors, amongst others 
(Bosse, ter Haar et al. 2013, Samartzis, Noske et al. 2013, Samartzis, Gutsche et al. 
2014, Bitler, Aird et al. 2015, Bitler, Fatkhutdinov et al. 2015, Shen, Peng et al. 2015, 
Wang, Li et al. 2016, Wang, Wang et al. 2016, Williamson, Miller et al. 2016, Bitler, 
Wu et al. 2017, Jones, Fleuren et al. 2017, Fukumoto, Park et al. 2018, Yang, Yang 
et al. 2018). Moreover, the use of antibodies to detect ARID1A expression by 
immunohistochemistry (IHC), has been carried out by Khalique and colleagues, which 
will allow patients to be stratified based on their ARID1A status into early phase clinical 
trials (Khalique, Naidoo et al. 2018). 
 
There are already three early phase studies retrospectively taking in account ARID1A 
mutational status and its association with therapy response. First, the OLAPCO trial 
takes in account ARID1A status to treat patients with a combination of olaparib 
(PARPi) and the AKT inhibitor AZD5363 (NCT02576444). Secondly, the randomised 
phase II study of nintedanib (Vascular Endothelial Growth Factor, VEGF, FGFR and 
Platelet Derived Growth Factor Receptor, PDGFR inhibitor) is being carried on in 
patients with ovarian or endometrium carcinoma, and will assess ARID1A status 
retrospectively (2013-002109-73). Finally, a trial due to start recruiting patients soon 
will assess the chemotherapeutic agent dasatinib in patients with recurrent or 
persistent ovarian, fallopian tube, endometrial or peritoneal carcinoma and will 
retrospectively compare ARID1A mutational and IHC status (NCT02059265) 
(Khalique, Naidoo et al. 2018). Moreover, a Phase II Proof of Concept Study is due to 
start in the Royal Marsden Hospital (NCRI) with the objective of assessing the Activity 
of the ATRi, AZD6738, as a single agent and in combination with the PARPi olaparib 
in ARID1A stratified gynaecological cancers (ATARi trial). The results of this trial will 
be highly informative and might encourage further stratification of patients taking in 
account ARID1A as biomarkers in other histologies if improvements in survival 
outcomes are seen. 
 
With regards to clinical trials assessing the effectivity of DDR inhibitors in GC, a 
translational phase II study using the PARPi olaparib or the ATRi AZD6738 will soon 
start recruiting patients with advanced oesophageal, gastro-oesophageal and GC 
(SOlAR trial), with one of the objectives of assessing ARID1A status as a candidate 
predictive biomarkers of both inhibitors response.   
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Although not many GC-specific studies have been carried out, the use of several DDR-
involved proteins inhibitors has been explored in other histologies before, and it is 
currently the focus of many investigations (Brandsma, Fleuren et al. 2017, Lord and 
Ashworth 2017). More specifically, because of the crucial role of ATR in the DDR 
process, and considering published preclinical data showing SL in particular molecular 
contexts, ATRi are being assessed in preclinical and clinical studies, in monotherapy 
or combination with other drugs (Sundar, Brown et al. 2017). 
 
Current clinical use of ATR inhibitors (ATRi) 
One of the first described ATRi was the selective and potent VE821 (Vertex 
pharmaceuticals), which showed significant synergistic effects in cell lines when 
combined with chemotherapeutic agents and radiation (Prevo, Fokas et al. 2012, 
Huntoon, Flatten et al. 2013, Josse, Martin et al. 2014, Abdel-Fatah, Middleton et al. 
2015). VE821 was demonstrated to have an enhanced effect in cell lines with p53 or 
ATM defects (Reaper, Griffiths et al. 2011). AZ20, and its improved oral version, 
AZD6738, were developed by AstraZeneca, showing similar features and compared 
with VE821 (Foote, Blades et al. 2013, Guichard, Brown et al. 2013, Sarris, Trantas et 
al. 2013). Both of these compounds are currently being tested in phase I clinical trials 
being VE821 now labelled as VX970/M6620. Preliminary data from the VX970 and 
AZD6738 clinical trials monotherapy and combination with several chemotherapy 
regimens reviewed in (Sundar, Brown et al. 2017) have revealed some good 
responses, especially in patients with tumours presenting defects in DDR (like for 
example loss of ATM) (O'Carrigan, Luken et al. 2016, Shapiro, Wesolowski et al. 2016, 
Yap, Krebs et al. 2016). AZD6738 is being evaluated in combination with PARPi in 
several trials (NCT03330847, NCT03682289, NCT03462342, NCT03428607, 
NCT02264678, NCT02576444) and partial responses have been reported (Yap, 
Krebs et al. 2016). Another trial studying the combination of VX970 with the PARPi 
veliparib and cisplatin is ongoing (NCT02723864). Additionally, a new oral version of 
the vertex ATRi (VX803/M4344) is currently undergoing a phase I dose escalation 
study in advanced solid tumours as monotherapy and in combination with carboplatin 
chemotherapy (NCT02278250).  
ATR is becoming a popular druggable target along the DDR pathway, and further 
clinical trials, evaluating these compounds in monotherapy or in combination with 
other therapies such as PARPi or immunotherapy, are needed to fully exploit the 
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potential of ATRi (Sundar, Brown et al. 2017). Additionally, the discovery of robust 
biomarkers that allow an effective stratification of the patients will help to achieve 
better results.  
 
High-throughput CRISPR/Cas9-based genetic screens to detect mechanisms of 
synthetic lethality 
Cas9 nuclease is a DNA endonuclease enzyme from the prokaryotic CRISPR immune 
system that is able to cleave DNA at a NGG sequence (also known as PAM site), to 
form DSBs (Deveau, Garneau et al. 2010, Garneau, Dupuis et al. 2010, Horvath and 
Barrangou 2010, Bhaya, Davison et al. 2011) (Figure 9). Cas9 can be recruited to 
PAM sites by a short 20 nucleotides guide RNA (gRNA) molecule, that specifically 
binds to a determined sequence of the genome (Mali, Yang et al. 2013). Once 
recruited to the gRNA sequence, Cas9 cleaves the DNA a few base pairs (bp) 5’ from 
the PAM site, generating a DSB. This mechanism has been exploited to precisely edit 
the genome, since the repair of the DSB can be carried out by HR, maintaining the 
original sequence or can alternatively be repaired using the NHEJ pathway, which is 
an error-prone pathway, that will cause the insertion or deletion of nucleotides in the 
area where the DNA has been cleaved, potentially resulting in a gene loss of function 
and defective protein expression (Mali, Yang et al. 2013). This approach is known as 
the Clustered Regularly Interspersed Short Palindromic Repeat Associated 9 
(CRISPR/Cas9) gene editing technology (Ran, Hsu et al. 2013). Genome-wide (GW) 
CRISPR/Cas9 screens represent the high-throughput application of the CRISPR/Cas9 
system, where thousands of mutations over the whole genome are caused in one 
reaction, in order to investigate potential synthetically lethal interactions. Nowadays, 
several approaches have been described to induce modifications in the DNA using 
CRISPR/Cas9 screens. CRISPRn (nuclease) libraries are available to induce 
knockout expression of genes, while CRISPRi (inhibition) libraries are used to induce 
repression of genes, and CRISPRa (activation) are used to cause gene activation 
(Miles, Garippa et al. 2016). Other further modifications of the CRISPR/Cas9 
methodology have been described, as for example, the use of dead Cas9 proteins that 
lack the catalytic activity to make DSB, but maintain the ability to bind the DNA and 
form single-stranded bubbling structure, where DNA modifying enzymes (i.e. 
deaminases) can be added to alter the DNA, typically causing point mutations (mostly 
missense mutations) around a 5-nucleotide window (CRISPRx approach)(Hess, 
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Fresard et al. 2016) (Figure 9). Screens can also be classified into positive or negative 
selection screens. Positive selection screens are useful to identify resistance-causing 
genes to a particular drug, where cells are exposed to high doses of drug (Surviving 
fraction of 0, SF0), and only cells with a resistance-conferring mutation are able to 
proliferate. One is able to detect an enriched population of certain sgRNA in the 
resistant population, compared with a time=0 sample. In contrast, negative selection 
screens are carried out using low drug concentrations (SF50-SF80), thus favouring the 
death of the cells with certain sensitivity-conferring mutations, consequently detecting 
a lack in certain sgRNAs representation in the final population, compared with T=0 




Figure 9. CRISPR/Cas9 mediated gene edition. Mechanism of Cas9-induced gene 
targeting. Cas9 interacts with a specific 20bp guide RNA that binds to the complementary 
genomic sequence adjacent to a NGG (PAM) site. Cas9 cleaves the DNA few base pairs from 
the PAM site, generating a double strand break (DSB). The repair of the DSB can be then 
carried out by HR, maintaining the original sequence or can alternatively be repaired 
using the NHEJ pathway, which is an error-prone pathway, that will cause the insertion 
or deletion of nucleotides in the area where the DNA has been cleaved, potentially 



















Aims and approaches  
 
Due to the increasing number of studies confirming the high frequency of ARID1A 
mutations in GC, efforts to identify targeted therapies towards this genetic alteration 
are clinically relevant. Furthermore, preclinical data demonstrating synthetic lethality 
with DDR inhibitors such as ATRi or PARPi, that have already been approved or are 
being tested in clinical practice in other histologies, provides a rationale to test these 
compounds in ARID1A deficient GC models. Moreover, determining potential 
resistance mechanisms to these therapies will allow the design of effective 
combinatorial approaches to achieve improved responses in GC patients with who 
have extremely limited treatment options.  
 
Therefore, the aims of this project are: 
 
1. To identify genetic dependencies for ARID1A deficiency through monotherapy 
or combination drug testing experiments, in a panel of gastric tumour cell lines. 
2. To validate genetic dependencies for ARID1A deficiency in GC in vitro models 
(patient derived-xenografts). 
3. To identify mechanisms of resistance to ATRi in GC through the use of high 
throughput CRISPRn, CRISPRx screens and the characterisation of ATRi 
resistant models.  
 
As part of these work I have (i) demonstrated the previously described synthetic 
lethality involving ATR inhibitors in ARID1A deficient cancers can be extended to GC 
models, both in vitro and in vivo, (ii) identified and validated a list of genetic 
determinants to ATRi resistance, including HUWE1, SMG8, SMG9, SMG1, HNRNPF, 
IRF9, CARD10, CDC25B and STAT2 iii) created ATRi resistant models that have 
allowed me to validate previous hypothesis, and added additional information about 
the resistance mechanisms that can arise from ATRi treatment (iv) identified mutations 




Materials and Methods 
 
Cell lines  
AGS, HEK 239T and NCI N87 cell lines were obtained from American Type Culture 
Collection (ATCC). SNU 1, SNU 5, SNU 484 and SNU 638 were purchased from 
Korean Cell Line Bank (KCLB). YCC6 cell line was a gift from Professor Sun Young 
Rha from the Yonsei Cancer Center in South Korea. ARID1A HCT 116 isogenic cell 
lines were obtained from Horizon Discovery. HCT 116 cells were grown in McCoys 
medium and DMEM was used for HEK2 39T cells. The rest of the cells were grown in 
regular RPMI 1640. All medium was supplemented with 10% FBS. No antibiotics were 
added to the media. Cell line identity was confirmed regularly by STR typing using the 
StemElite Kit (Promega), analysing eight ATR loci: vWA, TH01, CSF1PO, D16S539, 
D7S820, D13S317, D5S818 and amelogenin (for gender identification). Mycoplasma 
testing was carried out periodically using MycoAlert Mycoplasma Detection Kit 
(Lonza).  
 
Microsatellite instability determination 
Microsatellite instability determination was carried out by the Molecular Diagnostics 
Departments (The Centre for Molecular Pathology, The Royal Marsden NHS 
Foundation Trust, Sutton, UK). Briefly, the Type-it Microsatellite PCR kit (Qiagen, 
Hilden, Germany) was used to co-amplify five markers (NR27, NR21, NR24, BAT25 
and BAT26) in a standard multiplex PCR. The PCR conditions were: denaturation at 
95 °C for 5 minutes, 28 cycles of melting at 95 °C for 30 seconds, annealing at 60 °C 
for 90 seconds, and extension at 72 °C for 30 seconds, followed by a final extension 
phase at 60 °C for 3 minutes. The PCR products were denatured and separated by 
capillary electrophoresis using an ABI PRISM 310 DNA sequencer and were further 
analysed with the GeneMapper software (Applied Biosystems, Paisley, UK). MSI 
status was confirmed when two or more markers presented instability and 
microsatellite stable (MSS) status was confirmed when one or none of the markers 
presented instability. 
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In the case of the PDX in vivo experiment the studied markers were NR21, BAT26, 
BAT25, NR24 and MONO27, using penta-C and D as controls, which serve as internal 
controls.  
 
Genomic DNA extraction from cell lines 
Genomic DNA was extracted from cell lines using the QIAamp DNA Blood Mini Kit 
(Quiagen), according to the manufacturer’s instructions, eluted in 30 µl of nuclease-
free H2O and stored at -20°C. DNA concentrations were determined by measuring 
absorbance at 260nM using a the NanoDrop1000.  
 
Polymerase Chain Reaction (PCR) and gel electroforesis 
Generally, PCR Amplicons were generated using 100ng of DNA in 50 µl reactions, 
using the New England BioLabs Q5® High-Fidelity DNA Polymerase set, according to 
manufacturer’s protocol, using specific primers listed in Table 1. PCR was carried out 
on a thermocycler as follows: 98°C for 2’, followed by 30 cycles of 98°C for 30’’ 
(melting), 60°C for 30’’ (annealing) and 72°C for 20’’ (elongation), followed by a final 
72° for 2’ step.  Annealing temperature and elongation were adjusted for each reaction 
according to the primer requirements and length of the product, respectively.  All 
primers were ordered from Integrated DNA technologies (IDT) or Thermo Fisher 
scientific as lipolysed powder, which were resuspended in nuclease-free H2O 
(Ambion) to a concentration of 100 µM and stored at -20°C. Primers were then diluted 
to 10 µM for use in each PCR reaction.  PCR products were analysed by agarose gel 
electrophoresis by mixing with 6x loading dye (New England Biolabs) and separation 
by gel electrophoresis. Agarose gels were made as follows: 1-2% ultra-pure agarose 
(Life Technologies) dissolved in 1x TAE buffer + 1/10,000 GelRed nucleic acid stain 
(Biotium). Hyperlader 1 (Bioline) was used to estimate length of the PCR products. 
DNA was then visualised using an ultraviolet transiluminator (Syngene). 
 
TOPO cloning and sanger sequencing 
100ng PCR products from genomic DNA extracted from CRISPR-Cas9 targeted SNU 
484 cells or GW-CRISPR/Cas9 mutagenesis screen YCC6 resistant colonies were 
cloned into the pCR-Blunt II-TOPO vector, using the Zero Blunt TOPO PCR Cloning 
kit (Invitrogen) following manufacturer’s protocol. The final mix was incubated 1h at 
room temperature and prepared for transformation. For transformation, 150 µl of 
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competent cells were placed into a sharp-bottom Eppendorf and mixed gently with 5 
µl of cloned product. After 30 minutes of ice incubation, tubes were heated at 42ºC for 
45 seconds and cooled back on ice. 300 µl of outgrowth SOC media were added and 
the tubes were placed in the shaker for 1h at 37ºC. After incubation, tubes were 
spanned and plated in petry plates. Petry plates were then incubated upside down 
overnight at 37ºC. Next day; colonies were picked, expanded in antibiotic selective 
media and DNA was extracted after 18h of incubation, using the Qiaprep Spin 
Miniprep kit from Quiagen. PCR purification was carried out using the QIAquick PCR 
Purification Kit. 
 
Table 1. Summary of PCR and sanger sequencing primers used in this thesis 
 
 
For the sanger sequencing, 15 µl of purified DNA, was mixed with 2 µl of 10 µM forward 
or reverse primers for the target gene sequence and prepared at a final concentration 
of 100 ng/µl in the case of plasmidic DNA, or 10ng/µl for PCR purified DNA. Samples 
were outsourced to Eurofins Genomics (https://www.eurofinsgenomics.eu) and results 
were analysed using the sequence alignment tool of ApE Plasmid Editor free software.  
 
Chemicals  
Information about all chemicals used is listed in Table 2. 
 
Table 2. Drugs used in this thesis 
Drug Code Supplier 
VX970 (VE822) S7102 Selleckchem 
AZD6738 S7693 Selleckchem 
Olaparib S1060 Selleckchem 
Talazoparib S7048 Selleckchem 
BKM120 (buparisib) S2247 Selleckchem 
MK2206 (-2HCL) S1078 Selleckchem 
Reagent Sequence Supplier 
HUWE1 CRISPR Forward primer CCATGTAAACAGTCATAGCCAC IDT 
HUWE1 CIRSPR Reverse primer GGACAGGGCAGAGCTATAAG IDT 
IRF9 Forward primer CACGCCTGTAAAGCCAGTCC IDT 
IRF9 Reverse primer GGACAGGGCAGAGCTATAAG IDT 
U6-F GGCCTATTTCCCATGATTCCTTC IDT 
CRISPR-scaf-R ACTCGGTGCCACTTTTTCAA IDT 
ARID1A CRISPR Forward primer AGGGGGGGAGAAGACGAAGA Thermo Fisher 
ARID1A CRISPR Reverse primer AGGCCAGGGCTTTGTTGT Thermo Fisher 
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ACY1215 (ricolinostat) S8001 Selleckchem 
GSK126 S7061 Selleckchem 
Puromycin solution Ant-pr-1 Invitrogen 
Blasticidin solution And-bl-05 Invitrogen 
Doxycycline hyclate D9891 Sigma-Aldrich 
M4344 (PDX)  Merck 
 
Western blotting and antibodies  
Whole cell lysates were extracted using lysis buffer (1% Sodium deoxycholate, 1% 
TritonX-100, 1% Nonident P-40, 0.1% SDS, 150nM NaCl, 5mM EDTA, 50mM Tris, 
30mM NaF and water), supplemented with proteinase inhibitor (10X) and phosphatase 
inhibitor (100x), and separated using 3-8% Tris-Acetate gels (Invitrogen) or 4%–12% 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) Bis-Tris gel, 
transferred to nitrocellulose membrane, blocked in 5% milk or BCA and blotted with 
primary antibody in Milk or BCA overnight. Next day, a fluorescent secondary antibody 
was added, following 3 x 5 minutes’ washes with TBST. Membrane was again washed 
with 3 TBST x 5 minutes’ washes, and signal was then read using the Li-core 
(odyssey) system. Information about the antibodies used is shown in Table 3. All WB 
were performed by triplicate. Only the best result is represented in the figures. 
 












Specie Company Product code 
ARID1A 242 1:1000 (BSA) 1:5000 Rabbit CST 12354 
ß-Actin 44 1:2000 (Milk) 1:10000 Mouse CST 3700 
IRF9 (ISGF3) 48 1:500 (BSA) 1:1000 Mouse SC sc-135953 
HUWE1 
(lasu/ureb1) 
490 1:500 (BSA) 1:1000 Rabbit Bethyl A300-486A-T 
SMG1 410 1:1000 (BSA) 1:2000 Rabbit CST 9149 
UPF1 141 1:5000 (BSA) 1:5000 Rabbit CST 12040 
Ezrin 81 1:1000 (Milk) 1:5000 Rabbit CST 3145 









    Li-cor 925-32210 
Anti-Mouse IgG     CST 7076 
Anti-Rabbit IgG     CST 7074 
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Cellular viability assays 
5-days survival assays were performed in 384-well plates. Cells were plated at a 
concentration of 500 cells per well and drugged for 5 days, 24h after seeding. Viability 
was estimated using CellTitre-Glo luminescence reagent (Promega). Cell-based 
assays were performed by triplicate. Final number of cells was normalised to DMSO 
median and surviving fractions of cells were plotted in GraphPad Prism, where lines 
of best fit were drawn using a four-parameter nonlinear regression. SF50 (Surviving 
Fraction 50 = the concentration of drug required to cause a 50% inhibition of the cell 
population) or AUC (Area Under the Curve) values were calculated from these curves 
using GraphPad Prism software. Comparisons of dose-response curves were 
performed using two-way ANOVA testing. Comparisons of SF50 or AUC data were 
performed using the Mann-Whitney test for non-parametric samples.  
 
Cell proliferation experiment  
2000, 4000 and 6000 cells were seeded in a clear well 6-well plate and live-analysed 
for 7 days using the IncuCyte Zoom Live Cell Analysis System (Essenbio) at 37°C, 
5% CO2. Final number of cells was estimated through image analysis, and mean and 
standard deviation was calculated for each well and compared in between samples. 
Proliferating experiment was repeated more than three times, only the best result is 
shown in the figures.  
 
RNA extraction and Real time- PCR (RT-PCR) 
RNA was extracted using RNeasy Mini Kit (Quiagen) and RNA concentration was 
measured using the NanoDrop1000. cDNA conversion was carried out from 1 µg of 
RNA using iScript Kit (Bio-Rad). Quantitative PCR was first optimised carrying out a 
standard curve as an initial run, to determine the optimal primer concentration for 
ARID1A (Fw probe: 5'-TCATGCCCAACCTTCGTATC-3'; Reverse probe: 5'- 
GATGGCTGCTGGGAGTATG-3'), used at a final concentration of 900 nM. ß-Actin 
was used as an endogenous control, using a final primer concentration of 300 nM (Fw 
probe: 5’-CCCTGGCACCCAGCAC-3’: Rv Probe: 5’-GCCGATCCACACGGAGTAC-
3’). The experiment was done by triplicate in MicroAmp Optical 96-Well Reaction Plate 
from Thermo Fisher, and ran in the QuantStudio 6 Flex (Thermo Fisher), following the 
next temperature steps: 50ºC for 2’, 95ºC for 2min and 40 cycles of 15ºC for 15’’ and 
60ºC for 1’. 
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Raw data from the RT-PCR machine is presented as Cycle threshold (Ct), which 
indicates the number of PCR cycles required for fluorescence to reach a defined 
threshold. The difference in Ct values for the ARID1A (FAM) and ACTIN (VIC) signals 
were calculated to define the ∆Ct, which indicates the level of ARIDA expression 
relative to the endogenous control ACTIN. The fold-change for each replica well was 
used to define the median and standard deviation of the ARID1A expression levels in 
every cell line.  
 
Reverse siRNA transfection knockdown experiments  
Reverse transfections using the siRNA SMARTpool, siCON2 negative control (DE 
dharmacon) or the siAllstar negative control (Quiagen) were carried out in 6 well-plates 
using 5μl of the siRNA (20μM), mixed with 250μl of optiMEM and incubated at RT for 
10 minutes. 5 μl of RNAiMax (Invitrogen) were incubated with 250μl of optiMEM for 10 
minutes. Total volume of the transfection mix was added to the siRNA mix and 
incubated at RT for 30 minutes. Lysates were retrieved after 3 days, and proteins were 
extracted to test for protein expression by western blot. In the cases where a higher 
number of cells was needed experiments were performed in 10 cm plates, where 
quantities of the reagents were scaled to a final volume of 10 ml.  Viability assays were 
performed as described in cellular viability assays section. The de-convoluted siRNA 
target sequences used are as follows: siARID1A_1 GCAACGACAUGAUUCCUAU, 
siARID1A_2 GAAUAGGGCCUGAGGGAAA, siARID1A_3 
AGAUGUGGGUGGACCGUUA, siARID1A_4 UAGUAUGGCUGGCAUGAUC, 
siSMG1_1: GCAAAGAGCUGUUCAGGAA, siSMG1_2: 
GCGAAAGAUUGACAUCAUA, siSMG1_3: GUCAAGAGCUCUAUAGGAA, 
siSMG1_4: GUUAGAGCUUCGUUUAUUA. All siRNA experiments were done by 
triplicate. Only the best result is shown in the figures. 
Cells plated in wells transfected with the siRNA of interest were compared with cells 
in the wells transfected with the negative control siRNA (siCON2 or siAllstar). The 
surviving fraction was the calculated as follows: 
Surviving fraction = (Luminescence in siRNA of interest treated well)/(Luminescence 




In vivo assessment of ATRi efficacy in gastric cancer Patient-Derived 
Xenografts (PDX). 
In vivo efficacy study testing the M4344 oral ATRi (Merck) was carried out by 
CrownBio company, in an agreed academic collaboration with Merck Serono, in 
gastric adenocarcinoma PDX models (CrownBio HuPrime GC xenografts) implanted 
in female BALB/c Nude mice. Seven PDX were selected from CrownBio database, 
according to its ARID1A mutational status, which was provided by the company 
(exome sequencing and RNA sequencing information) and additionally validated in-
house. ARID1A protein expression testing was done by Saira Khalique and The Breast 
Cancer Now laboratory (The Institute of Cancer Research, London, UK) by IHC and 
ARID1A DNA sequencing was done the Tumour Profiling Unit (The Institute of Cancer 
Research, London, UK), using the PGM 318 Chip (IonTorrent) using a previously 
designed panel of genes, containing ARID1A, created by Saira Khalique as previously 
described (Khalique, Naidoo et al. 2018).  Briefly, ARID1A loss of protein expression 
was tested through IHC of Formalin-fixed paraffin-embedded (FFPE) sections across 
all the tumour samples, using the D2A8U ARID1A antibody at a 1:250 dilution, (Cell 
Signalling Technology) and the Dako-Autostainer Link 48 with the EnVision FLEX kit 
as per manufacturer’s instructions (Agilent Technologies). HCT 116 ARID1A WT and 
deficient cell pellets were used as positive and negative controls, respectively, and 
two independent pathologists’ who were blinded to the mutational status of the sample 
determined the results obtained. Additionally, microsatellite instability status was 
determined as described above.  
For the in vivo experiment, M4344, rather than VX970 has been used, as M4344 is an 
oral compound that has previously been observed in other tumour models to have 
superior in vivo efficacy and it is currently being assessed in phase I clinical trials in 
monotherapy or in combination with PARPi. Although single agent M4344 delivered at 
20mg/kg daily is largely well tolerated in other in vivo tumour models, an additional 
single agent M4344 arm at a reduced dose of 10mg/kg daily was included as a 
precaution in the event that tolerability issues are experienced in the mice. 
Therefore, to assess the sensitivity of the PDXs to M4344, six experimental arms were 
designed, where seven randomised distributed mice, bearing tumours with an 
approximate size of 100-200mm3, were treated with either: M4344 20mg/kg twice a 
day (BID), twice per week; M4344 10mg/kg once a day (SID), twice per week; ATRi 
M4344 3mg/kg daily, Talazoparib 0.1 mg/kg 2x daily and ATRi M4344 3mg/kg daily + 
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Talazoparib 0.1 mg/kg 2x daily, all treatments given by oral gavage. Model GA2148 
was used to escalate the doses, that were lessened in the rest of the models, due to 
severe body weight loss in mice receiving the highest doses of the ATRi. The other 
models were treated with 10mg/kg twice a week or 5 mg/kg M3433 daily instead of 20 
and 10 mg/kg. Sample sizes for treatment groups were calculated on Cohen principle 
(1998), considering the following basics: Effect on 75% are measured as significant, 
assuming normal distribution, p-value (α) <0.05 and a ß of 0.95. Calculation of the 
variance is assumed to be about 40% for a randomised population (tumours are 
randomised to have equally distributed standard variations within the treatment 
groups). Plasma samples were retrieved from each animal at 2 and 6 hours after 
treatment for pharmacokinetic studies. Furthermore, for the cases were reduced 
tumour growth has been observed, mice were continued to be treated until the tumour 
developed acquired resistance and re-grown. Those tumours were then harvested for 
further molecular characterisation through whole exome sequencing, RNA sequencing 
and mass spectroscopy-based proteomic profiling (Figure 10). 
 
YCC6 VX970 resistant cell lines 
To generate YCC6 VX970 resistant cells, two independent 20-30% confluent flasks 
were treated with increasing concentrations of VX970, starting from SF80 and steadily 
increasing dose every week, for a total of 5 consecutive months, until they became 
resistant to 5 or 8 times-fold the initial SF50 (from 54nM to 230nM and 460nM, 
respectively). Then, single cells where sorted in 96 well-plates by flow cytometry, using 
the FACS Aria (Becton Dickinson). 8 proliferating colonies (6 of them resistant to 460 
nM flask, and two of them resistant to 260nM VX970), where then expanded and 
treated, with same concentrations of drug for 2 weeks, before testing for ATRi (VX970 
and AZD6738) sensitivity, compared with parental YCC6 cell line. Cells were 
expanded and lysates were retrieved to simultaneously extract DNA, RNA and 
proteins for exome sequencing, RNA sequencing or Mass spectrometry, respectively.  
 
Proteomic analysis by mass spectrometry in ATRi resistant clones 
Protein extraction, preparation and mass spectrometry processing and analysis was 
carried out by the Proteomics & Metabolomics Laboratory (Institute of Cancer 
Research, London, UK). Briefly, cell pellets were lysed by probe sonication/boiling, 
and protein extracts were subjected to trypsin digestion. The tryptic peptides were 
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labelled with the Amine-reactive TMT10plex Isobaric Label reagent set (Thermo 
Fisher Scientific), which enables multiplexed protein identification (9,410 proteins) and 
quantitative analysis by tandem mass spectrometry (MS). Labelled products were then 
combined at equal amounts, and fractionated with high-pH C18 high-performance 
liquid chromatography (HPLC). LC-MS analysis was performed on the Dionex 
Ultimate 3000 system coupled with the Orbitrap Fusion Mass Spectrometer. Data 
analysis was carried out using online Perseus software (Marx Plank institute). 
 
Next Generation Sequencing (NGS) 
Exome sequencing was carried out by Tumour Profiling Unit (The Institute of Cancer 
Research, London, UK). Briefly, DNA extracted from cells from the GC panel was 
exome sequenced using the HiSeq2500 (v4, Illumina), after preparing the samples 
according to manufacturer’s instructions, using the Agilent SureSelectXT V6 exome 
library kit (Illumina) and using PE 100 cycles to a median depth of >100X for all 
samples. FastQ files were generated and further processed by the Breast Cancer 
Research Bioinformatics Group (The Institute of Cancer Research, London, UK). 
 
Analysis of cell cycle distribution by FACS 
For the cell cycle analysis, 60,000c/ml cells were seeded in 6-well plate and incubated 
48h before VX970 or DMSO control was added to the media in two different 
concentrations (75nM and 150nM). Cells were then exposed to the drug for 24 or 48h, 
stained with 20µM EdU (5-ethynyl-2´-deoxyuridine, a nucleoside analog to thymidine, 
incorporated into DNA during active DNA synthesis) for one hour, when they were 
harvested and fixed overnight with cold ethanol 70%. Staining was then carried out 
using the Click-IT EdU kit (Thermo Fisher Scientific). Next day, cells were 
permeabilised and Alexa647 was added to the media. Cells were then digested with 
RNAse A (Sigma Aldrich), before propidium iodide (PI, a DNA intercalating agent that 
allows us to measure cell viability or DNA content in the cells) was added to the cells 
(Sigma Aldrich). Detection of EdU or PI staining was analysed on a BD LSR II flow 
cytometer (BD Biosciences). EdU was measured with the red laser detecting Alexa647 
blue at 635 nm and using the 60/20 filter, while PI was measured at 488nM detecting 
PE/Texas red using the 610/20 filter. Debris and doublets were gated out from a 
FSC/SSC dot plot and DNA dye area/width dot plot, respectively and the selected 
population was analysed regarding its cell distribution on the cell cycle using the FACS 
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diva software. Flow cytometry analysis was supervised by Radhika Patel and the flow 
cytometry unit (The Institute of Cancer Research, UK). 
 
ARID1A CRISPR/Cas9 mutagenesis 
60% confluent cells were transfected in 6-well plates, following a standard forward 
transfection protocol using 2500ng Geneart Platinium Cas9 nuclease (Invitrogen) per 
well, 5µl of Lipofectamine Cas9 Plus Reagent, 7.5µl Lipofectamine CRIPRMAX 
Reagent (Invitrogen) and 650ng of ARID1A sgRNA, previously generated with the 
GeneArt Precision sgRNA Synthesis Kit (Invitrogen) (sgRNA sequence ARID1A.1: 
AAGAACTCGAACGGGAACGC: sgRNA sequence ARID1A.2: 
CGGACCTGAAGAACTCGAAC: sgRNA sequence ARID1A.3: 
GAAGAACTCGAACGGGAACG). A sgRNA with no homology to any known 
mammalian gene was used as a negative control. Single cells were sorted with FACS 
Aria (Becton Dickinson) in 96-well plates and left to proliferate. Colonies were 
harvested and tested for ARID1A protein expression by western blot, and for 
mutations, by PCR and Sanger sequencing using the following primer sequences, 
amplifying the region surrounding the gRNA target sequence (Forward: 
AGGGGGGGAGAAGACGAAGA; Reverse: AGGCCAGGGCTTTGTTGT). 
 
Positive selection genome-wide CRISPR/Cas9 screen  
Doxycycline (Dox) inducible-Cas9 expressing cells were generated by transduction of 
YCC6 cells with the Edit-R Inducible Lentiviral hEF1a-Blast-Cas9 Nuclease 
(Dharmacon) and selected in 7µg/ml blasticidin for five days (YCC6iCas9). Cas9 
catalytic activity was tested using a two-fluorescence protocol, transducing cells with 
a GFP (Green Fluorescent Protein)/RFP (Red Fluorescent Protein, Cherry) 
expressing construct (GFP/RFP/empty), or with the same construct carrying an 
additional gRNA sequence towards GFP protein (GFP/RFP/gfp-sgRNA). Cells where 
then treated with Dox for at least 2 days, retrieved, and green and red fluorescence 
was analysed by flow cytometry using the BD LSRII cell analyser. More than 50% of 
the cells showing a decrease in green fluorescence, in the cells infected with the 
GFP/RFP/gfp-sgRNA construct, compared with the empty one was considered as a 
positive result for Cas9 catalytic activity. 
Next, cells were seeded aiming a 1000x representation per sgRNA in the library, and 
infected at a multiplicity of infection (MOI) of 0.3, to avoid multiple sgRNA infections 
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per cell, with a previously published and validated GW human lentiviral CRISPR library 
(Kosuke Yusa, Human GW CRISPR guide RNA library V1)(Koike-Yusa, Li et al. 2014). 
Efficiently transduced cells were selected twice with 5 µg/ml puromycin for two and 
five days, consecutively, when a sample T=0 was taken (<1000x sgRNA 
representation number of cells). After the T=0 sample was taken, 1 million cells were 
plated per each 15-cm plate, maintaining the 1000x sgRNA representation, and 100 
nM VX970 (SF0) was added to the cells. Cells were fed and drugged twice a week for 
three weeks, before T=1 was taken.  Additionally, twenty-four surviving colonies were 
picked and analysed for the presence of sgRNA sequences by PCR and Sanger 
sequencing, as described above.  
DNA from sample T=0 and T=1 was extracted and PCR of the CRISPR guide regions 
were carried out. Guides in each sample were sequenced by the Tumour Profiling Unit 
(The Institute of Cancer Research, London, UK), using a U6 custom primer on the 
HiSeq (Illumina), which sequences the CRISPR sgRNA to generate gRNA count data. 
Bioinformatic analysis were performed by the Breast Cancer Research Bioinformatics 
Group (The Institute of Cancer Research, London, UK). MAGeCK (Model-based 
Analysis of GW CRISPR/Cas9 Knockout) software was used to generate sgRNA 
counts according to the sequences present in the GW CRISPR library. Using the 
normalised read count data from MAGeCK, quality checks (QC) were performed (read 
counts per guide, distribution of read counts), to confirm the robustness of the data. 
For downstream analysis of gRNA read count data, two approaches were used: Z-
score analysis and MAGeCK analysis. 
For the Z-score analysis (where Z=0 represents no effect on viability and positive Z 
scores represent gain of viability), the guides with a maximum read count of zero in 
the T=0 sample were firstly identified and removed from the analysis. Then, the raw 
read counts were converted to parts per ten million (pptm) counts to account for 
variation in the amounts of DNA sequenced. The raw pptm counts were further 
converted to pseudocounts by adding a factor of 0.5 and then were log2 transformed 
before calculating the viability effect (VE) and drug effect (DE) Z-scores (equation 1 
and 2). VE is defined as the rate of decrease in abundance of each gRNA in the 
population over time in the absence of drug treatment (DMSO) while DE is defined as 
the difference in abundance of each gRNA between VX970 and vehicle (DMSO) 
treated samples at a specified time point during the experiment. To remove variation 
in DE that can be attributed to VE, a linear model of DE~VE was fitted and then 
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adjusted DE using equation 3 to give corrected DE. I considered a threshold of Z-
score larger than 2 for resistant sgRNAs and Z-score ranks for positive selection were 
generated by sorting results based on their Z-score. 
Equation 1: 
Viability Effect (VE) = !"#$ %& '!"#$ %( ')*+,-.(!"#$ %& '!"#$ 0( )
"2!(!"#$ %& '!"#$ %( )
 
Equation 2: 
Drug Effect (DE) = !345 % '!"#$ % ')*+,-. 6789( '!"#$(%))
"2!(6789( % '!"#$ % )
 
Equation 3: 
𝐷𝐸< 𝐷𝐸	𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝐷𝐸 − 𝑐 − (𝑉𝐸	𝑥	𝑚) 
*Being DMSO: log2 PPTM count of DMSO samples at time points T=1 and T=0; Drug: 
log2 PPTM counts of drug samples at time point T; MAD: mean absolute deviation; C: 
intercept; m: slope.  
 
In addition to our Z-score analysis, MAGeCK analysis was also used for the analysis. 
Briefly, MAGeCK algorithm normalises read counts according to the median, in order 
to adjust for the effect of the library size and read count distribution. Then, the variance 
of read counts is estimated and a negative binomial model is used to test weather 
sgRNA abundance differs significantly between treatment and control arms. SgRNAs 
are ranked according to the p-values calculated from the negative binomial model, and 
used to identify positively or negatively selected genes, using modified robust ranking 
aggregation algorithm (RRA). Additionally, positively and negatively regulated 
pathways can be reported, by applying RRA algorithm to the rankings of genes in a 
particular pathway. 
A final rank list of hits was generated by consolidating results from both Z-scores and 
MAGeCK approach by calculating a single score using the product of their rank values 
(sqrt (Z-score rank)*(MAGeCK rank).  
An initial validation of the hits was carried out in single 96 well CRISPR/Cas9 arrayed 
reaction plate using 5 or more parallel crRNA per targeted gene, plus 2 negative 
control sgRNAs (with no homology towards any human gene). Cell growth after 
mutagenesis and treatment was monitored using the IncuCyte Zoom Live Cell 
Analysis System (Essenbio) along time, at 37°C, 5% CO2. In each well, 1500 
YCC6iCas9 cells were reversely transfected with 5 µl of 2µM sgRNa and 5 µl of 2uM 
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tracrRNA in 20 µl of OptiMEM, using 3.5µl of 1:10 diluted RNAiMAX (Invitrogen), and 
incubated for 24h. Next day, media was removed and fresh media, containing 80nM 
VX970 was added (dose high enough to kill all cells in a normal condition). Plates were 
left in the IncuCyte for two weeks, until negative control cells were all dead and cells 
were fed twice a week with fresh drug. Drug-free media was then added to the cells, 
that were left to recover for one week, prior IncuCyte growth graphs were generated. 
Additionally, CellTitre Glo (CTG) analysis was carried out to measure the number of 
living cells in each well, and these results were compared with the growth graphs to 
determine which crRNAs caused resistance to the lethal doses of VX970.  
In parallel, I sanger sequenced the DNA of the picked resistant colonies and 
determined the sgRNAs that were inserted in the cells. This was done by extracting 
DNA and PCR amplification, using the U6 forward primer 
(GGCCTATTTCCCATGATTCCTTC) and a Scaf modified reverse primer 
(ACTCGGTGCCACTTTTTCAA), which are located next to the sgRNA sequence in 
the constructs, using 10 µl of Q5 buffer, 1µl 10mM dNTPs, 2 µl 10µM U6 primer, 2µl 
10µM Scaf primer, 0.5µl Q5 polymerase, 32.5 µl Nuclease-free water and 100ng DNA. 
The program used comprised an initial incubation of 98°C for 2 minutes, 30 cycles of 
98°C for 20 seconds (melting), 60°C for 30 seconds (annealing), 72 °C for 30 seconds 
(elongation), and a final extension step of 72°C for two minutes. The PCR product was 
then purified using the QIAquick PCR Purification Kit (Quiagen) and sent for sanger 
sequencing (Eurofins). For the colonies with more than one sgRNA inserted, I did a 
TOPO cloning experiment to generate ssDNA copies (see above).  
Colonies with a single sgRNA insertion, validated in the previous experiment, were 
selected for further analysis. The resistant colonies where then tested for protein 
expression loss by WB (see above for protocol), using specific antibodies (Table 3). 
Then, ATR inhibition resistance of the colonies was checked by 5-days survival assays 
performed in 384-well plates (as described before). For the colonies presenting ATRi 
resistance, ssDNA was generated through TOPO cloning and bacterial transformation 
(see above) and final product was sent to sanger sequence surrounding the sgRNA 
targeting region, using specific primers listed in Supplementary Table 1. Additionally, 
cell cycle experiments were carried on (see section above), and siRNA or 
CRISPR/Cas9 mutated clones were generated to validate the hits that were not 
represented in the picked colonies.  
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Dense Tiling ATR CRISPRx Screen 
In order to find out which mutations along the ATR sequence confer resistance to the 
ATRi VX970, a two-arm CRISPRx screen was carried out. In these screen, I used 
base editors to generate point mutations by promoting the direct and irreversible 
conversion of one base pair to another at a target genomic locus (leaded by the 
sgRNA) without requiring double-stranded DNA breaks (DSBs), homology-directed 
repair (HDR) processes, or donor DNA templates (Komor, Kim et al. 2016, Nishida, 
Arazoe et al. 2016, Komor, Zhao et al. 2017).  
For the first arm, a dense CRISPR library comprising 552 guides targeting all ATR 
sequence was synthesised (Twist biosciences) and cloned into the BbsI site of pKLV5-
U6gRNA5-PGKPuroBFP. Ten million YCC6 cells were infected at a low MOI (to 
assure single guide insertion per cell) and selected in 5 µg/ml puromycin for 5 days. 
Afterwards, the cells were seeded in 10 cm plates and transfected when 80% confluent 
with 10µg of plasmidic DNA constructs carrying regular Cas9 (pCW-Cas9, Addgene 
#50661) or, the following base editors: SaBE4-Gam (Addgene, #100809) as a 
cytosine deaminase, and ABE7.10 (Addgene, #102919), an Adenine deaminase. GFP 
expressing plasmid, pEGFP-N1 (Clontech) was used as a negative control and 
forward transfection was carried out following the regular Lipofectamine 2000 protocol 
(Invitrogen) following the principal described by (Gaudelli, Komor et al. 2017). Media 
was changed after 5 hours and cells where left incubating for 48h, before they were 
seeded at a concentration of 50,000 cells/ml in a new 10-cm plate, the day before the 
VX970 treatment started. Cells were treated twice a week for 2 weeks with 100 nM 
VX970, until negative control cells were all dead. Resistant cells were then expanded 
and retrieved for further analysis. 
In the second approach, the same 552 sgRNA library was cloned into a 
pGH224_sgRNA_2xMS2_Puro (Addgene, #85413) construct, and transduced into 
deadCas9 (dCas9) expressing YCC6 cells (YCC6dCas9). To create YCC6dCas9 cells, 
YCC6 cells were transduced with a pGH125_dCas9-Blast lentiviral construct 
(Addgene, #85417), carrying a dead form of Cas9, with no catalytic activity to make 
DSB, but with the capacity to bind the DNA and form single-stranded bubbling 
structures described in (Hess, Fresard et al. 2016), where the base editors will 
deaminase a cytidine or adenosine, causing point mutations (mostly missense 
mutations) around a 5-nucleotide window. Then, cells were infected with the gRNA 
tiling library at a low MOI and selected in puromycin for 5 days, prior they were 
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transfected with 10µg of plasmidic constructs carrying the following base editors: 
pGH156_MS2-AID-Hygro (Addgene, #85415) and pGH183_MS2-AIDΔDead-Hygro 
(Addgene #85414), as a negative control. Transfection was carried out following the 
regular Lipofectamine 2000 protocol (Invitrogen) in 10 cm plates, and left 48 hours to 
cause mutations along the ATR gene. Next, cells were seeded at a concentration of 
50,000 cells/ml in new 10-cm plates and fed with 100 nM VX970 for two weeks. 
Resistant colonies were harvested and retrieved for further analysis. 
RNA was extracted from resistant cells of both arms, using the RNAeasy mini kit 
(Quiagen), and cDNA was prepared using three ATR specific primers and the 
SuperScript III Reverse transcriptase kit (Invitrogen) with the following conditions: 
Mixed in TUBE 1 (per sample): 1µg RNA, 1 µl of 10mM dNTPs, 1µl of 10µM primer 
(ATR specific) and 6µl of nuclease-free H2O, in a total volume of 10µl. Tube 1 was 
then incubated at 65°C for 5 minutes and immediately put on ice for 1-2 minutes. Mixed 
in TUBE 2 (per sample): 4µl of 5x buffer, 0.5µl of SSIII (reverse transcriptase), 1µl of 
1MDTT and 4.5 µl of H2O, in a total volume of 10 µl. I then added tube 2 to tube 1 and 
heated the mix at 25 °C for 10 minutes, 50°C for 50 minutes and 75°C for 15 minutes.  
Next, I carried out a tiling ATR PCR (PCR1), where I amplified the whole ATR 
sequence in amplicons no longer than 300bp. I used 36 primer pairs (listed in 
Supplementary Table 2) that included an PB3 sequence, used as a bridge to add a 
barcoded IonA sequence in the second PCR (Forward primer), and an IonP1 tail 
(reverse primer). All PCR1 reactions were checked on a 2% agarose gel and mixed 
for PCR purification, using the AMPure XP beads (Auto Q Biosciences) following 
manufacturer’s protocol. DNA resulting from PCR1 was then mixed in one reaction 
and amplified in PCR2, when the 5’ barcoded Ion torrent tail was added. Final product 
was purified again following the same beads protocol used before, and processed 
using the Ion Chef PGM Hi-View templating kit (IonTorrent). Samples were then 
sequenced using the PGM 318 Chip v2 at a 45pM molarity (IonTorrent). Sample 
processing from PCR purification 2 and sequencing was performed by the Tumour 
Profiling Unit (Institute of Cancer Research, London, UK). FastQ files were generated 
and aligned to ATR cDNA sequence by Steven Pettitt (The Breast Cancer Now 
laboratory, The Institute of Cancer Research, London, UK) using Novoalign (Novocraft 
technologies). Coverage was calculated per base using samtools pileup with a 
maximum depth of 50,000 (github.com/samtools). Bam files were then compared with 
consensus ATR cDNA sequence and mutations were listed and localised in the protein 
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structure of ATR using the Integrative Genome Viewer (Broad institute) and the 
Chimera software (UCSF), respectively.  
 
Statistical analysis: 
Statistical analysis was performed using Microsoft Excel or GraphPad Prism. All tests 
were two-sided unless otherwise stated Mann-Whitney tests were used to compare 
non-parametric datasets and Student’s t-tests used for parametric datasets. 
Additionally, GW CRISPR/Cas9 mutagenesis screen data and next-generation 
sequencing (NGS) data was analysed by the Breast Cancer Research Bioinformatics 
Group (The Institute of Cancer Research, London, UK), using R and following the 
above specifications. Venn-diagrams for the cross referencing with Wang et al was 
carried out using the online software described in (Heberle, Meirelles et al. 2015). See 





1. ATR sensitivity in ARID1A deficient gastric cancer 
models 
 
Characterisation of ARID1A status and mutational signature in gastric tumour 
cell lines. 
Recent studies have demonstrated that defects in ARID1A sensitise tumour cells to 
ATRi, both in vivo and in vitro, by triggering premature mitotic entry, genomic instability 
and apoptosis (Williamson, Miller et al. 2016). This SL has been established in the 
context of ovarian clear carcinomas, where loss of ARID1A is a common event 
(Katagiri, Nakayama et al. 2012, Lowery, Schildkraut et al. 2012). One of the multiple 
functions attributed to ARID1A consists in its recruitment to double stand breaks 
(DSB), via its interaction with the upstream DNA damage checkpoint kinase ATR. 
ARID1A seems to facilitate efficient processing of DSB to single-strand ends and 
sustains DNA damage signalling (Shen, Peng et al. 2015). ARID1A mutations have 
been reported in around 20% of GCs (Wang, Kan et al. 2011, Cancer Genome Atlas 
Research 2014, Wu, Wang et al. 2014, Cristescu, Lee et al. 2015), being associated 
with MSI, upregulation of the PI3K pathway, and wild type TP53 status (Cancer 
Genome Atlas Research 2014, Cristescu, Lee et al. 2015, Kim, Jung et al. 2015, Han, 
Kim et al. 2016, Lee, Yu et al. 2017). Whether ARID1A, through its interaction with 
ATR, plays a role in maintaining genomic integrity that could be exploited as a 
therapeutic liability by the use of ATRi, remains unresolved in GC.  
 
To assess if the previously described synthetic lethal effect of ATR inhibition in 
ARID1A deficient models (Williamson, Miller et al. 2016), was also applicable to GC, I 
characterised a panel of six commonly available gastric tumour cell lines, as well as 
the isogenic HCT 116 ARID1A WT and null colorectal tumour cell lines, that represent 
controls for ARID1A expression and ATRi sensitivity.  
Additionally, I included the YCC6 gastric tumour cell line, as a gift from Professor Sun 
Young Rha from the Yonsei Cancer Center in South Korea. First, I undertook 
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microsatellite analysis of these tumour cell lines. Five microsatellite markers (NR27, 
NR21, NR24, BAT25 and BAT26) were assessed using a multiplex PCR assay system 
(Buhard, Cattaneo et al. 2006, Patil, Bronner et al. 2012, Pagin, Zerimech et al. 2013). 
This analysis revealed MSI in SNU 1, SNU 638 and HCT 116 cell lines (Table 4).  
Next, I performed whole-exome DNA sequencing to identify the mutational profile 
across this panel of tumour cells line (Table 4 and Table 5). Generally, MSI cells were 
found to harbour a larger number of mutations compared with the microsatellite stable 
ones (MSS), as expected from cells with the inability to repair mismatch defects that 
can arise from DNA duplication. Information about cancer genome census gene 
mutations of all cell lines can be found in Table 5. More specifically, our exome-
sequencing results confirmed the presence of ARID1A loss of function mutations in 
SNU 1, SNU 5, YCC6 and the HCT 116 ARID1A deficient cell line (ARID1A deficient 
group). SNU 638 possessed a heterozygous frameshift mutation in ARID1A, while no 
ARID1A mutations were detected in SNU 484, NCI N87, AGS and HCT 116 WT cells 
(ARID1A proficient group) (Table 6, Figure 1A). The ARID1A loss of function 
mutations detected in the GC tumour cell lines comprised truncating mutations; large 
deletions or frameshift indels that resulted in premature stop codons (Table 6). The 
variation of ARID1A expression was confirmed by qPCR mRNA measuring (Figure 
1B), and protein expression was determined by western blotting (Figure 1C). 
Reduced mRNA levels and loss of protein expression were found in the GC tumour 
cell lines harbouring homozygous loss of function ARID1A mutations, although these 
two features were not highly correlated in a quantitative way (Figure 1B and Figure 
1C), consistent with a model of post-transcriptional regulation of ARID1A previously 
reported by others (Wiegand, Shah et al. 2010, Wu, Wang et al. 2014, Kartha, Shen 
et al. 2016, Roumeliotis, Williams et al. 2017). Even though the SNU 638 GC tumour 
cell line showed to have a heterozygous frameshift deletion, I found normal ARID1A 
protein expression levels, as well of mRNA levels, compared with the ARID1A 
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Table 5. Exome sequencing mutations listed in the Cancer Genome Census found in our 
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PEB3      
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CSMD3              
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UX1   
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EGFR         
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ELN             
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STAT3             
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TEC     
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TMEM127             
TNC             
TNFRSF14             
TO 1             
TP53 
TP63  
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TRIM33             
TRIP11             
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TSHR              
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Table 6. ARID1A mutations and characteristics identified from exome sequencing of gastric 
tumour cell lines and HCT 116 colorectal ARID1A isogenic pair. Large deletions in SNU 5 
and YCC6 were defined by the absolute lack of reads along the deleted area.  
 
 
Sensitivity to ATR inhibition in gastric tumour cell lines. 
To test if ARID1A deficient tumour cell lines showed an enhanced sensitivity to ATR 
inhibition, compared with the ARID1A proficient tumour cell lines, 5-day drug exposure 
dose-response sensitivity curves were carried out in 384-well plates. Cells were 
exposed to one of two different small molecule ATRi, VX970 and AZD6738. I found 
that the HCT 116 isogenic ARID1A deficient cell line was sensitive to both VX970 and 
AZD6738, compared with the HCT 116 ARID1A proficient cell line (two-way ANOVA 
p-value< 0.001 for both ATRi) (Figure 2A and 2B). Furthermore, YCC6 and SNU 5 
GC tumour cell lines, both of which harbour large homozygous ARID1A deletions and 
complete loss of protein expression, displayed profound sensitivity to both small 
molecule ATRi (SF50 = 0.054nM and 0.082nM respectively), whereas SNU 1, 
harbouring two frameshift ARID1A mutations, showed moderate sensitivity (SF50 = 
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SNU 5 Complete 
deletion 
Deletion - Homozygous - 
SNU 484 - - - - - 
SNU 638 1:27092739 Frameshift 
del  
AG>A Heterozygous X921X 
NCI N87 - - - - - 




Deletion - Homozygous - 
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with the GC tumour cell lines with ARID1A deletions (AGS SF50 = 0.452nM, SNU 484 
SF50>1µM, NCI N87 SF50 = 260nM) (Figure 2C, Figure 2E). I also analysed the area 
under the curve (AUC) values for GC tumour cell lines with proficient ARID1A 
expression compared with those that are ARID1A deficient and noticed a trend to 
higher sensitivity levels in the ARID1A deficient models, although this difference was 
not statistically significant (VX970 Mann Whitney p-value = 0.057, AZD6738 Mann 
Whitney p-value = 0.114) (Figure 2D and Figure 2F). 
 
 
Figure 1. Characterisation of ARID1A status in GC tumour cell lines. A. Representation 
of protein coding sequences and major domains in ARID1A. ARID1A gene deletions in YCC6 
and SNU 5 GC tumour cell lines are illustrated in orange and blue, respectively. The ARID1A 
mutations in SNU 638 and SNU 1 GC tumour cell lines are shown in green and purple, 
respectively. The location of the ARID1A frameshift mutation in the ARID1A deficient HCT 116 
isogenic colorectal cell line in illustrated in red. B. Relative levels of ARID1A mRNA expression 
measured by quantitative PCR in GC tumour cell line panel. HCT 116 ARID1A WT (+/+) and 
ARID1A deficient (-/-) isogenic colorectal tumour cell lines are positive and negative controls. 
C. Western blot showing loss of ARID1A protein expression in the GC tumour cell lines 
harbouring truncating mutations or gene deletions in ARID1A. HCT 116 ARID1A +/+ and 
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Figure 2. Sensitivity to ATR inhibition in ARID1A deficient GC tumour cell lines. A. Drug 
sensitivity curves showing increased sensitivity to ATR inhibition (VX970) in ARID1A deficient 
compared with ARID1A proficient HCT 116 isogenic colorectal tumour cell line (two-way 
ANOVA, p<0.001) B. Drug sensitivity curves showing increased sensitivity to ATR inhibition 
(AZD6738) in ARID1A deficient compared with ARID1A proficient HCT 116 isogenic colorectal 
tumour cell line (two-way ANOVA, p<0.001). C. Drug sensitivity curves for VX970 across the 
panel of gastric tumour cell lines. D. Box and whiskers plot showing no statistical difference in 
sensitivity to VX970 (AUC) in ARID1A deficient compared with ARID1A proficient GC tumour 
cell lines (Mann-Whitney U, p=0.057) E. Drug sensitivity curves for AZ6738 across the panel 
of gastric tumour cell lines. F. Box and whiskers plot showing no statistical difference in 
sensitivity to AZD6738 (AUC) in ARID1A deficient GC tumour cell lines compared with 
ARID1A proficient GC tumour cell lines (Mann-Whitney U, p=0.1143). Cells were seeded in 
384-well plates and exposed to a 5-days treatment across 8 different concentrations of drug, 
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PARP inhibitor sensitivity in gastric tumour cell lines. 
ARID1A deficiency has been shown to sensitise tumour cells to PARP inhibitors 
(PARPi) in vitro and in vivo, through the impairment of the checkpoint activation and 
repair of DNA DSBs, which could also provide a potential therapeutic strategy for 
patients with ARID1A-mutant tumours (Shen, Peng et al. 2015).   
In relation to this, I wanted to explore whether the ARID1A deficient GC tumour cell 
lines were also sensitive to the clinical PARPi, olaparib and talazoparib (BMN673). I 
generated PARPi sensitivity curves in a 5-day 384-well plates format and I found that 
there was a difference in the sensitivity to talazoparib in the HCT 116 ARID1A deficient 
cell line compared with HCT 116 WT (two-way ANOVA p-value <0.001) (Figure 3A), 
but no difference in sensitivity for olaparib (two-way ANOVA ns) (Figure 3B). This 
could be explained by the fact that talazoparib has a higher capacity to trap PARP into 
the DNA than olaparib (Murai, Huang et al. 2014), and this ability has been shown to 
be directly associated with the capacity of the PARPi to kill tumour cells (Shen, Aoyagi-
Scharber et al. 2015).  
In contrast, no difference in PARPi sensitivity relating to ARID1A status was seen 
when I tested these same inhibitors in the panel of GC tumour GC (AUC values 
comparison between the ARID1A proficient cell lines with the deficient ones for 
olaparib, Mann Whitney p-value = 0.999; talazoparib, Mann Whitney p-value = 0.628) 
(Figure 3C-3F), suggesting an independent or, at least non-exclusive ARID1A-
mediated response to PARPi in these GC models.  
 
Small molecule inhibition to PI3K, HDAC6 and EZH2 in GC tumour cell lines 
As mentioned earlier, ARID1A mutations often correlate with PI3K pathway 
upregulation in patient samples (Samartzis, Noske et al. 2013, Cancer Genome Atlas 
Research 2014, Huang, Lin et al. 2014, Cristescu, Lee et al. 2015). This phenomenon 
has been described in various histologies, including GC (Cancer Genome Atlas 
Research 2014, Cristescu, Lee et al. 2015, Zhang, Yan et al. 2016). It is therefore 
unsurprising that PI3K inhibitors (PI3Ki) have been reported to be especially potent in 
ARID1A deficient cells (Zhang, Yan et al. 2016, Lee, Yu et al. 2017, Yang, Yang et al. 
2018). Considering the published literature, I exposed the HCT 116 isogenic cell lines 
as well as the panel of GC tumour cell lines with the pan-PI3Ki BKM120 and AKT 
inhibitor MZ2206, in a 384-well plate format over 5 days, to assess whether the  
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Figure 3. PARP inhibition in GC tumour cell lines. A. Drug sensitivity curves showing 
increased sensitivity to PARPi (talazoparib) in ARID1A deficient HCT 116 compared with 
ARID1A proficient isogenic HCT 116 colorectal tumour cell line (two-way ANOVA p-
value<0.001). B. Drug sensitivity curves showing no difference in sensitivity to PARPi 
(olaparib) in ARID1A deficient HCT 116 compared with ARID1A proficient isogenic HCT 116 
colorectal tumour cell line. C. Drug sensitivity curves to olaparib in the panel of GC tumour cell 
lines. D. Box and whiskers plot showing no difference in sensitivity to olaparib in ARID1A 
deficient compared with ARID1A proficient GC tumour cell lines (Mann-Whitney U, p=0.999) 
E. Drug sensitivity curves to talazoparib in the panel of GC tumour cell lines. F. Box and 
whiskers plot showing no difference in sensitivity to talazoparib in ARID1A deficient compared 
with ARID1A proficient GC tumour cell lines (Mann-Whitney U, p=0.628). Cells were seeded 
in 384-well plates and exposed to a 5-days treatment across 8 different concentrations of drug, 
ranging between 0.0001μM to 1μM for talazoparib or from 0.001μM to 10μM for olaparib. Error 



















































































































































ARID1A deficient genotype also conferred sensitivity to these inhibitors in our models. 
I found that the HCT 116 ARID1A deficient cells showed enhanced sensitivity to 
BKM120 compared with the HCT 116 ARID1A proficient (two-way ANOVA <0.001) 
(Figure 4A). However, I did not find any difference in sensitivity when I compared the 
both isogenic cells after exposing them to MK2206 (two-way ANOVA p-value = ns) 
(Figure 4B). Furthermore, ARID1A expression did not account for any differences in 
sensitivity to BKM120 or MK2206 in the panel of GC tumour cell lines (Figure 4C-4F).  
 
Due to the fact that PIK3IP1 is a negative regulator of PI3K/AKT pathway which has 
been identified as a direct ARID1A/EZH2 target, that seems to contribute to the EZH2 
inhibition synthetic lethal effect in ARID1A deficient cell lines (Bitler, Aird et al. 2015), 
I decided to test whether the ARID1A deficient cell lines were also sensitive to the 
GSK126 EZH2 inhibitor (EZH2i). I also undertook experiments using the HDAC6 
inhibitors, as ARID1A mutations have been shown to inactivate the apoptosis-
promoting function of p53 by upregulating HDAC6, indicating that pharmacological 
inhibition of HDAC6 could be a therapeutic strategy for ARID1A-mutated cancers 
(Bitler, Wu et al. 2017). 
 
Following these reports, I assessed HDAC6 (ACY1215) and EZH2i (GSK 126) 
sensitivity across the panel of GC tumour cell lines. Although these compounds have 
shown promising activity in ovarian ARID1A deficient models (Bitler, Aird et al. 2015, 
Bitler, Aird et al. 2016, Bitler, Wu et al. 2017, Fukumoto, Park et al. 2018), I did not 
detect any significant differences in sensitivity to ACY1215 inhibitor or GSK 126 
inhibitor associated with ARID1A expression in the HCT 116 ARID1A isogenic cell 
lines, nor across the panel of GC tumour cell lines (Figure 5A-5F), in a 5-day-38 well 
plate format. Taken together, this data suggested that the previously reported SL 
relationships between ARID1A and small molecule inhibitors of PI3K, EZH2 or HDAC6 





Figure 4. PI3K inhibition in GC tumour cell lines. A. Drug sensitivity curves showing 
increased sensitivity to BKM120 (pan-PI3K inhibitor) in ARID1A deficient HCT 116 compared 
with ARID1A proficient isogenic HCT 116 colorectal tumour cell line (two-way ANOVA p-
value<0.001). B. Drug sensitivity curves showing no difference in sensitivity to MK2206 (AKT 
inhibitor) in ARID1A deficient HCT 116 compared with ARID1A proficient isogenic HCT 116 
colorectal tumour cell line. C. Drug sensitivity curves to BKM120 in the panel of GC tumour 
cell lines. D. Box and whiskers plot showing no difference in sensitivity to BKM120 in ARID1A 
deficient compared with ARID1A proficient GC tumour cell lines (Mann-Whitney U, p=0.857) 
E. Drug sensitivity curves to MK2206 in the panel of GC tumour cell lines. F. Box and whiskers 
plot showing no difference in sensitivity to MK2206 in ARID1A deficient compared with 
ARID1A proficient GC tumour cell lines (Mann-Whitney U, p=0.228).  Cells were seeded in 
384-well plates and exposed to a 5-days treatment across 8 different concentrations of drug, 
ranging between 0.001μM to 10μM for both inhibitors. Error bars represent standard deviation 
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Figure 5. HDAC6 and EZH2 inhibition in GC tumour cell lines. A. Drug sensitivity curves 
showing no difference in sensitivity to ACY1215 (HDAC6 inhibitor) in ARID1A deficient HCT 
116 compared with ARID1A proficient isogenic HCT 116 colorectal tumour cell line. B. Drug 
sensitivity curves showing no difference in sensitivity to GSK126 (EZH2 inhibitor) in ARID1A 
deficient HCT 116 compared with ARID1A proficient isogenic HCT 116 colorectal tumour cell 
line. C. Drug sensitivity curves to ACY1215 in the panel of GC tumour cell lines. D. Box and 
whiskers plot showing no difference in sensitivity to ACY1215 in ARID1A deficient compared 
with ARID1A proficient GC tumour cell lines (Mann-Whitney U, p=0.800) E. Drug sensitivity 
curves to GSK126 in the panel of GC tumour cell lines. F. Box and whiskers plot showing no 
difference in sensitivity to GSK1215 in ARID1A deficient compared with ARID1A proficient GC 
tumour cell lines (Mann-Whitney U, p=0.227).  Cells were seeded in 384-well plates and 
exposed to a 5-days treatment across 8 different concentrations of drug, ranging between 





















HCT 116 ARID1A +/+

















HCT 116 ARID1A +/+










































































































ATRi and PARPi combination screens 
Because ATRi and PARPi combination could represent a promising strategy for 
cancer patients with defects in DNA repair genes (Jones, Fleuren et al. 2017), and this 
strategy is currently being evaluated in the context of clinical trials (e.g. NCT03462342 
or NCT02264678), I wanted to see if the addition of PARPi to ATRi exposure could 
enhance the sensitivity in our models. The 5-day dose-response assays showed 
enhanced sensitivity to the ATRi + PARPi combination in all cases (VX970/AZD6738 
+ olaparib/talazoparib) in the ARID1A deficient cells, both in the gastric panel (Figure 
6A and 6B) and the HCT 116 isogenics (Figure 6C and 6D). Although the ARID1A 
proficient models were generally less sensitive to the combination treatment, some of 
them presented a good response, as in the case of NCI N87 (Figure 6A and 6B). 
Area under the curve (AUC) analysis of dose-response curves was performed for the 
HCT 116 isogenic pair, confirming a decrease in the surviving fraction of cells in the 
ARID1A deficient cells, compared with ARID1A WT cells, especially when I combined 
VX970 with both PARPi (Figure 6E). 
 
ATR and PI3K inhibitors combination screens 
Despite the modest described effect of PI3Ki in our panel of gastric cell lines, I decided 
to determine if the addition PI3Ki to ATRi increased the sensitivity of tumour cells in 
those cell lines that were deficient for ARID1A, as they might not operate together in 
the same pathway or not be effective in monotherapy, but could still have an impact 
in combination, through the impairment of a compensatory mechanism to ATR 
inhibition in ARID1A deficient models by the upregulation of PI3K pathway. 
Differences between ARID1A deficient group of cells and ARID1A WT cells, were less 
evident in the case of ATRi plus PI3Ki combinations, although significant cell kill was 
observed in the case of YCC6, SNU 5 and SNU 1 ARID1A deficient cell lines when I 
combined both ATRi with both PI3Ki (Figure 7A and 7B). A modest effect was also 
observed in the HCT 116 isogenics, both for the surviving fraction analysis (Figure 7 
C and 7D) and for the AUC analysis (Figure 7E). Generally, BKM120 seemed to have 







Figure 6. ATR and PARP inhibitor combination in GC tumour cell lines. A. Surviving 
fraction heatmap showing sensitivity to ATRi in combination with talazoparib in all GC tumour 
cell lines. Blue shading represents a high surviving cellular fraction and white represents a low 
surviving cellular fraction, The Y axis shows ATRi concentrations (µM) and the X axis shows 
concentrations of PARPi (µM). B. Surviving fraction heatmap showing sensitivity to ATRi in 
combination with olaparib in all GC tumour cell lines. C. Surviving fraction heatmap showing 
HCT 116 isogenic cells sensitivity to ATRi in combination with increasing doses of talazoparib. 
D. Surviving fraction heatmap showing HCT 116 isogenic cells sensitivity to ATRi in 
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Figure 6 (continuation). E. Histograms showing differences in AUC between HCT 116 WT 
and HCT 116 ARID1A deficient cell line among all ATRi and PARPi combinations. Cells were 
seeded in 384-well plates and exposed to a 5-days treatment across 8 different concentrations 
ranging between 0.0001μM to 1μM for VX970, AZD6738 and BMN673 or 0.001μM to 10μM 
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Figure 7. ATR and PI3K inhibitors combination in GC tumour cell lines. A. Surviving 
fraction heatmap showing sensitivity to ATRi in combination with BKM120 in all GC tumour 
cell lines. Blue shading represents a high surviving cellular fraction and white represents a low 
surviving cellular fraction, The Y axis shows ATRi concentrations (µM) and the X axis shows 
concentrations of PARPi (µM). B. Surviving fraction heatmap showing sensitivity to ATRi in 
combination with MK2206 in all GC tumour cell lines. C. Surviving fraction heatmap showing 
HCT 116 isogenic cells sensitivity to ATRi in combination with increasing doses of BKM120. 
D. Surviving fraction heatmap showing HCT 116 isogenic cells sensitivity to ATRi in 





























































































































































































































































































































































































































Figure 7 (continuation). E. Histograms showing differences in AUC between HCT 116 WT 
and HCT 116 ARID1A deficient cell line among all ATR and PI3K inhibitor combinations. Cells 
were seeded in 384-well plates and exposed to a 5-days treatment across 8 different 
concentrations ranging between 0.0001μM to 1μM for VX970 and AZD6738 or 0.0001μM to 
10μM for BKM120 and MK2206. Error bars represent standard deviation between reps (n=4). 
 
Creation of ARID1A isogenic models to assess ARID1A-driven ATR inhibition 
sensitivity 
Given the limited number of cell lines in the GC cell line panel used in the experiments 
described above, I thought I might be underpowered to detect differences in drug 
sensitivity associated with ARID1A expression. Furthermore, every tumour cell line 
has a different mutational background (specially in the case of the MSI models), which 
can influence the outcome of the treatment sensitivity. Additionally, the isogenic model 
I used as a control, the HCT 116 cell line is a MSI colorectal cell line, which does not 
represent the gastric rumour genetic background. Consequently, I decided to create a 
new gastric isogenic model, using the CRISPR/Cas9 technique, selecting the MSS, 
ARID1A WT, and most ATRi resistant cell line of our panel, SNU 484, in order to 
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After two consecutive rounds of CRISPR/Cas9 mutagenesis, using three different 
gRNAs, and following an extensive clone-screening, I came to the conclusion that 
SNU 484 cells were addicted to at least a basal ARID1A expression, as any of the 
surviving clones harboured a homozygous ARID1A mutation, and thus complete 
ARID1A loss. I then selected a clone with an 8-nucleotide heterozygous deletion (DNA 
change: g.687_694delAACGCGGG: protein change: N106Pfs*2) according to the 
Sanger sequencing results (Figure 8A). This clone, showed a significantly lower 
mRNA expression when compared with the ARID1A WT cells (CRISPR negative 
control) (Figure 8B), and undetectable ARID1A protein expression (Figure 8C), 
despite its heterozygosity (Figure 8A). Regardless of the remaining of the WT allele, 
I thought it was a valuable isogenic model, as haploinsufficiency phenomenon 
(phenotype is present even with a partial loss of the functional alleles with gene 
dosage effect) seems to operate within the ARID1A deficiency context (Wiegand, 
Shah et al. 2010, Wu, Wang et al. 2014, Kartha, Shen et al. 2016). I thought this could 
be relevant in our model, and thus it could mimic what happens in patients (Wu and 
Roberts 2013, Wu, Wang et al. 2014). When I tested for ATRi sensitivity response 
over five days, I saw that ARID1A deficient cells were significantly more sensitive to 
ATR inhibition compared with the wild type cells, both in the case of VX970 (Two-way 
ANOVA p-Value < 0.001) (Figure 8D) and in the case of AZD6738 (Two-way ANOVA 
< 0.001) (Figure 8E). Moreover, I found than ARID1A mutated cells had a higher 
proliferative rate, compared with the WT cells, which is consistent with a tumour 
suppressor gene role (Wu, Wang et al. 2014), although ARID1A appears to not be a 
pure tumour suppressor gene, being involved in gene expression regulation, genome 
maintenance and repair (Wu, Wang et al. 2014, Sun, Wang et al. 2018). I then 
validated these results using an orthogonal method, silencing ARID1A using siRNAs 
in SNU 484 and AGS cell lines. ARID1A silenced cells showed increased sensitive to 
both VX970 and AZD6738 inhibitors (SNU 484 and AGS two-way ANOVA p-value 
<0.001 for both inhibitors), although the effect was less profound than in the case of 
the CRISPR/Cas9 mutated isogenic cells (Figure 8H-8L).  
I finally tested for the ATRi and PARPi combination in the SNU 484 isogenic cell line, 
not finding a profound difference in the survival fraction nor in the AUC values of cells 
to any combination when I compared ARID1A deficient and proficient cells (Figure 9A 




Figure 8. Enhanced ATRi sensitivity in SNU 484 ARID1A deficient isogenic GC tumour 
cell lines. A. ARID1A sequence alignment by ApE software in 6 TOPO cloned colonies from 
SNU 484 ARID1A CRISPR/Cas9 mutated cell line, shows an 8-nucleotide deletion (DNA 
change: g.687_694delAACGCGGG: aminoacid change: N106Pfs*2) in 50% of the sequences 
(red), when compared with the consensus sequence (green). SNU 484 ARID1A isogenic 
tumour cells created using the CRISPR/Cas9 technique, using a gRNA towards ARID1A 
sequence or a gRNA no homology to any known mammalian gene as a negative control. All 
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cell lines where plated in 384-well plates and exposed to a 5-days treatment across 8 different 
concentrations ranging between 0.0001μM to 1μM of both drugs. Error bars represent 
standard deviation between reps (n=14). B. and C ARID1A relative quantitative PCR mRNA 
levels and western blot protein expression in SNU 484 isogenic cell line, respectively. D. 
VX970 dose response cell survival curves for the gastric SNU 484 ARID1A E. AZD6738 dose 
response cell survival curves for the gastric SNU 484 ARID1A isogenic tumour cells F. 16-
days proliferation curves generated using the IncuCyte Zoom Live Cell Analysis System 
(essenbio) comparing SNU 484 GC ARID1A isogenic cells G. WB showing a reduction in 
ARID1A protein in SNU 484 using lysates corresponding to siRNA Knockdown experiments 
H and I. H. Drug sensitivity curve to VX970 for SNU 484 GC cell line, after reverse transfection 
with siRNA targeting ARID1A (green) or with a siRNA control that has no homology to any 
known mammalian gene (siAllstar, black). I. Drug sensitivity curve to AZD6738 for SNU 484 
GC cell line, after reverse transfection with siRNA targeting ARID1A (green) or with a siRNA 
control that has no homology to any known mammalian gene (siAllstar, black). J. WB showing 







Figure 8 (cont.) K and L. K. Drug sensitivity curve to VX970 for AGS GC cell line, after 
reverse transfection with siRNA targeting ARID1A (green) or with a siRNA control that has no 
homology to any known mammalian gene (siAllstar, black). L. Drug sensitivity curve to 
AZD6738 for AGS GC cell line, after reverse transfection with siRNA targeting ARID1A (green) 
or with a siRNA control that has no homology to any known mammalian gene (siAllstar, black). 
48h after transfection, cells were exposed to the ATRi across 8 different concentrations 
ranging between 0.0001μM to 1μM of drug for 4 days. Error bars represent standard deviation 























































Figure 9. Sensitivity to ATR inhibition in combination with PARP inhibition in ARID1A 
deficient isogenic GC tumour cell lines. A. Surviving fraction heatmap showing SNU 484 
ARID1A isogenic cell lines sensitivity to ATRi in combination with PARPi. Cells where seeded 
in 384-well plates by triplicate and exposed to a 5-days treatment of VX970 or AZD6738, in 
combination with talazoparib or olaparib. Y axis shows ATRi concentrations in an µM scale, 
while X axis shows PARPi concentrations in µM. B. Histograms showing differences in AUC 
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2. In vivo assessment of ATRi Efficacy in Gastric Cancer 
Patient-Derived Xenografts 
 
Patient-derived xenografts (PDX) consist of tumour fragments originated in patients, 
that are directly implanted and cultured in immunodeficient mice. PDXs have become 
an important tool for translational cancer research, as they conserve the cellular and 
histological structure of the tumour originated in the patient, as well as the genetic 
profile present in the original tumour (Reyal, Guyader et al. 2012, Tentler, Tan et al. 
2012), which makes them optimal for the evaluation of therapeutic responses (Pompili, 
Porru et al. 2016). PDXs represent valuable models to predict the effect that a drug is 
going to have in a particular genetic context or an individual patient from which it has 
been derived, and their use has become common in translational cancer medicine, 
where the aim is to deliver treatments that are tailored according to the individual 
(Pompili, Porru et al. 2016). 
 
I selected several GC PDX from CROWNbio database, with the aim of validating the 
ARID1A and ATR SL found in the GC cell lines. 
Following statistical power calculations, assuming normal distribution, and considering 
an effect larger than 75%, an α lower than 0.05, and a ß higher than 0.95 as significant, 
I determined the number of animals were needed on each arm, to have the statistical 
power to detect true differences. Thus, the experiments were carried out in a total of 
7 mice per arm, in 6 arms. 
M4344, rather than VX970 was used, as M4344 is an oral compound that has 
previously been observed in other tumour models to have superior in vivo efficacy, 
and it is currently being assessed in phase I clinical trials in monotherapy or in 
combination with PARPi.  
I annotated ARID1A mutations detected by whole exome sequencing within the PDXs 
reported by CROWNbio, and validated these mutations using the Ion Torrent 
sequencing platform and a pre-designed panel of genes that included ARID1A. 
Furthermore, tumours were characterised for microsatellite instability status by 
sequencing a panel of five markers. Only one PDX presented MSI and it was the GC2 
ARID1A deficient model. Information about the PDX models is listed in Table 7.  
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Table 7. Information about the PDX models 
 
 
The design of the PDX experiment is shown in Figure 10. Briefly, four ARID1A 
deficient PDX models and 3 ARID1A proficient models were selected. Interestingly, 
some of the models with ARID1A mutations seemed to be heterozygous for the 
mutations (according to the frequency of sequencing reads), but they showed a 
complete loss of protein. This is consistent to what has previously been reported in 
the ARID1A SNU 484, where a heterozygous mutation of ARID1A showed a complete 
loss of protein expression. This has also been described in patients by IHC of tumours 
with mutations in ARID1A (Wiegand, Shah et al. 2010, Wu, Wang et al. 2014, Kartha, 
Shen et al. 2016). Tumours were then processed and implanted into mice and 
randomised into different arms, at a final number of 7 mice per arm, and treated with 
either vehicle; M4344 20mg/kg, M4344 10mg/kg, M4344 3mg/kg, talazoparib 0.1 
mg/kg and ATRi M4344 3mg/kg + talazoparib 0.1 mg/kg, all treatments given by oral 
gavage. Mice were treated for several weeks and tumour volume and body weigh was 
monitored twice a week. In the event of resistant tumour growth, tumours reaching 
1000mm3 were collected to be molecular characterised for further ATRi resistance 
prospective studies (Figure 10). Model GC1, the first PDX model to undergo drugging 
with M4344, was used to optimise the dose and scheduling for the remaining 
experiments. The subsequent experiments were treated with 10mg/kg twice a week 
or 5 mg/kg M3433 daily, as severe body weight loss was noted in mice receiving the 
highest doses of ATRi. Although the reduced dose and modified scheduling of M4344 














GC1 Yes Yes Very	slow 982del	(41),	
P1349Lfs*132	(64)
No No
GC2 No Yes Slow K1072Nfs*21	 (48) No Yes
GC3 Yes No Slow 982_982del	 (52),	
P2139fs	(40)
No No
GC4 Yes Yes Slow K1072Nfs*21	 (50) No No
GC5 Yes No Fast - Yes No
GC6 Slight	body	
weight	loss
Yes Moderate - Yes No




Figure 10. PDX experimental design. Four ARID1A deficient PDX models and 3 ARID1A 
proficient models were selected from CROWNbio database and validated for ARID1A 
mutations (Ion Torrent NGS) and protein expression by Next-Generation Sequencing (NGS) 
and IHC, respectively. Tumours were then processes and implanted into Balb/c nude mice 
with a body weight of approximately 20g. When tumours reached an approximate volume of 
100-200mm3, mice were randomised to different arms, at a final number of 7 mice per arm, 
and treated with either vehicle, M4344 20mg/kg daily, M4344 10mg/kg daily, ATRi M4344 
3mg/kg daily, talazoparib 0.1 mg/kg 2x daily and ATRi M4344 3mg/kg daily + talazoparib 0.1 
mg.kg 2x daily, all treatments given by oral gavage. Mice were treated for several weeks while 
tumour volume and body weigh was monitored twice a week. In the event of resistant tumour 
growth, tumours reaching 1000mm3 were collected to be molecular characterised for further 
ATRi resistance mechanism studies. All in vivo experiments were performed by CrownBio 
company. 
 
Despite this, all PDX models with an ARID1A deficiency (GC1-GC4) showed a 
significant growth inhibition to ATRi treatment when compared with the vehicle, in a 
dose-dependent way (Figures 11C-14C, two-way ANOVA p-values <0.0001). In the 
case of the ARID1A proficient models, two of them did not show a profound sensitivity 
to the ATRi monotherapy (GC5 and GC6) (Figures 15C-16C), although mild 
differences could be detected.  However, model GC7, also ARID1A proficient, showed 
a profound effect in terms of tumour inhibition in response to M4344, that was dose 
dependent (Figure 17C). Next, I wanted to see if the addition of PARPi could show an 
enhancement to the sensitivity to ATRi, as I had seen in the cell lines. Previous studies 
report a sensitisation to PARPi in ARID1A deficient models (Shen, Peng et al. 2015, 
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belonging to the ARID1A deficient models were treated with the ATRi + PARPi 
combination, I could see a clear enhancement of the response for the combination 
arm, compared with the monotherapies or vehicle, suggesting a synergy between the 
two drugs (Figures 11D-14D, two-way ANOVA p-values < 0.0001). The effect seen in 
the GC5 and GC6 ARID1A proficient models was much less evident, showing a very 
modest separation in between the different treatments (Figures 15D-16D). Again, the 
GC7 model proved to be exquisitely sensitive to ATRi, although being ARID1A 
proficient (Figure 17D).  
 
Taken together, it is evident that a dose-dependent tumour inhibition to M4344 was 
elicited in ARID1A deficient PDX models. However, sensitivity is not restricted to the 
ARID1A deficient context, as marked tumour inhibition was also observed in the 
ARID1A proficient model GC7.  Comparison of data from whole exome sequencing, 
RNA sequencing and proteomics between the vehicle and ATRi treated tumours will 





Figure 11. GC1 ARID1A deficient PDX is highly sensitive to ATR inhibition. A. HCT 116 
colorectal isogenic cell line was used as a positive control for the ARID1A expression testing 
by IHC, using the D2A8U ARID1A antibody (CST) at a 1:250 dilution. B. FFPE sections from 
the tumour was stained for ARID1A expression showing complete protein loss, according to 
the controls. C and D. Average of tumour volume measurements of all mice in each group 
along time and ATRi treatment (C) or ATR + talazoparib treatment (D). Error bars represent 
Standard error of the mean (n=7). Two-way ANOVA p-values of groups M4344 20mg/kg, 
10mg/kg, 3mg/kg and 3mg/kg + talazoparib were lower than 0.0001. Dotted line represents 
the end of the treatment due to body weight loss >25% in some of the groups. D.  Box and 
whiskers representation showing the differences between the final tumour volume in between 
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Figure 12. GC2 ARID1A deficient PDX is highly sensitive to ATR inhibition. A. HCT 116 
colorectal isogenic cell line was used as a positive control for the ARID1A expression testing 
by IHC, using the D2A8U ARID1A antibody (CST) at a 1:250 dilution. B. FFPE sections from 
the tumour was stained for ARID1A expression showing complete protein loss, according to 
the controls. C and D. Average of tumour volume measurements of all mice in each group 
along time and ATRi treatment (C) or ATR + talazoparib treatment (D). Error bars represent 
Standard error of the mean (n=7). Two-way ANOVA p-values of groups M4344 10mg/kg, 
5mg/kg, 3mg/kg and 3mg/kg + talazoparib were lower than 0.0001. Dotted line represents the 
end of the treatment due to body weight loss >25% in some of the groups. D.  Box and 
whiskers representation showing the differences between the final tumour volume in between 
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Figure 13. GC3 ARID1A deficient PDX is highly sensitive to ATR inhibition. A. HCT 116 
colorectal isogenic cell line was used as a positive control for the ARID1A expression testing 
by IHC, using the D2A8U ARID1A antibody (CST) at a 1:250 dilution. B. FFPE sections from 
the tumour was stained for ARID1A expression showing complete protein loss, according to 
the controls. C and D. Average of tumour volume measurements of all mice in each group 
along time and ATRi treatment (C) or ATR + talazoparib treatment (D). Error bars represent 
Standard error of the mean (n=7). Two-way ANOVA p-values of groups M4344 10mg/kg, 
5mg/kg and 3mg/kg + talazoparib were lower than 0.0001. Dotted line represents the end of 
the treatment due to body weight loss >25% in some of the groups. D.  Box and whiskers 
representation showing the differences between the final tumour volume in between treatment 
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Figure 14. GC4 ARID1A deficient PDX is highly sensitive to ATR inhibition. A. HCT 116 
colorectal isogenic cell line was used as a positive control for the ARID1A expression testing 
by IHC, using the D2A8U ARID1A antibody (CST) at a 1:250 dilution. B. FFPE sections from 
the tumour was stained for ARID1A expression showing complete protein loss, according to 
the controls. C and D. Average of tumour volume measurements of all mice in each group 
along time and ATRi treatment (C) or ATR + talazoparib treatment (D). Error bars represent 
Standard error of the mean (n=7). Two-way ANOVA p-values of groups M4344 10mg/kg, 
5mg/kg and 3mg/kg + talazoparib were lower than 0.0001. Dotted line represents the end of 
the treatment due to body weight loss >25% in some of the groups. D.  Box and whiskers 
representation showing the differences between the final tumour volume in between treatment 
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Figure 15. GC5 ARID1A proficient PDX is mildly sensitive to ATR inhibition. A. HCT 116 
colorectal isogenic cell line was used as a positive control for the ARID1A expression testing 
by IHC, using the D2A8U ARID1A antibody (CST) at a 1:250 dilution. B. FFPE sections from 
the tumour was stained for ARID1A expression showing complete protein loss, according to 
the controls. C and D. Average of tumour volume measurements of all mice in each group 
along time and ATRi treatment (C) or ATR + talazoparib treatment (D). Error bars represent 
Standard error of the mean (n=7). Only two-way ANOVA p-values of the M4344 10mg/kg 
group, were lower than 0.0001. Dotted line represents the end of the treatment due to body 
weight loss >25% in some of the groups. D.  Box and whiskers representation showing the 






































M4344 10mg/kg BID x twice per week p.o.
M4344 5mg/kg BID p.o.






























Talazoparib 0.1mg/kg bd p.o.
M4344 3mg/kg p.o. plus Talazoparib 0.1mg/kg bd p.o.






























Talazoparib 0.1mg/kg bd p.o.
M4344 3mg/kg p.o. plus Talazoparib 0.1mg/kg bd p.o.





























M4344 10mg/kg BID x twice per week p.o.








































































































Figure 16. GC6 ARID1A proficient PDX is mildly sensitive to ATR inhibition. A. HCT 116 
colorectal isogenic cell line was used as a positive control for the ARID1A expression testing 
by IHC, using the D2A8U ARID1A antibody (CST) at a 1:250 dilution. B. FFPE sections from 
the tumour was stained for ARID1A expression showing complete protein loss, according to 
the controls. C and D. Average of tumour volume measurements of all mice in each group 
along time and ATRi treatment (C) or ATR + talazoparib treatment (D). Error bars represent 
Standard error of the mean (n=7). Only two-way ANOVA p-values of the M4344 10mg/kg 
group, were lower than 0.0001. Dotted line represents the end of the treatment due to body 
weight loss >25% in some of the groups. D.  Box and whiskers representation showing the 
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Figure 17. GC7 ARID1A proficient PDX is highly sensitive to ATR inhibition. A. HCT 116 
colorectal isogenic cell line was used as a positive control for the ARID1A expression testing 
by IHC, using the D2A8U ARID1A antibody (CST) at a 1:250 dilution. B. FFPE sections from 
the tumour was stained for ARID1A expression showing complete protein loss, according to 
the controls. C and D. Average of tumour volume measurements of all mice in each group 
along time and ATRi treatment (C) or ATR + talazoparib treatment (D). Error bars represent 
Standard error of the mean (n=7). Two-way ANOVA p-values of groups M4344 10mg/kg, 
5mg/kg and 3mg/kg + talazoparib were lower than 0.0001. Dotted line represents the end of 
the treatment due to body weight loss >25% in some of the groups. D.  Box and whiskers 
representation showing the differences between the final tumour volume in between treatment 
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3. VX970 positive selection Genome-Wide CRISPR/Cas9 
mutagenesis screen 
 
Although ATRi seem to be a promising therapy for DDR defective cancers, resistance 
mechanisms are likely to arise from monotherapy treatments. This can be illustrated 
with the example of Cell Division Cycle 25A gene (CDC25A), which has been 
demonstrated to cause ATRi resistance due to its failure to induce premature mitosis 
when CDC25A protein expression is lost (Ruiz, Mayor-Ruiz et al. 2016). Another 
relevant example of DDR inhibition resistance is the case of the appearance 
resistance-causing reverting mutations in BRCA1/2 deficient cancers in the context of 
PARPi-BRCA1/2 SL (Edwards, Brough et al. 2008, Barber, Sandhu et al. 2013, 
Weigelt, Comino-Mendez et al. 2017). 
To try to understand the mechanisms of resistance most likely to cause disease-
recurrence in GC patients, I carried out a positive selection GW CRISPR-Cas9 
mutagenesis screen (CRISPR screen) using the Kosuke Yusa, Human GW CRISPR 
guide RNA library, encompassing 87,897 single guide (sg)RNAs targeting more than 
17,000 genes) (Koike-Yusa, Li et al. 2014). Using this high-throughput technology, I 
was able to perform multiple pooled reactions of Cas9-mediated and sgRNA-targeted 
mutagenesis, aiming to cause independent protein loss of function (LOF) events. After 
mutagenesis, some of the cells can become resistant to the drug due to a specific 
protein loss, mediated by a particular sgRNA, that can be tracked and detected using 
NGS techniques (Wang, Wei et al. 2014, Aguirre, Meyers et al. 2016, Tzelepis, Koike-
Yusa et al. 2016, Pettitt, Krastev et al. 2018).  
Following this principal, I aimed to identify the genes that are responsible for ATRi 
resistance in YCC6 gastric tumour cell line, to identify novel mechanisms of resistance 
that could, potentially be translated into the clinical practice. A workflow including 
screen optimisation tests, experimental phase and computational analysis required to 




Figure 18. Genome-wide SF0 positive selection CRISPR/Cas9 screen workflow. First, 
Dox inducible Cas9 YCC6 cells were created, sorted into individual clones and tested for Cas9 
expression. One of the clones was selected (clone 9) and Cas9 catalytic activity was assessed 
by the two-fluorescence allele method. Cell seeding density and drug dose was optimised in 
the same format used in the screen. For the screening experiment, Cas9 was induced 24 
hours before the cells were transduced with the lentiviral vectors containing the library of GW 
sgRNA at a low multiplicity of infection, to ensure no more than one sgRNA integration per 
cell. After 5 days of stringent puromycin selection, sample T=0 was taken and cells were 
harvested and re-seeded, 24 h before 100nM VX970 was added to the culture media. Cells 
were drugged twice a week for three weeks. They were then left in drug-free medium for two 
weeks, prior to the harvesting of the resistant cells for sgRNA sequencing (sample T=1). 
Additionally, some resistant colonies were picked and sgRNA inserted in them were sanger 
sequenced. For the computational analysis, FASTQ files were generated from the HiSeq 
sequencing and sgRNA read count data was calculated using MAGeCK algorithm. After 
normalisation of sgRNA counts and quality control check, Z-score and MAGeCK analysis was 
undertaken, comparing T1 to T0 counts, and results were consolidated using MAGeCK and 
Z-score ranking system. Top hits were taken in account for further validation and functional 
enrichment analysis.  
 
First, I transduced YCC6 gastric tumour cells with a Dox-inducible Cas9 expressing 
construct (YCC6iCas9), using the Edit-R Inducible Lentiviral hEF1a-Blast-Cas9 
Nuclease (Dharmacon). One of the Cas9 expressing clones was selected, after a 24h 
of Dox treatment (Clone 9) for further experiments (Western blot showing loss of 
protein expression in clone 9, compared with YCC6 parental cell line is shown in 
Figure 19.A). To determine the efficiency of the CRISPR-Cas9 editing (Cas9 catalytic 













































constructs for the green fluorescent protein (GFP) and red fluorescent protein (Cherry, 
RFP) (GFP/RFP/empty), or with lentiviruses carrying GFP, and a Gfp-targeting gRNA 
(GFP/RFP/Gfp-sgRNA). I then exposed the cells to Dox for 72 hours and changes in 
green and red fluorescence were quantified using flow cytometry. I detected a 
profound decrease in green fluorescence in the GFP/RFP/Gfp-sgRNA cells, 
demonstrating the ability of Cas9 to generate homozygous mutations in our YCC6iCas9 
cells, when induced by the Dox treatment (Figure 19B).  
 
Cell density and drug concentration was optimised before the actual experiment, using 
the same format plates and testing a range of VX970 concentrations in a variety of cell 
densities. A dose of 100nm VX970 in 1 million cells per 15cm plates was selected as 
the surviving fraction = 0 (SF0, or 100% lethal dose). 
 
Following optimisation experiments, I transduced YCC6iCas9 and non-Dox treated cells 
(negative control) with the GW sgRNA library at a low multiplicity of infection (MOI), to 
achieve no more than one sgRNA infection per cell (Figure 19C). After puromycin 
selection, I retrieved T=0 sample and harvested the cells, seeding one million cells per 
15 cm plate, following a final x1000 representation per sgRNA in the library, and 
exposed the cells to 100nM of VX970, a lethal dose for a non-mutated population 
(SF0), twice a week for a total of three weeks, until the negative control cells were 
dead. I left the surviving colonies for two weeks in drug-free media, then picked 24 
resistant colonies, that were expanded and retrieved for further analysis. The 
remaining resistant cells were harvested (T=1 sample) and DNA was extracted and 
prepared for sgRNA counts NGS.   
Following DNA sequencing, the resulting data have been analysed both, through 
determination of a Z-score statistic (where Z=0 represents no effect on viability and 
positive Z-scores represent gain of viability), as well as the Model-based Analysis of 
GW CRISPR/Cas9 Knockout (MAGeCK), method for prioritising sgRNAs, genes and 
pathways in genome-scale CRISPR/Cas9 knockout screens (Li, Xu et al. 2014), to 
provide robust normalisation of the sequenced reads (figure 20A). I observed that 
there was an excellent correlation of the data from our screen when the sgRNA log-
fold change determined by the MAGeCK method was compared with the median Z-
score for each gene (correlation=0.936, p-value<2.2 x 10-308) (Figure 20B). 
	 94	
 
Figure 19. Preparation of the models, dose optimisation and genome-wide 
CRISPR/Cas9 screen workflow. A. YCC6 cells transduced with Edit-R Inducible Lentiviral 
hEF1a-Blast-Cas9 Nuclease vector (Dharmacon) express Cas9 protein, shown by Western 
blot after 24h of 1µg/ml Dox treatment (clone 9). B. iCas9 cells have a catalytic active Cas9. 
Scheme illustrating the two-allele system used to generate inducible-Cas9 YCC6 cells. 
GFP/RFP/Empty cells where transduced with GFP and cherry lentiviral constructs, while 
GFP/RFP/gfp-sgRNA cells where additionally transduced with a sgRNA towards GFP, able to 
cleave GFP protein and thus decreasing green fluorescence when Cas9 active, detected by 
flow cytometry. C. CRISPR screen workflow. On day one, all cells except the Dox – (negative 
control) were treated with 1 µg/ml of Dox. On day two, cells were transduced with the GW 
sgRNA library at a MOI of 0.3. The following day, successfully transduced cells were selected 
in puromycin for 5 days, when they were harvested and seeded in 15 cm plates at a 
determined concentration. On day 9, 100nM VX970 was added to the media and cells were 
left in drug for three weeks, being fed with fresh drug, twice a week. Resistant colonies were 
then left to grow in drug-free media for two more weeks, when resistant colonies or cells where 
retrieved for sequencing. 
 
 
These analyses have allowed us to identify the genes that display the greatest sgRNA 
enrichment in ATRi resistant cells retrieved at T1 (after treatment), compared with cells 
retrieved at T0 (before treatment) (sgRNA fold change). These include, HECT-UBA 
and WWE domain containing 1-E3 ubiquitin protein ligase (HUWE1), SMG8, 
nonsense mediated mRNA decay factor (SMG8), heterogeneous nuclear 
ribonucleoprotein F (HNRNPF), interferon regulatory factor 9 (IRF9), cell division cycle 
B
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25B (CDC25B), signal transducer and activator of transcription 2 (STAT2), SMG9, 
nonsense mediated mRNA decay factor (SMG9), caspase recruitment domain family 
member 10 (CARD10), cleavage stimulation factor subunit 2 tau variant (CSTF2T), 
Rho GTPase activating protein 22 (ARHGAP22), coiled-coil domain containing 7 
(CCDC7), WDFY family member 4 (WDFY4), FXYD domain containing ion transport 
regulator 4 (FXYD4), tyrosine kinase 2 (TYK2), RIC8 guanine nucleotide exchange 
factor A  (RIC8A), myopalladin (MYPN), neuropeptide Y receptor Y4 (NPY4R), 
chromosome 11 open reading frame 86 (C11orf86), CCHC-type zinc finger nucleic 
acid binding protein (CNBP) and TRAF-type zinc finger domain containing 1 
(TRAFD1) (Figure 20C).  
 
The workflow that I used to further validate the hits I found in the NGS results is 
represented in Figure 21. The top 20 candidate genetic determinants of resistance to 
ATR inhibition in the YCC6 gastric tumour cell line were selected from the hits that had 
the highest rank product score (combination of MAGeCK and Z-Score value fold-
change between sample T=1 and sample T=0), and that had positive results for more 
than 2 independent sgRNAs for the targeted gene. 
Additionally, I sanger sequenced the DNA extracted from the picked colonies, to 
identify genes targeted by sgRNA in resistant clones (Table 8).  
 
To avoid any potential off-target effects of the sgRNA identified in the screen, I carried 
out a CRISPR/Cas9 mini-screen arrayed validation experiment. Drug dose was 
optimised by doing a two-weeks exposure drug curve in a 96 well-plate, testing 
different cell concentrations, and selecting the dose-cell concentration where all cells 
died after that time (SF0).  Additionally, transfection conditions (reagents and method) 
was optimised previous to the experiment commencement.  
 
First, infected YCC6iCas9 cells with all sgRNA targeting genes identified as candidate 
genetic determinants of ATR resistance (average of 5 sgRNA per gene), either in the 
picked colonies, or the sequenced resistant population, in a 96-well format, using the 
IncuCyte Zoom Live Cell Analysis System, that monitored cell growth in every well 
after CRISPR/Cas9 mutagenesis. Furthermore, I undertook CTG analysis (Promega) 
at the end of the screen, which is a luminescent cell viability assay where quantitation 
of the ATP present in metabolically active cells is used to determine the number of 
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viable cells in culture. Information regarding the sgRNA used for the validation 
experiment is present in Supplementary Table 2.  
CTG reads showed cell proliferation and hence, VX970 resistance for several wells, 
and this correlated with the growth graphs from the incucyte image analysis. All 5 
sgRNAs towards SMG8 and HNRNPF caused resistance to VX970. 4 out of 5 sgRNAs 
for CDC25B and for CARD10; 3 out of 5 for HUWE1, 2 of 5 for FOXM1 and one sgRNA 
out of 5 for SMG9, STAT2, ZNF592, FXYD4 and JAK1 caused resistance to the ATRi 
(Figure 22), while no proliferative living cells were found in the negative control wells. 
The sgRNA arrayed validation experiment was carried out three times, and an extra 
plate was used to further expand the mutated clones to have them as models for future 
experiments. 
Following the results from the arrayed CRISPR/Cas9 screen validation, GW clone 9 
and 10 picked colonies were used to validate IRF9 and HUWE1 hits as ATRi 
resistance-causing genes. Colony GW9 (IRF9 -/-), carried a sgRNA towards exon 1 of 
IRF9 (AAGAGTTCTGAATTTAAGG) and presented IRF9 protein loss (Figure 23A), 
and ATRi resistance to both, VX970 (Figure 23B) and AZD6738 (figure 23C) when 
compared with the parental YCC6iCas9 (both VX970 AND AZD6738 two-way ANOVA 
p-values <0.001). 
After TOPO cloning, sanger sequencing of the IRF9 region confirmed the presence of 
the c.266_284delACAAGAGTTCTGAATTTAA deletion (protein change in 
approximately half of the copies, and the deletion c.271_285delAGTTCTGAATTTAAG 
in the other half (Figure 23D), consistent with the absolute protein loss found in the 
western blot (Figure 23A). Both deletions were predicted to cause early truncated 
proteins, according to the online software MutationTaster 
(http://www.mutationtaster.org). Moreover, cell cycle analysis of EdU and PI double 
stained cells showed decrease in the percentage of cells stalled in inactive S phase in 
the IRF9 deficient cells, compared with the WT YCC6 (t-test p-value<0.001) (Figure 
23E and F), consistent with the arising of resistance to ATRi. 
Colony GW10 (HUWE1-/-) carried a HUWE1 targeting sgRNA 
(GCTCTGACGCGTAAGTGAC), and showed complete protein expression loss 
(Figure 24A) and resistance to both ATRi (two-way ANOVA p-value <0.001 for VX970 
and AZD6738) (figures 24B and C). After TOPO cloning, sanger sequencing revealed 
a deletion in approximately half of the reads (c.5976_5986delGTCACTTACGC), and 




Figure 20. Genome-wide CRISPR/Cas9 screen computational Analysis. A. Z-score and 
MAGeCK analysis workflow. B. Concordance of MAGeCK sgRNA mean log fold change (T1-
T0) with median Z-score. C. Box and whiskers plot showing the top 20 candidate genetic 
determinants of ATRi resistance (red) for the GW CRISPR/Cas9 screen in YCC6 cell line. 
Each red point represents the fold change (T1 compared with T0 sample) for an individual 
sgRNA, targeting a potential resistance gene. All top 20 show a p-value <0.00035 












































































































































Figure 21. Genome-wide CRISPR/Cas9 YCC6 screen validation pipeline. Top hits from 
the screen, including 20 top hits from the NGS results, genes listed in the gene cancer census 
GW CRISPR/Cas9 screen  validation experiment
Top hits from the GW CRISPR/Cas9 screen 
CRISPR/Cas9 arrayed screen validation after gRNA 
transfection in Cas9 expressing YCC6 clone 
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list present in the top 50 hits, plus gRNA inserted in the picked colonies were selected and 
transfected to the Cas9 expressing YCC6 cells in a arrayed 96-well plate format. Cells were 
analysed by the incucyte image analysis system over time, and by cell titre-glo proliferation 
analysis at a final time. Selected validated hits which had associated resistant picked colonies 
with no more than one sgRNA insertion, were further validated by sanger sequencing of DNA, 
protein expression testing (western blot), ATRi resistance checking and cell cycle analysis 
(FACS) (HUWE1 and IRF). For the validated genes that were not represented in the picked 
colonies, further validation models were created by siRNA transfection and knockdown or by 
single CRIPR/Cas9 mutagenesis and those models were then characterised and used for 
validation experiments. Future testing in parallel clones or orthogonal models will be 
performed for the strong candidate genes found. 
 
 
Table 8. sgRNA detected in the picked resistant colonies from the genome-wide 
CRISPR-Cas9 mutagenesis screen in YCC6 gastric tumour cell line. Highlighted in green 








sgRNA sequence Position in 
rank on hit list 







GW3 KLLN CGGAAAGTAGTTCCGACTG 157 
GW4 KLLN CGGAAAGTAGTTCCGACTG 157 







GW7 CWF19L1 GCCACCCGGTTTATAGCTC 317 
GW8 FDFT1 TCTCCATGAACCGCCAGTC 82 
GW9 IRF9 AAGAGTTCTGAATTTAAGG 4 










GW12 THUMPD1 GTCGCCGTATTCGTTGAGG 298 














Figure 22. Validation CRISPR/Cas9 mini-screen. Results from the validation CRISPR/Cas9 
mini-screen according to the luminescence reads (cell titre-glo) per well, normalised to 
negative control wells (sgRNA- negative C sgRNA). 31 genes were studied, testing for a total 
of 159 sgRNAs. Two different negative control sgRNAs were additionally used. 1500 
YCC6iCas9 cells per well were seeded and reversely transfected with specific sgRNA before 
they were exposed to 80nM VX970 for two weeks, being fed twice week. Plates were then left 
to recover for one week with drug-free media. Log10 values of viability per well (sgRNA) are 
plotted (red dots) in the Y-axis for the top 20 validated genes (X-axis). Complete death is 

























































































Figure 23. Validation of IRF9 as a candidate for ATRi resistance mediator in IRF9 
isogenic cells. A. WB showing a loss in IRF9 protein in the resistant clone harbouring a gRNA 
towards IRF9, compared with the parental YCC6 cell line. B. Drug sensitivity curves showing 
decreased sensitivity to VX970 in IRF9 -/- cells compared with YCC6 IRF9 WT cells (two-way 
ANOVA, p<0.001) C. Drug sensitivity curves showing decreased sensitivity to AZD6738 in 
IRF9 -/- cells compared with YCC6 IRF9 WT cells (two-way ANOVA, p<0.001). Cells were 
seeded in 384-well plates and exposed to a 5-days treatment across 8 different concentrations 
of drug, ranging between 0.0001μM to 1μM. Error bars represent standard deviation between 
reps (n=14). D IRF9 sequence alignment by ApE software in 15 TOPO cloned colonies from 
YCC6 IRF9 -/- resistant clone shows two different mutations present in all copies 
(c.266_284del ACAAGAGTTCTGAATTTAA and c.271_285del AGTTCTGAATTTAAG). E. 
Cell cycle analysis done by FACS with a double EdU (Y-axis, APC-A) and PI (X-axis, TX-Red) 
staining revealed a decrease of the number of cells stalled in inactive S phase in the IRF9 -/- 
cells, compared with the YCC6 WT ones. F. Calculation of the fold chance of the percentage 






































































































cells in inactive S phase in the DMSO control as a quantitative measurement of figure E 
(difference between YCC6 WT and IRF9 -/- t-test p-value <0.001).  
 
 
Both alterations were predicted to cause early truncated proteins, according to 
MutationTaster. Similarly, to what I saw in the IRF9 -/- clone, EdU/PI cell cycle analysis 
showed a decrease of the cells in inactive S phase in the HUWE1-/- deficient clone, 
compared with the WT after 48h of VX970 treatment (Figure 24E). These differences 
are quantified in Figure 24F (t-test p-value >0.001). 
 
Due to the large list of potential ATRi resistance causing candidate genes I have 
described in this section, and with the aim of shortlisting the ones that are more 
relevant in cancer, I cross-referenced our data regarding to the YCC6 gastric tumour 
cell line to other available data from other screens. I had previously carried out a 
CRISPR screen in the ovarian clear cancer cell (OCCC) tumour cell line TOV21G, 
following the same format than the one carried out in the YCC6 screen (data not 
shown). Additionally, a recent publication carried out a SF50 CRISPR screen where 
they have described both, ATRi sensitivity and resistance causing genes in three cell 
lines, including the 239A (Kidney), HCT 116 (Colorectal) and MCF10A (Breast) tumour 
cell lines, using the AZD6738 ATRi. Selecting only the genes that had a Z-score >2 
from the resistance causing genes list, I was able to observe a surprisingly high 
overlap of genes in between the four cell lines and our YCC6 screen (Figure 25A, 
Supplementary Table 3). I found two genes that were currently represented in all five 
cell lines which were CDC25B and TRIT1. 24 of the genes found to be significant in 
YCC6, were also ATRi resistance-causing mediators in three of the four additional cell 
lines, and 249 genes were found in two out of four cell lines (Supplementary Table 
3).  
This analysis has allowed me to select the genes for further study, in order to define 
its implication in ATRi resistance from a mechanistic perspective. Therefore, I cross-
referenced the top 50 hits from our YCC6 screen and determined their effect in the 
other cell lines, defining a list of genes illustrated in Figure 25B. I observed that 
CDC25B is present in all five analysed cell lines; SMG8 in four cell lines; HUWE1, 
HNRNPF, SMG9, STAT2, KIF5B, IFNAR1 and RET in three out of five cell lines. As I 
have already been able to validate the implications of many of these genes in our 96 
well-plate arrayed screen, I had a strong rationale to generate isogenic models that 
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can represent these potential main drivers of ATRi resistance and will guarantee the 
generation of valuable information that can potentially be used in the clinical practice.  
 
 
Figure 24. Validation of HUWE1 as a candidate for ATRi resistance mediator in HUWE1 
isogenic cells. A. WB showing a loss in HUWE1 protein in the resistant clone harbouring a 
gRNA towards HUWE1, compared with the parental YCC6 cell line. B. Drug sensitivity curves 
showing decreased sensitivity to VX970 in HUWE1 -/- cells compared with YCC6 WT cells 
(two-way ANOVA, p<0.001) C. Drug sensitivity curves showing decreased sensitivity to 
AZD6738 in HUWE1 -/- cells compared with YCC6 WT cells (two-way ANOVA, p<0.001). Cells 
were seeded in 384-well plates and exposed to a 5-days treatment across 8 different 
concentrations of drug, ranging between 0.0001μM to 1μM. Error bars represent standard 





























































































cloned colonies from YCC6 HUWE1 -/- resistant clone, shows two different mutations present 
in all copies (c.5976_5986del GTCACTTACGC and c.5979_5980ins A). E. Cell cycle analysis 
done by FACS with a double EdU (Y-axis, APC-A) and PI (X-axis, TX-Red) staining revealed 
a decrease of the number of cells stalled in inactive S phase in the HUWE1 -/- cells, compared 
with the YCC6 WT ones. F. Calculation of the fold chance of the percentage of cells in inactive 
S phase after 48h of 150nM VX970 treatment divided by the percentage of cells in inactive S 
phase in the DMSO control as a quantitative measurement of figure E (difference between 
YCC6 WT and HUWE1 -/- t-test p-value <0.001).  
 
 
Figure 25. Candidate ATRi resistance causing genes identified from GW CRISPR 




with http://www.interactivenn.net showing the overlapping candidate ATRi resistance causing 
genes with Z-score >2 identified from our GW CRISPR screens performed in YCC6 and 
TOV21G cell lines, and the 293A, HCT 116 and MFC10A available data extracted from Wang 
et al, 2018. B. Heatmap of overlapping candidate genes from figure A present in the top 50 






4. Creation and characterisation of YCC6 ATR inhibitor 
resistant clones 
 
In order to discover genetic determinants to ATRi resistance in GC, I generated YCC6 
VX970 resistant cells by seeding them at a low density and exposing them to 
increasing doses of VX970 for approximately six months, in two parallel experiments 
(see Figure 26A). Cells from the first experiment reached a high level of resistance to 
VX970 (H), approximately 8-fold higher than the initial SF50 (54 nM), after being 
exposed to VX970 at a concentration of 430nM. Cells from the second experiment 
reached a medium resistance level (M) of approximately 5-fold increase, compared 
with the initial SF50 of VX970, proliferating at a concentration of 260nM VX970. Both 
Highly resistant (H) and Medium resistant (M) YCC6 populations proved to be resistant 
to ATR inhibition when exposed to a range of VX970 concentrations in a five-days 
exposure drugging experiment (Figure 26B) compared with the parental population in 
a dose-dependent fashion (two-way ANOVA p-values <0.001). These findings were 
validated by using another ATRi, AZD6738, which showed the same effect as VX970 
(all two-way ANOVA p-values <0.001) (Figure 26C), suggesting that these findings 
were not private to VX970, but to ATR inhibition, as a class effect.  
I then generated resistant clones by single cell sorting the resistant population by 
FACS. Pellets were retrieved from the 8-surviving independent clones (6 H clones and 
2 M clones) that demonstrated profound resistance to both, VX970 and AZD6738 
ATRi, compared with the parental cell line (all two-way ANOVA p-values <0.001) 
(Figures 26D and E). Next, I expanded the clones during exposure to VX970 to 
extract the protein fraction, for purposes of the proteomic mass spectrometry analysis 
(MS). Finally, clone M2 was discarded from the analysis due to its very slow growth 
rate.  
 
Interestingly, I visualised a change in the morphology of the clones as they became 
resistant to ATRi (Figure 27). Originally, YCC6 is an epithelial cell line, which is mainly 
constituted by small semi-rounded epithelial cells, although some larger and amoeboid 
cells can be observed. Conversely, clones H2, H3, H4 and H6 presented a pattern 
mesenchymal-like cells with a more elongated morphology. In the case lf H1 clone, I 
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could see large cells with an amoeboid structure, which might be a result of the 
selection of these cells from the parental population. In contrast, I did not see a change 




Figure 26. YCC6 ATRi resistant cell experiment design. YCC6 cells were exposed to 
increasing concentration of VX970 until they became resistant to ATR inhibition. After sorting 








































































































resistance (VX970 and AZD6738) in comparison with the parental cell line. Colonies were 
expanded and pellets were retrieved to extract DNA, RNA and protein in order to perform 
exome sequencing, RNA sequencing and Mass Spectrometry, respectively. B and C Drug 
sensitivity curve for AZD6738 and VX970 in the generated ATRi resistant pool, compared with 
the parental population. Green curve shows dose-response to ATRi for cells resistant to 
430nM (H). Orange curve shows dose-response to ATRi for cells resistant to 260nM (M). All 
two-way ANOVA p-values for both groups were lower than 0.001. D and E. Drug sensitivity 
curve for AZD6738 and VX970 in the FACS sorted clones (H clones come from H resistant 
parental population while M clones come from M parental population. All two-way ANOVA p-
values for both groups were lower than 0.001. Cells were seeded in 384-well plates and 
exposed to a 5-days treatment across 8 different concentrations of drug, ranging between 




Figure 27. Detection of morphological changes in YCC6 ATRi resistant clones. 
Pictures taken from the ATRi resistant clones (highly resistant H1, H2, H3, H4, H5 and H6 and 
medium resistant M1) using the EVOS imaging system (20x Objective, Invitrogen) show 
changes in cell shape, compared with the parental cells. 
 
 





Principal components analysis (PCA) analysis was carried out with the proteomic data, 
comparing the expression profiles between the clones and the parental cell line, to 
check for the quality of the biological replicates in both experiments. PCA plots 
demonstrated a very high reproducibility of the results in between replicates (Figure 
28). Additionally, these analyses showed that clones H5 and M1 clustered separately 
to an H1, H2, H3, H4 and H6 cluster, and to the parental cell lines, which showed a 
completely different proteomic profile. This is consistent with the change to a 
mesenchymal cell morphology that was observed in the H1, H2, H3, H4 and H6 cluster 
but not in the H5 and M1 clones. According to these observations, I decided to do all 
the further statistical evaluations comparing the parental cells to i) all resistant clones 
grouped together; ii) H5 and M1 cluster; iii) H1, H2, H3, H4 and H6 cluster (Figure 
28).  
 
Proteomic mass spectrometry analysis was undertaken in seven ATRi resistant 
clones, compared with the parental YCC6 cell line, by measuring the expression of 
9,410 proteins in a mass spectrometry multiplexed reaction. After applying the Welch 
t-test analysis, comparing the protein expression levels in all the resistant clones with 
the parental cells, 204 proteins showed a consistent statistically significant differential 
expression in between the two groups, establishing a cut-off of FDR (multiple 
comparisons corrected p-value) lower than 0.05, plus an absolute log2 fold-change 
higher than 0.5 or lower than -0.5. Thus, I detected a significant under or over 
expression of a large list of proteins in the resistant clones represented in a volcano 
plot (Figure 29A). LGALS2 (Beta-Galactoside-Binding Lectin L-14-II), MUC13 (Mucin 
13, Cell Surface Associated), TSPAN8 (Tetraspanin 8), VIL1 (Vilin 1), ECM1 
(Extracellular matrix protein 1), KRT7 (Keratin 7) and RIC8 (RIC8 Guanine Nucleotide 
Exchange Factor A) were amongst the most significantly overexpressed in the 
resistant clones, compared with the parental cells (all p-values <0.05). MAP1B 
(Microtubule Associated Protein 1B), NCAM1 (Neural Cell Adhesion Molecule 1), 
CD44 (Extracellular Matrix Receptor III), CD70 (Tumour Necrosis Factor Ligand 
Superfamily Member 7), MT2A (Metallothionein 2A) and MTF1 (Transcription Factor 
MTF-1) were amongst the proteins that were downregulated. Protein-protein 
interaction networks using STRING online software and Cytoscape software revealed 
a large network of protein interactions in our hits (Figure 29B).  
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Figure 28. ATRi resistant clones’ data analysis workflow. Principal component analysis of 
proteomics data revealed 3 independent clusters of clones, dividing the parental cells from a 
M1/H5 group and a H1/H2/H3/H4/H6 group. Therefore, further analyses were done in 
comparison of the three clusters. First, upregulated and downregulated genes or pathways 
were determined and compared from the mass spectrometry and RNA sequencing data. 
Then, a description of new acquired mutations in the resistant clones, compared with the 
parental cell lines was determined using the exome sequencing data. After cross-referencing 
results from DNA and RNA/Protein results, I looked for common resistance-causing genes, 
comparing the results to the candidate resistance-causing genes from the GW CRISPR/Cas9 







New mutations in resistant clones
Mutational pathway analysis
YCC6 ATRi resistance GW CRISPR/Cas9 screen
Top 100 candidate resistance genes
Functional pathway analysis
YCC6 Parentals M1H5H1 H2 H3 H4 H6
Proteomics
















Figure 29. Mass spectrometry transcriptomic data reveals common differentially 
expressed proteins in all YCC6 ATRi resistant clones. A. Volcano plot representing Log10 
Log2 fold change











































multiple comparisons corrected Whelch’s test p-values against the Log2 fold-change of the 
differences between all resistant clones and the parental YCC6 cell line B. Protein interaction 
map generated by STRING online software showing protein interactions from the differentially 
up (Red) and downregulated (Blue) genes showed in figures A and B. Only proteins showing 
at least one interaction are included in the network. Statistical significance means differences 
in protein expression levels with a FDR corrected Whelch’s test p-value <0.01 and Log2 fold 
change differences lower than -0.5 or larger than 0.5. All experiments were performed in two 
biological replicates.  
 
Interestingly, several protein complexes were found to be represented by several of 
its components, where typically all units in a complex followed the same trend. 
Proteins that form part of the ATP complex (ATP11A, ATP5J, ATP5O, ATP5A1, 
ATP5I, ATP5B, MT-ATP6, ATP5C1), were found to be downregulated in the resistant 
cells, compared with the parentals. Also, conserved oligomeric Golgi (COG) complex, 
in charge of protein glycosylation (COG2 COG3 and COG6) were downregulated in 
the resistant cells. Proteins ALDH9A1, ALDH1A3, ALDH3A2, part of the Aldehyde 
Dehydrogenase (ALDH) complex, which plays a role in aldehyde metabolism, were 
found to be downregulated in the resistant clones, compared with the parentals. Of 
note, ALDH complex has been previously associated to cellular detoxification, DNA 
damage protection and cancer (Jelski, Zalewski et al. 2008, Orywal and Szmitkowski 
2017). Additionally, several potential mediators to ATRi resistance found were listed 
in the cancer genome census and thus related to carcinogenesis (present in the 
cancer genome census list) (Sondka, Bamford et al. 2018), including MLLT4 (Afadin, 
Adherens Junction Formation Factor), PIK3CB (Phosphatidylinositol-4,5-
Bisphosphate 3-Kinase Catalytic Subunit Beta), MGMT (O-6-Methylguanine-DNA 
Methyltransferase), STAT3 (Signal Transducer And Activator Of Transcription 3), 
STAT5B (Signal Transducer And Activator Of Transcription 5B) NF1 (Neurofibromin 
1), PCBP1 (Poly(RC) Binding Protein 1), DNM2 (Dynamin 2), PARP4 (Poly(ADP-
Ribose) Polymerase Family Member 4) and CRNKL1 (Crooked Neck Pre-MRNA 
Splicing Factor 1). I then cross-referenced the proteins that were expressed at a lower 
level in the resistant clones, compared with the parental cell line with the candidate 
ATRi resistance hits from the GW CRISPR screen data and found that ARHGAP21 
(Rho GTPase Activating Protein 21) and TYK2 (Tyrosine Kinase 2) were present in 
both datasets.  
When I compared the cluster containing clones H1, H2, H3, H4 and H6 to the parental 
cells (Figure 30), CDH1 (E-Cadherin), GNA (Guanine nucleotide-binding protein 
alpha-1 subunit), JAK1 (Janus Kinase 1), NOTCH1 and 2 (Notch 1 and 2), SMAD2  
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Figure 30. Mass spectrometry transcriptomic data reveals common differentially 
expressed proteins in H1/H2/H3/H4/H6 YCC6 ATRi resistant clones. A. Volcano plot 
representing Log10 multiple comparisons corrected Whelch’s test p-values against the Log2 
Log2 fold change




















































fold-change of the differences between the H1/H2/H3/H4/H6 resistant cluster, compared with 
the parental YCC6 cell line. B. Protein interaction map generated by STRING online software 
showing protein interactions from the differentially up (Red) and downregulated (Blue) genes 
showed in figures A and B. Only proteins showing at least one interaction are included in the 
network. Statistical significance means differences in protein expression levels with a FDR 
corrected Whelch’s test p-value <0.01 and Log2 fold change differences lower than -0.5 or 
larger than 0.5. All experiments were performed in two biological replicates.  
 
 
and 4 (SMAD Family Member 2 and 4), KIAA1598 (Shootin 1) and MSI2 (Musashi 
RNA Binding Protein 2) were identified as candidates to ATRi resistance-causing 
proteins. Importantly, SMG1 (Nonsense Mediated MRNA Decay Associated PI3K 
Related Kinase), pivotal in regulating the nonsense-mediated mRNA decay pathway, 
that controls the degradation of mRNA transcript carrying premature stop codons 
(Azzalin and Lingner 2006, Azzalin and Lingner 2006, Fernandez, Yamashita et al. 
2011, Lee, Pratt et al. 2015), was found to be downregulated in the resistant cell lines 
when compared with the parental cell line (Welch t-test FDR = 0.0098). Upregulation 
of SMG1 as a mechanism of ATRi resistance is consistent with the GW CRISPR/Cas9 
screen results, where I found SMG8 and SMG9, negative regulators of SMG1 to cause 
resistance to ATRi when lost (positive selection GW CRISPR-Cas9 mutagenesis 
screen section, Figures 20C, 22 and 25). 
 
Finally, when I compared the H5-M1 cluster with the parental cell line, 40 differentially 
expressed proteins were identified, including VHL (Von Hippel-Lindau Tumor 
Suppressor), STAT5B Signal Transducer And Activator Of Transcription 5B and YAP1 
(Yes Associated Protein 1), previously being related to cancer. Additionally, VIL (Villin 
1), ANO1 (Anoctamin 1), MRAS (Muscle RAS Oncogene Homolog), ZADH2 (Zinc 
Binding Alcohol Dehydrogenase Domain Containing 2), RBP7 (Retinol Binding Protein 
7) and TSFM (Ts Translation Elongation Factor, Mitochondrial) were amongst the top 
deregulated proteins in the resistant clones, compared with the parental cell line 
(Figure 31). No interactions were detected amongst this list of proteins. 
 
The top one-hundred most upregulated and downregulated genes found in the 
resistant clones, comparing all clones and the two different clusters to the parental cell 






Figure 31. Mass spectrometry transcriptomic data reveals common differentially 
expressed proteins in H5/M1 YCC6 ATRi esistant clones. A. Volcano plot representing 
Log10 multiple comparisons corrected Whelch’s test p-values against the Log2 fold-change 
of the differences between the H5/M1 resistant cluster, compared with the parental YCC6 cell 
line. Statistical significance means differences in protein expression levels with a FDR 
corrected Whelch’s test p-value <0.05 and Log2 fold change differences lower than -0.5 or 
larger than 0.5. All experiments were performed in two biological replicates. No protein 
interactions were seen. 
 
Following the fact that SMG1 was one of the proteins found to be upregulated in the 
ATRi resistant clones, and because this finding correlates with our results from the 
GW CRISPR screen and the cross-referencing data with Wang et al. study, I decided 
to validate the overexpression of SMG1 and its downstream protein UPF1 in the 
resistant clones, compared with the parental YCC6 cells. The H2, H3, H4 and M1 
resistant clones but not the H2, H5 and H6 showed an increase of both proteins 
parental cell line (Figure 32A). I then wondered if the silencing of SMG1 would be 
enough to rescue the resistance to ATRi and thus performed a siRNA knockdown 
experiment in one of the clones expressing higher levels of SMG1 protein, H3. 
Although SMG1 was not completely silenced (Figure 32B), the moderate reduced 
levels of protein were enough to re-sensitise H3 cells to both, VX970 and AZD6738 
ATRi (Two-way ANOVA p-values <0.001), demonstrating that the overexpression of 






































Figure 32. Silencing of SMG1 re-sensitises the resistant clones H3 to VX970. A. Western 
blot showing that colonies H2, H3, H4 and M1 overexpress SMG1 and UPF1, compared with 
the YCC6 parental cell line. B. Western blot showing SMG1 and UPF1 expression in the H3 
siRNA knockdown cells, compared the the control H3 cells. C and D. Drug sensitivity curves 
for VX970 and AZD6738 in the silenced cells from B, compared with the parental H3 cells. All 






















































































5. Dense Tiling ATR CRISPRx Screen 
 
ATR is a member of the phopho-inositide 3-kinase related kinases family (PIKK), in 
charge of monitoring the progression of replication forks in S phase, maintaining 
genomic stability and promoting a complete and accurate replication of the genome 
by mediating the phosphorylation of a large number of substrates (Casper, Nghiem et 
al. 2002, Cimprich and Cortez 2008, McNees, Tejera et al. 2010, Flynn and Zou 2011). 
Structurally, it contains several HEAT (Huntington, Elongation factor 3, Protein 
phosphatase 2A, and PI3K TOR1) repeats in the N-terminal part, that are thought to 
be involved in protein-protein interactions (like the interaction with its partner ATRIP), 
as well as in DNA-Protein interactions (Ball, Myers et al. 2005, Chen, Zhao et al. 2007, 
Rubinson, Gowda et al. 2010), and a C-terminal catalytic kinase domain (PI3K/PI4K), 
flanked by a FAT (FRAP, ATM, TRRAP) and FATC (FAT-C) domains, that are known 
to mediate protein-protein interactions and ATR activation through 
autophosphorylation and TopBP1 stimulation (Mordes and Cortez 2008, Mordes, Glick 
et al. 2008).  
 
Traditionally, the genome editing techniques comprising the introduction of DSB at a 
determined genomic locus, selecting for the cells where the NHEJ error-prone DNA 
damage repair pathway had allowed the appearance of indels and disruption of the 
targeted gene (Komor, Badran et al. 2017). Techniques that facilitate targeted gene 
editing through the use of base editors without causing DSB in the genome have been 
developed, thanks to the use of base editors. Base editors consist of a hybrid of a 
cytidine deaminase enzyme and a catalytically inactive Cas9 protein, which binds to a 
determined locus of interest through its union to a specific guide RNA. When the base 
editor binds the DNA, a loop structure is formed, that exposes a region of around 5 
nucleotides of DNA where the deaminase carries out its function, resulting in the 
appearance of point mutations (Komor, Kim et al. 2016, Gaudelli, Komor et al. 2017, 
Kim, Komor et al. 2017).  
Following this principal, and to identify regions in the ATR protein that may be 
important for the development of ATRi resistance, due to either the impairment of ATR 
function or its role in modulating other DDR downstream effectors, I used a tiling 
CRISPR library comprising 552 guides designed to result in a dense coverage of 
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mutations across the entire ATR gene. Thus, I carried out a tiling CRISPRx screen in 
YCC6 cells that enabled us to mutagenize, select the ATRi resistant cells and 
sequence them to identify ATRi resistance-conferring mutations. In this experiment, I 
have used the fourth generation Staphylococcus aureus Cas9-derived BE4 (SaBE4-
Gam, BE4) cytidine deaminase (Komor, Zhao et al. 2017), and the newly described 
adenine deaminase ABE7.10 (ABE) in comparison with a regular nCas9, to cause 
missense mutations in YCC6 cells all along the ATR region, using the pKLV5-
U6gRNA5-PGKPuroBFP shRNA library. The YCC6 cells were also modified to 
constitutively express deadCas9 (dCas9) protein and then transfected with a modified 
cytidine deaminase, pGH156_MS2-AID-Hygro (AID), combined with the 
pGH224_sgRNA_2xMS2_Puro library of sgRNA bearing two MS2 hairpin-binding 
sites allowing specific mutagenesis with limited off-target damage (Hess, Fresard et 
al. 2016) permitting comparison of orthogonal methods (Figure 33). Finally, I used a 
catalytically inactive MS2-AID∆Dead as a negative control. After drugging the cells for 
two weeks with 100nM of VX970, resistant cells were harvested and RNA was 
extracted and converted to cDNA and prepared for sequencing (Figure 34). Briefly, 
the ATR sequence was amplified and purified in two sequential PCR reactions, were 
Ion Torrent adaptors where added for further sequencing of a panel of 36 amplicons, 
representing the whole ATR coding sequence, using the PGM 318 Chip (Ion Torrent). 
 
 
Figure 33. CRISPRx screen workflow. CRISPRx screens were carried out in two parallel 
arms. First (upper panel), YCC6 cells were transduced with the pKLV5-U6gRNA5-
PGKPuroBFP ATR dense tiling lentiviral sgRNA library and selected in puromycin for 5 days. 
Cells were then transfected with GFP control, Cas9 nuclease or constructs carrying BE4 or 
ABE base editor sequences. Cells were incubated for 2-3 days before being re-seeded in 
YCC6 cells (ARID1A 
deficient, ATRi sensitive) 
Puromycin selection 
pKLV5-U6gRNA5-PGKPuroBFP ATR 
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SF0 VX970 (time= 2 
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and base editors (BE4, ABE) 
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10cm plates, at a 50,000 cells/ml concentration, 24 hours’ prior VX970 treatment started, at a 
dose of 100nM. Cells were drugged for two weeks, being fed with fresh drug twice a week. 
Resistant cells were left to expand for an extra week, and harvested to send for NGS. For the 
second approach (lower panel), YCC6 cells were transduced with a dCas9 expressing 
construct and selected in blasticidin. Once selected, they were transduced with the 
pGH224_sgRNA_2xMS2_Puro sgRNA library, and selected in puromycin. Cells were then 
transfected with dead AID, as a negative control, or the AID base editor construct, and left 







Figure 34. Ion Torrent CRISPRx Sample preparation. RNA was extracted from the resistant 
cells and was converted to cDNA in three independent reactions, using ATR specific primers, 
each of them complementary to one third of the protein sequence. The resulting cDNA was 
used to amplify all ATR sequence in 36 independent reactions, using 36 tiling primer pairs, to 
generate 250-300 bp amplicons. Primers used for PCR 1 included a PB3 sequence, used as 
a bridge to add a barcoded IonA sequence in the second PCR, and an Ion Torrent P1 
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and mixed to purify DNA. DNA for PCR1 was mixed in one reaction per sample and amplified 
by PCR2, adding the 5’ barcoded tail. Final product was purified and sent for sequencing.  
 
Sequencing coverage was generated with a maximum depth of 50,000, and only 
sequences that perfectly matched to the barcodes, and with an average quality score 
greater than Q20 were selected for further analysis. After the alignment of sequencing 
reads to the version 19 of the human consensus sequence, the sequenced sequences 
were visualized with IGV tool to direct inspection of mutations. Only mutations that 
were present in any of the base editor samples, but not present in the negative control 
arm were selected and localised to the protein structure (Figure 35A and 35B). 
Although I have sequenced the whole resistant population of cells in one reaction, and 
therefore expect a low frequency of a determined mutation, only mutations that were 
detected in more than one read were considered for further analysis.  
 
A summary of all mutations detected by NGS is listed in Table 9. All base editors 
proved to be functional and caused point mutations in the targeted sequence. I did not 
see an association between the type of substitutions and the library or base editor 
used, although nCas9, BE4 and ABE were responsible for most of the mutations, 
compared with the more modest role of AID. 54% of the mutations localised in ATR 
coding sequence were found to cluster in the FAT domain. Two mutations, G2635G 
and E2419K were found in the catalytic (CAT) or FATC domains, respectively (Figure 
35A and 3B5), and the remaining mutations affected residues located in the area in 
between the HEAT repeats (residues 974-977) (32%). Additionally, I detected a cluster 
of mutations beyond the C-terminal part of ATR coding sequence, which do not directly 
affect the protein but could have an impact in the mRNA stability and protein 
expression (not included in the general count, data not shown). T974T, K2025N and 
D977V mutations were found in more than one sample, caused by both MS2 structure-
based AID and the cytidine and adenine deaminases BE4 and ABE, suggesting that 
these are less likely to be off-target effects specific to one base editor or method and 






Table 9. Mutations found in the CRISPRx screen VX970 resistant YCC6 cells. 
 
Base editor DNA change Coverage Number of reads Protein change 
ABE 8027G>A 210 2 G2635G 
AID 7377G>A 165 3 E2419K 
nCas9 6609A>T 7452 85 I2163L 
nCas9 6598T>G 7094 146 V2159G 
nCas9 6597G>T 8490 204 V2159F 
ABE 6545A>T 77 2 A2141A 
ABE 6532A>C 103 2 Q2137P 
ABE 6531C>T 102 2 Q2137* 
ABE 6522G>A 105 2 A2134T 
AID 6404G>C 27 2 W2094C 
BE4 6194A>T 1064 10 K2025N 
AID 6194A>T 1783 9 K2025N 
nCas9 6193A>T 9 8 K2025I 
ABE 5603A>G 427 3 R1827S 
AID 3071C>T 175 2 D984D 
BE4 3052A>T 2113 28 D977V 
AID 3052A>T 225 2 D977V 
ABE 3052A>T 4223 34 D977V 
BE4 3044G>A 2712 29 T974T 
AID 3044G>A 278 5 T974T 
ABE 3044G>A 5103 37 T974T 





Figure 35. The majority of the ATRi-resistance causing mutations locate in the FAT or 
catalytic domains. A. Mutational information obtained from Ion Torrent sequencing of ATRi-












































































resistant cells cDNA revealed a cluster of mutations in the FAT, CAT (PI3K, PI4K catalytic) 
and FATC domains of ATR, and in a region located in between the two HEAT repeats. B. 
Location of the mutations from figure A associated with ATRi resistance on a model of the 
ATR protein structure. Mutations are represented in red. TopBP1 binding domain represented 
in blue, according to Mordes et al. (Mordes, Glick et al. 2008) and Liu et al. (Liu, Shiotani et 
al. 2011). VX970 binding pocket in the catalytic domain is represented in orange, according 






Rationale of this thesis 
One of the current strategies in the understanding of cancer consists in the 
identification of driver DNA mutations or molecular mechanisms that contribute to the 
carcinogenic process. The main aim of this approach is to improve clinical practice, 
moving towards personalised medicine where a deeper understanding of the 
molecular profile of each patient leads to the appropriate selection of targeted 
therapies, that exploit the genetic vulnerabilities found within each tumour.  
 
Despite the recent advances in this field, including a comprehensive knowledge of the 
genome, only a small number of genetic targets are validated as predictive biomarkers 
to select for therapy, or to stratify patients into different treatment arms within the 
context of clinical trials. This is well illustrated in GC, where there is a lack of robust 
molecular biomarkers and limited treatment options, making it the third leading cause 
of cancer-related deaths worldwide. Therefore, the identification of robust synthetic 
lethal (SL) targets in GC, which can be exploited therapeutically, represents an urgent 
need.  
 
Summary of the work presented in this thesis 
1. ARID1A and ATR are synthetically lethal in vitro  
Alterations in the SWI/SNF complex are very common in cancer (Reisman, Glaros et 
al. 2009, Kadoch and Crabtree 2015), with more than 20% of human cancers bearing 
mutations in at least one subunit of the complex (Kadoch, Hargreaves et al. 2013, 
Shain and Pollack 2013). From all subunits in the SWI/SNF complex, ARID1A is the 
SWI/SNF subunit gene that is most frequently mutated in cancer, maintaining the 20% 
rate of mutations in the general cancer population (Jones, Wang et al. 2010, Jones, Li 
et al. 2012, Wu, Wang et al. 2014) including GC, where it results in a loss of protein 
expression in most cases (Wang, Kan et al. 2011, Jones, Li et al. 2012, Zang, 
Cutcutache et al. 2012). Despite the frequency and possible functional implications of 
ARID1A loss in GC, it is currently not being used as a biomarker, nor as a therapeutic 
target, and a deep understanding of the role of ARID1A in carcinogenesis and its 
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potentially SL with other genes, that can be therapeutically targeted, is required for 
maximal clinical benefit. 
 
In the first part of my thesis, I describe the characterisation of a panel of seven gastric 
tumour cell lines, plus the ARID1A isogenic HCT 116 colorectal tumour cell line, in 
terms of exome sequencing and ARID1A status determination (at a DNA, RNA and 
protein level). I have additionally tested their response to a collection of small molecule 
inhibitors, that had previously been reported to be preferentially sensitive in ARID1A 
deficient cell lines of other histologies (Bitler, Aird et al. 2015, Shen, Peng et al. 2015, 
Williamson, Miller et al. 2016, Bitler, Wu et al. 2017, Jones, Fleuren et al. 2017). These 
included ATRi (AZD6738 and VX970), PARPi (olaparib and talazoparib), PI3K 
pathway inhibitors (BKM120 and MK2206), HDAC6 inhibitors (ACY1215) and EZH2 
inhibitors (GSK126), and drug combinations including ATRi plus PARPi; and ATRi plus 
PI3Ki. I have shown how ARID1A deficient cell lines, especially those carrying large 
deletions or that predict for early protein frameshift mutations with complete loss of 
protein function (YCC6, SNU 5 and HCT 116 ARID1A -/-), show exquisite sensitivity 
to ATRi, compared with those with the models expressing ARID1A (SNU 638, AGS, 
NCI N87 and HCT 116 WT). In the case of the SNU 1 cell line, which has shown to 
have complete ARID1A loss of expression due to two frameshift mutations detected 
by exome sequencing, I only saw a moderate ATRi response. This could be explained 
by a residual expression of ARID1A protein, undetectable by WB. Alternatively, it is 
possible that ARID1A is not the only ATRi sensitising factor in these ARID1A deficient 
cell lines, thus not being a completely penetrant SL in GC. Further research using 
larger panels of GC cell lines and those of other histologies, that express different 
levels of ARID1A will be necessary to better describe the implications of ARID1A 
status in ATRi response.  
When I tested PARPi in our cell lines, I could only see a differential sensitivity in the 
HCT 116 isogenic cells, where the ARID1A -/- cell line was more sensitive compared 
with the ARID1A WT cell line. This difference was not detected in the panel of GC cell 
lines, showing that the ARID1A-PARP SL described by Shen and colleagues is not 
extensive to our GC models (Shen, Peng et al. 2015).  
Despite the promising results that ATRi have shown as monotherapy, they will more 
likely be used in combination treatment with other drugs that exploit its mechanism of 
action inducing replication stress and genomic instability. Combinations with other 
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drugs that can synergise in the induction of DNA damage, are more likely to increase 
the effect, thereby avoiding the development of resistance. This approach has already 
been used in several cancers combining ATRi with other DNA damaging agents, 
including a number of intra strand cross-linking inducing agents like cisplatin, 
carboplatin or mitomycin C (Reaper, Griffiths et al. 2011, Huntoon, Flatten et al. 2013, 
Hall, Newsome et al. 2014, Mohni, Thompson et al. 2015, Vendetti, Lau et al. 2015, 
Li, Yang et al. 2016, Liu, Ge et al. 2017, Min, Im et al. 2017), nucleoside analogues 
like gemcitabine (Hall, Newsome et al. 2014, Ma, Li et al. 2017)  and PARPi (Peasland, 
Wang et al. 2011, Huehls, Wagner et al. 2012, Ogiwara, Ui et al. 2013, Abu-Sanad, 
Wang et al. 2015, Mohni, Thompson et al. 2015, Kim, George et al. 2017), amongst 
others. Taking this into consideration, I set out to test the combination of ATRi with 
PARPi. Apart from the potential synergy of this drug combination in the treatment of 
DDR deficient cancers, ATR inhibition has been shown to overcome resistance to 
PARPi in patient-derived cell lines (Yazinski, Comaills et al. 2017), a promising 
therapeutic strategy that is being investigated in several clinical trials (NCT03330847, 
NCT03682289, NCT03462342, NCT03428607, NCT02264678, NCT02576444 and 
NCT02723864). In our GC models, cell growth inhibition was observed in both, 
ARID1A deficient and proficient cell lines when exposed to the combination of ATRi 
and PARPi, although a greater effect was seen in the ARID1A deficient ones.  
 
Since loss of ARID1A expression has been suggested to be predictive for the 
overactivation of PI3K pathway as a compensatory effect, and this could result in the 
sensitisation of tumour cells to PI3Ki (Samartzis, Gutsche et al. 2014, Zhang, Yan et 
al. 2016, Lee, Yu et al. 2017), I hypothesised that the combination with PI3Ki could be 
synergistic in our ARID1A deficient and proficient models. 
My data from PI3Ki monotherapy only showed ARID1A-associated vulnerability in the 
HCT 116 isogenic model and not in our GC panel of cell lines. However, the sensitivity 
to ATRi and PI3Ki combinations was more evident in selected ARID1A deficient cell 
lines such as YCC6, SNU 5 and SNU 1 than in the ARID1A WT cell lines, supporting 
the rationale for testing ATRi and PI3Ki combinations in an ARID1A deficient context 
 
In contrast to what Bitler and colleagues have published in several studies using 
ovarian cancer models (Bitler, Aird et al. 2015, Bitler, Wu et al. 2017), HDAC6 and 
EZH2 inhibitors did not show any ARID1A-associated sensitivity in our panel of cell 
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lines. This could be due to a histology specific effect of those inhibitors, or could also 
be related to experimental conditions as Bitler et al. prove these effects using 3D long-
term culture experiments, whilst my experiments have been performed in a 2D short-
term exposure format (Bitler, Aird et al. 2015, Bitler, Wu et al. 2017).  
 
From all the inhibitors I tested in these thesis, I observed that ATRi presented the 
largest ARID1A associated effect. In order to validate this effect, and to avoid the 
potential confounding factors of comparing cell lines with different genetic 
backgrounds, I generated a GC isogenic model using the CRISPR/Cas9 technology. 
Despite the extensive screening and the several CRISPR/Cas9 mutational rounds 
undertaken in the SNU 484 cell line, and in AGS cell line (results not shown for AGS), 
I was not able to generate ARID1A homozygously mutated clones, as the cells seem 
to be addicted to ARID1A expression and died when ARID1A expression was 
completely abrogated. However, because ARID1A levels are regulated post-
transcriptionally (Wiegand, Shah et al. 2010, Wu, Wang et al. 2014, Kartha, Shen et 
al. 2016, Roumeliotis, Williams et al. 2017), and a haploinsufficiency phenomenon (the 
loss of function phenotype is present even with a partial loss of the functional alleles) 
seems to operate in oncologic patients within the ARID1A deficiency context 
(Wiegand, Shah et al. 2010, Wu, Wang et al. 2014, Kartha, Shen et al. 2016), I think 
the SNU 484 ARID1A isogenic cell line is still a valid model to represent ARID1A 
deficiency and proficiency in GC (Wu and Roberts 2013, Wu, Wang et al. 2014).  
Finally, orthogonal validations carried out through the performance of an ARID1A-
siRNA transient silencing transfection experiment confirmed our observations, 
showing that the silencing of ARID1A sensitises the cells to ATRi.   
 
In conclusion, sensitivity to ATR inhibition has been observed in ARID1A deficient GC 
tumour cells and ARID1A isogenic models, which supports the previously identified 
hypothesis of ATR as a synthetically lethal partner to ARID1A deficiency. It is likely 
that this represents a partial penetrant effect where other proteins are involved in the 
sensitisation of the tumour cells to the inhibition of a pivotal protein in DDR cascade, 
such as ATR. However, this will need to be clarified by increasing the number of 
models of study and undertaking new mechanistic approaches which will inform us 
about the role of ARID1A in ATRi response. 
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2. In vivo assessment of ATR inhibitor efficacy in gastric cancer Patient-Derived 
Xenografts. 
For the in vivo experiments, a different ATRi has been used for this experiment 
(M4344). Despite this, our data is consistent in between experiments, as we are 
looking for an ATRi class effect, that is not private to any specific inhibitor. This was 
the rationale of performing all in vitro experiments using two parallel ATRi, VX970 and 
AZD6738. In addition, M4344 is an oral compound that has previously been observed 
in other tumour models to have superior in vivo efficacy than VX970 (now called 
M6620, which is not available in oral gavage), and it is currently being assessed in 
phase I clinical trials in monotherapy and in combination with PARPi, what makes it 
more likely to be used for the new starting clinical trials.  
 
The results presented through the use of in vitro gastric tumour cell lines showed a 
preferential effect for ARID1A in sensitising the cells to VX970 and AZD6738 ATRi. 
With the aim of testing this SL in vivo, I selected seven PDX models, which represent 
ARID1A deficiency and proficiency within the context of GC. Taking into consideration 
that the animals were only treated over a short time due to weight loss, I observed 
significant tumour inhibition in all four ARID1A deficient PDX models (GC1-4), that 
were administered with M4344, compared with vehicle controls in a dose-dependent 
manner. Moreover, the addition of the PARPi, talazoparib, enhanced this effect in two 
of the four ARID1A deficient PDX models, compared with the vehicle treated controls 
(all p-values <0.0001). In two out of the three ARID1A proficient tumours (GC5 and 
GC6), the effect seen with ATRi monotherapy or combination treatment was small. 
However, the remaining ARID1A proficient model, GC7, was highly sensitive to ATR 
inhibition, despite also being treated for a short time, strongly suggesting that ARID1A 
is not the only determinant of ATRi sensitivity. In order to identify candidate biomarkers 
of sensitivity, I will focus on molecularly characterising the PDX tumours derived from 
the GC7 model. Additionally, I will also molecularly characterise the remaining 
resistant tumours propagated, and compare to vehicle controls from the other PDX 
models, to identify determinants to ATRi resistance in GC.  
 
Considering our in vitro and in vivo data together, I have demonstrated a sensitisation 
of ARID1A deficient GC models to small molecule ATR inhibition. This has been 
previously reported in ovarian models, where defects in ARID1A sensitised tumour 
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cells to ATRi, both in vivo and in vitro, by triggering premature mitotic entry, genomic 
instability and apoptosis (Williamson, Miller et al. 2016). Although the effects described 
in our gastric tumour models were less profound than what described by Williamson 
et. al, which might be due to the involvement of other genetic factors such as MSI, that 
could contribute to the observed sensitivity, both studies suggest that ATR is a 
synthetically lethal partner to ARID1A. Thus, I believe it should be considered as a 
biomarker in an ATRi context, and could represent a promising therapeutic strategy, 
given that there is a high frequency of ARID1A mutations across all cancers and the 
promising results seen in clinical trials utilising DDR inhibitors. Further study of the 
collected resistant PDX tumours, along with additional mechanistic approaches is 
required to determine the exact role of ARIDA in the ATRi response and its implication 
in DDR.  
 
3. ATR inhibitor resistance mechanisms in gastric cancer 
Genomic instability constitutes one of the hallmarks of cancer. Genomic instability is 
characteristic of most of the tumours, and this seems to be related with the high 
proliferative rate of cancer cells, together with the inability of the DDR machinery to 
efficiently repair DNA damage (Lindahl and Barnes 2000, Hoeijmakers 2009, Lord and 
Ashworth 2012). Although genomic instability remains one of the main causes of 
cancer, it can also be exploited as a vulnerability in cancer cells that can be 
therapeutically targeted. Traditionally, this strategy has been exploited by the use of 
chemotherapeutical agents, or radiotherapy, which still remain the standard of care in 
many cancers, where no targeted therapies are available. In the last few decades, 
several drugs targeting DDR proteins have been developed. One of the most 
successful examples of this approach is the use of PARPi for the treatment of 
BRCA1/BRCA2-deficient tumours, which is currently being exploited for the treatment 
of several types of cancer (Farmer, McCabe et al. 2005, Lord and Ashworth 2012, 
Lord and Ashworth 2017, Ashworth and Lord 2018, Ferrara, Simionato et al. 2018). 
Following the example of PARPi, ATRi have also been tested in several clinical trials, 
and they seem to be a promising therapy for cancers with DDR defects due to the 
central role of ATR in regulating DDR processes and the development of specific and 
potent ATRi (Sundar, Brown et al. 2017). 
 
As in other monotherapies, clinical resistance to DDR inhibitors is inevitable. An 
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example of this is the appearance of resistance-causing reversion mutations in 
BRCA1/2 deficient cancers in the context of PARPi-BRCA1/2 SL (Edwards, Brough et 
al. 2008, Barber, Sandhu et al. 2013, Weigelt, Comino-Mendez et al. 2017). To the 
date, only two published studies have informed about ATRi resistance-causing genes. 
The first study demonstrated how CDC25A deficient mouse embryonic stem cells 
were able to resist high doses of ATRi due to their failure to prematurely enter mitosis 
in response to the drug-induced DNA damage (Ruiz, Mayor-Ruiz et al. 2016). The 
other manuscript published data validating the hypothesis of CDC25A as an ATRi-
resistance causing gene in a CRISPR/Cas9 screen undertaken in three different 
tumour cell lines, along with CDC25B, cyclin-dependant kinase 2 (CDK2), Kelch Like 
ECH Associated Protein 1 (KEAP1) and several genes involved in the cyclin C 
complex (Chen, Alexe et al. 2018).  
 
3.1. Positive selection genome-wide CRISPR/Cas9 mutagenesis screen reveals 
ATR inhibitor resistance-mediating genes 
In order to pinpoint the potential mechanisms of ATRi resistance, I have undertaken a 
positive selection GW CRISPR/Cas9 mutagenesis screen that has revealed a list of 
candidate genes causing ATRi resistance when gene function is lost. I have validated 
many of the top hits found to be relevant in the initial GW screen by undertaking an 
arrayed mini-CRISPR/Cas9 screen. This included the cell cycle regulators CDC25B 
and FOXM1, the apoptosis-related gene CARD10, the E3 ubiquitin ligase HUWE1, 
the nuclear ribonucleoprotein HNRNPF, the nonsense mediated decay pathway 
regulators SMG8 and SMG9, and genes coding for proteins involved in the 
Interferon/JAK/STAT pathway, such as STAT1, STAT2 and IRF9, amongst others. 
Given that HUWE1 and IRF9 were validated from my screen, I decided to study the 
role of these genes in ATRi resistance, through the use of these Isogenic HUWE1 -/-
/+/+ and IRF9 -/-/+/+ models, picked from the GW screen.  
 
I subsequently demonstrated that loss of function mutations in HUWE1 induced 
resistance to ATR inhibition (VX970 and AZD6738) in YCC6 gastric tumour cells. Cell 
cycle experiments, using these isogenic models have revealed a decrease of the 
number of cells in inactive S phase, an indicator of S phase arrest, after inducing DNA 
damage by ATRi treatment in HUWE1 -/- cells, in comparison to the WT parental cells. 
Which seems to indicate an enhancer ability of HUWE-/- cells to repair DNA damage 
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in a more efficient way in response to ATRi. HUWE1 is an E3 ubiquitin ligase part of 
the HECT (homologous to E6-associated protein C-terminus) family in charge of the 
ubiquitination and degradation of a high number of substrates, including p53 (Chen, 
Kon et al. 2005), MCL-1 (Zhong, Gao et al. 2005), c-MYC/n-MYC (Zhao, Heng et al. 
2008, Myant, Cammareri et al. 2017), CDC6 (Hall, Kow et al. 2007), TOPBP1 (Herold, 
Hock et al. 2008), POLβ/ϒ (Parsons, Tait et al. 2009, Markkanen, van Loon et al. 
2012) and BRCA1 (Wang, Lu et al. 2014). Apart from its interaction with BRCA1 and 
its known role in base excision repair (Parsons, Tait et al. 2009, Markkanen, van Loon 
et al. 2012), HUWE1 has also been described to participate in DNA damage response, 
by its direct association with replication forks, mediated by PCNA, and the activation 
of H2AX, a key recruiter of DDR proteins (Choe, Nicolae et al. 2016). Conversely, both 
oncogenic and tumour suppressor roles have been attributed to HUWE1, and both 
activating and silencing mutations have been found in different cancer types 
(Adhikary, Marinoni et al. 2005, Hall, Kow et al. 2007, Bernassola, Karin et al. 2008, 
Zhao, Heng et al. 2008, Zhao, D'Arca et al. 2009, Wang, Lu et al. 2014, Wang, Lu et 
al. 2014, Choe, Nicolae et al. 2016, Myant, Cammareri et al. 2017, Yang, Sun et al. 
2017, Yang, Cheng et al. 2018), demonstrating that HUWE1 plays a wide number of 
roles through the modulation of a large number of substrates. Loss of HUWE1, has 
been shown to lead to accelerated proliferation, repression of apoptosis and 
tumourigenesis through the increase of levels of MYC (Myant, Cammareri et al. 2017), 
and MCL-1 (Zhong, Gao et al. 2005), which results in increased proliferation, a failure 
of cells to enter apoptosis and thus, the ability to resist death after the ATRi treatment. 
Data published by other groups have shown that HUWE1 depleted cells demonstrate 
increased resistance to several DNA damaging agents, mediated by an increase of 
BRCA1 levels, and a decrease of p53 and MCL-1 roles in DDR, cell cycle regulation 
and apoptosis, leading to genomic instability and tumourigenesis in tumour cells 
(Wang, Lu et al. 2014).  
 
Contrary to what our data suggests, and to the previously described studies, Choe et 
al. reported a model where loss of HUWE1 expression was able to confer sensitivity 
to replication fork stalling agents such as hydroxyurea (HU) and UV light. They showed 
a reduction in the progression of replication forks by DNA fibre assays and an increase 
in the inactive S phase population when HUWE1 was lost in BrdU/PI stained cell cycle 
experiments. Considering this data, I hypothesise this conflicting results might be due 
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the ability HUWE1 to modulate different DDR proteins in a context-dependent manner, 
influencing the pathway of choice in the DDR (Wang, Lu et al. 2014). Furthermore, the 
effect of ATR inhibition in cancer cells could have different consequences than HU 
treatment of UV light induced mutagenesis. Going forward, I will test if the HUWE1 
deficient models are also resistant to other DNA damaging agents, including DSB 
causing agents such as carboplatin. In addition, I will also assess whether HUWE1 
depletion increases genomic instability in the YCC6 cells trough DNA fibre assay 
experiments and the determination of ϒ-H2AX levels, to better understand the effect 
of losing HUWE1 function in terms of DNA repair dynamics. Due to the wide range of 
HUWE1 substrates, further evaluation of protein levels modulation by western blot or 
mass spectrometry will be useful to determine which pathways are involved in the 
ATRi induced resistance in our models. Finally, given that YCC6 cell line is an ARID1A 
deficient cell line, and ARID1A has also been related to DNA damage processes 
(Shen, Peng et al. 2015, Williamson, Miller et al. 2016), it would be important to test 
this effect in other GC ARID1A deficient and proficient models, to further determine 
the role of ARID1A in this process. 
 
Similar to what I saw in the HUWE1 deficient cells, IRF9 deficient YCC6 cells followed 
the same trend in the cell cycle experiments, although the effect was less profound. 
IRF9 is the DNA binding domain of the IFN-stimulated gene factor 3 (ISGF3) complex, 
with is also constituted by the STAT1/2 heterodimer, downstream of the type I 
interferon pathway (IFN), in charge of mediating major innate immune responses to 
infectious agents through the modulation of the interferon stimulated genes (ISGs) 
(Platanias 2005). Although interferon regulatory factors (IRFs) have been associated 
with other signalling pathways, different from its well-known role in the immune 
response processes, the implications of IRF9 in tumourigenesis remain unclear, and 
it is possible association to DDR has not been studied yet. Nevertheless, some other 
IRF family members have previously been related to the tumourigenic processes. 
Studies carried out in human breast cancer tissues, revealed a downregulation of 
IRF5, which was associated with an increased metastatic potential of the cancer cells 
(Bi, Hameed et al. 2011, Pimenta and Barnes 2013). In addition, some other authors 
have defined a role of loss of IRF1 in the development of human leukaemia, 
oesophageal and GC, being considered as a tumour suppressor gene (Boultwood, 
Fidler et al. 1993, Willman, Sever et al. 1993, Ogasawara, Tamura et al. 1996, 
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Tamura, Ogasawara et al. 1996, Nozawa, Oda et al. 1998). Likewise, the other 
partners of IRF9 in the ISGF3 complex, STAT1 and STAT2 seem to have tumour 
suppressive functions and have been found to show reduced expression in melanoma 
and chronic myeloid leukaemia (Wong, Krauer et al. 1997, Landolfo, Guarini et al. 
2000). What it is interesting it is that I have found all three genes (IRF9, STAT1 and 
STAT2) as top ATR resistance candidates in our screen, which suggests a tumour 
suppressor role that can be extended to the whole ISGF3 complex. Nevertheless, the 
fact that our experiments have been done in vitro, in a model lacking an immune 
microenvironment, makes the interpretation of this data more complex, as there is a 
possibility for these results to be triggered by the lentiviral infection of the cells, part of 
the protocol of the CRISPR/Cas9 screen. Although we cannot entirely exclude the 
possibility of off target effects caused by the lentiviral infectious process, this is not 
likely to be the case as I have found dysregulation of this pathway in the YCC6 ATRi 
resistant clones which have not been infected with lentivirus, suggesting that the 
proposed resistance mechanism is real. Moreover, other studies have demonstrated 
IRF9 to be implicated in resistance to antimicrotubule agents’ and in the regulation of 
IL6 and PD-L1, both related with the carcinogenic process, using cell lines as a model 
(Luker, Pica et al. 2001, Morimoto, Kishida et al. 2018, Nan, Wang et al. 2018). Despite 
of this, it would be interesting to validate these results using in vivo models with a 
competent immune system, as well as undertaking further experiments that can inform 
us about the role of IRF9, STAT1/2 in the DDR response, through the modulation of 
its target genes (ISGs). Finally, an abstract presented in ESMO 2018 (Annals of 
Oncology, Volume 29, Issue suppl_8, 1 October 2018, mdy303.019), Dillon et al. 
reported an IFN-mediated response in vivo cancer models when treated with a 
combination of the ATRi, AZD6738 and radiotherapy, that caused an increase in the 
number of several immune cell types. Considering this, it is possible that within the 
context of ATR inhibition, the loss of IRF9 or other factors involved in the IFN pathway 
could impair the recruitment of immune cells, favouring resistance. Further in vivo 
experiments will be necessary to evaluate this hypothesis in GC. 
 
The use of high-throughput genetic CRISPR/Cas9 screens has allowed us to identify 
potential candidate genes that are relevant to the acquired resistance to ATRi. 
Because this screen has been performed on a GW scale, I have defined a long list of 
genes that are potential candidates implicated in this process. One challenge of 
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working with big data is how to prioritise the results, as well as the discrimination of 
the positives from the false positives. This makes, the use of validation experiments 
in several orthogonal methodologies and models absolutely necessary to select the 
true candidates and validate their implication in the genetic pathway. At the same time 
that I performed the CRISPR screen in the YCC6 GC cell line, I also carried out a 
parallel screen in the OCCC TOV21G. In this thesis, I have focused on the YCC6 
screen, as I am principally interested in mechanisms of resistance arising in GC. 
Nevertheless, I have also used the results from the TOV21G screen to cross-reference 
the data from both screens, to give robustness to the data, to help us narrow the list 
of top candidate genes for further following up, and to identify mechanisms that are 
common to other models and not private to the GC models used in this thesis. 
Additionally, a recent study published data from three other cancer cell line models 
revealing genetic determinants of response to ATRi in the  kidney cancer cell line 
293A, the colorectal cancer cell line HCT 116 and the breast epithelial cell line 
MCF10A (Wang, Wang et al. 2018). Despite of the fact the authors used a different 
ATRi in their study (AZD6738), I considered that it would be informative to annotate 
the genes that remain significant independently of the ATRi used or the histology of 
the models. Analysing this combined set of data has allowed me to 1) generate a list 
of ATRi resistant-causing relevant genes across cancer and ATRi 2) narrow down the 
list of genes I want to focus my attention in the next steps of the project. This analysis 
has shown that CDC25B is the gene with a largest effect in causing ATRi resistance 
as, it is a candidate resistance gene present in all 5 cell lines analysed. CDC25B is a 
member of the CDC25 family of phosphatases that can also be found in the CDC25C 
and CDC25A isoforms in humans, and catalyses the dephosphorylation and activation 
of the cyclin dependent kinases (CDKs) required for mitotic entry and cell cycle 
progression in cells (Sohn, Kristjansdottir et al. 2004). While CDC25A has been linked 
to the G1/S checkpoint, the three isoforms are known to have a pivotal role in G2/M 
transition and control mitosis by the modulation of cell cycle regulatory proteins as 
CDK1/2 and CDC2 (Boutros, Lobjois et al. 2007, Aressy and Ducommun 2008). 
CDC25A has been identified as a determinant of resistance to ATR inhibition in murine 
embryonic stem cell based CRISPR/Cas9 positive selection mutagenesis screen. This 
is described to occur through the cell’s failure to enter mitosis prematurely in response 
to the drug, as CDC25A is a key mediator of apoptosis, after DNA damage (Ruiz, 
Mayor-Ruiz et al. 2016). In the latter study, Ruiz et al. investigated the possibility for 
	 138	
CDC25B to play similar roles to CDC25A in ATRi resistance, finding no clear effect of 
ATRi resistance in CDC25B deficient cells. Moreover, ATR inhibition did not increase 
CDC25B expression, suggesting a different function to CDC25A in mediating the DNA 
damage cascade in those models. In our initial screen as well as in the validation data, 
I detected CDC25A to be a determinant of ATRi resistance, although the effect seems 
to be much less profound than the one observed for CDC25B. It is possible that these 
differences are due to a model-specific features and that the activation of either 
CDC25A or B depends on the genetic context of each cell line. Furthermore, our model 
is ARID1A deficient, which is a protein implicated in the DDR, and described be 
recruited to DSBs through its interaction with ATR, facilitating DSB end processing to 
generate RPA-coated ssDNA, and sustaining ATR activity in response to DNA 
damage (Shen, Peng et al. 2015). As all the components of the CDC25 family are 
directly regulated by ATR and its downstream effectors, it is possible that ATR 
influences the expression CDC25s to regulate mitosis. As discussed above, a recent 
study has described some ATRi resistance-conferring genes including both CDC25A 
and CDC25B in three different cell lines (HCT 116, MCF10A and 293A). Although 
none of these cell lines are from GC histology, nor ARID1A deficient, this data strongly 
supports a model where both isoforms are implicated in ATRi response and 
resistance. The role CDC25C is less clear; and there is no available data that 
associates its loss to ATRi resistance mechanisms.  
Going forward, it would be informative to evaluate whether the levels of ϒH2AX, a 
marker of genomic instability, or the decrease of premature mitotic entry occurs in the 
absence of CDC25B in our models, and, if the use of WEE1 inhibitors (WEE1i), can 
re-sensitise our cells to ATRi through the induction of the pro-mitotic factor CDK1, as 
described in CDC25A null models. This would be the rational for combining ATRi and 
WEE1i in the clinic, with the aim of avoiding drug-resistance. Related to this, I also 
found FOXM1 loss to cause ATRi resistance from the YCC6 GW CRISPR screen. 
Recent publications have defined FOXM1 as a direct regulator of mitosis, controlled 
by the ATR-CHK1-CDC25 axis (Saldivar, Hamperl et al. 2018). In the model Saldivar 
et al. propose, an ETAA1-DNA damage mediated activation of ATR causes the 
phosphorylation of CHK1, which inhibits CDC25 proteins, which are then not able to 
activate CDK1 and subsequently FOXM1, controlling S/G2 transition and mitosis, to 
ensure the correct replication of DNA before the cell divides. In the context of ATRi, 
cells undergo accelerated mitosis and this is associated with high levels of 
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phosphorylated FOXM1 in S phase (Saldivar, Hamperl et al. 2018). Because of the 
direct implications of FOXM1 downstream the ATR/CHK1/CDC25s pathway, it makes 
sense to think that loss of FOXM1 could mimic what happens when CDC25A or 
CDC25B are not present. If CDC25A deficient cells fail to enter mitosis in response to 
drug, due to an impairment of CDK1 activation after DNA damage, causing resistance 
to ATR inhibition (Ruiz, Mayor-Ruiz et al. 2016), it seems logical to expect that FOXM1 
loss would have similar consequences in the cells. Thus, FOXM1 could be another 
mediator of ATRi resistance, as CDC25 proteins loss causes a reduction in CDK1 and 
FOXM1 activity after DNA damage. With this in mind, I am developing both, CDC25B 
and FOXM1 deficient models, which would be useful to test whether they are both 
involved in mediating ATRi resistance through the impairment of premature mitosis 
(Ruiz, Mayor-Ruiz et al. 2016).  
 
Apart from CDC25B/A and FOXM1, I have validated other interesting ATRi 
determinants of resistance in the arrayed CRISPR/Cas9 screen experiment that have 
been found to be important in the other cell lines analysed (Figure 25B). As an 
example, CARD10, encodes for a structural protein, member of the CARMA 
(membrane associated guanylate kinase-like domain) family of proteins, that 
participates in apoptosis mediation, and plays a role in the activation of the NF-kappa-
B (NF-κB) signalling pathway, forming a complex with BCL10 and MALT1 (CBM) 
(Grabiner, Blonska et al. 2007, Jiang, Grabiner et al. 2011). Interestingly, NF-κB is a 
cancer-related pathway that has been described to be activated through ATM 
phosphorylation in response to DNA damage to induce the expression of anti-
apoptotic genes, which is a process that has also been related to the development of 
resistance to chemotherapy (Zhang, Pan et al. 2017), making CARD10 an interesting 
ATRi resistance gene to study further. 
 
Finally, I also validated SMG8 and SMG9 as ATRi resistance genes. SMG8 and SMG9 
are both members of the non-sense mediated decay (NMD) pathway, in charge of the 
post-transcriptional modulation mRNAs expression and degradation of defective 
mRNAs that contain premature stop codons, preventing aberrant protein truncation 
(Popp and Maquat 2013, Lykke-Andersen and Bennett 2014, Lykke-Andersen and 
Jensen 2015, Karousis, Nasif et al. 2016). SMG8 and SMG9 form a heterodimer that 
acts as a negative regulator of the PIKK SMG1 (Arias-Palomo, Yamashita et al. 2011, 
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Fernandez, Yamashita et al. 2011), pivotal in the NMD pathway. In addition to its role 
in the NMD pathway, SMG1 it is known to play a role in the maintenance of the 
genomic instability, similar to other PIKKs like ATR and ATM (Brumbaugh, Otterness 
et al. 2004). Moreover, the three PIKKs converge in the phosphorylation of UPF1, 
which is an 5’-3’ DNA and RNA helicase in charge of facilitating several RNA 
degradation pathways (including NMD), as well of a mediator of DNA replication in S 
phase of cell cycle (Azzalin and Lingner 2006). Depletion of UPF1, leads to the 
impairment of the NMD pathway, as well as to the accumulation of genomic instability 
and an S phase cell cycle arrest (Azzalin and Lingner 2006, Azzalin and Lingner 2006). 
Depletion of ATR has been shown to lead to the impairment of UPF1 chromatin 
loading and accumulation of DNA damage (Azzalin and Lingner 2006) which suggests 
a central role of ATR in UPF1 regulation. Being a helicase, it has been hypothesised 
that UPF1 it might be in charge of unwinding the DNA in front of the replication fork, 
physically interacting with DNA polymerase delta, a main polymerase in DNA 
replication (Azzalin and Lingner 2006). This could be an explanation for the S phase 
arrest observed in UPF1 knockdown cells, and would suggest multiple roles for this 
protein. As SMG1 is known to have the ability to phosphorylate UPF1, especially in 
the context of the NMD pathway, it is reasonable to think that it might be implicated in 
UPF1 regulation upon other conditions, like ATR depletion. SMG1 depletion in the 
cells, leads to the accumulation of DNA damage, which could be explained by the 
aberrant regulation of UPF1 (Azzalin and Lingner 2006). Thus, in an ATR depleted 
situation, the impairment of SMG8 and SMG9 (as negative regulators of SMG1), could 
potentially lead to the upregulation of SMG1, activating UPF1 at the DNA fork, and 
thus facilitating the DNA repair in the cells before mitosis, causing resistance to ATRi. 
Interestingly, one of the proteins found upregulated in our ATRi resistant clones was 
SMG1, supporting its implication in mediating ATRi resistance. Consistent with my 
hypothesis, siRNA knockdown experiments have demonstrated that SMG1 
downregulation is able to re-sensitise the cancer cells to ATRi, underlying the role of 
SMG1 as a mediator of ATRi resistance. Further experiments will be carried out to 
determine if this resistance is mediated through the modulation of UPF1 and the 
facilitation of DDR in condition of ATR depletion. These observations open the 
possibility to develop and test SMG1 inhibitors in combination with ATRi, to avoid 
resistance in the cancer cells, which can be widely relevant in the clinical practice, now 
that ATRi are starting to be used in clinical trials.  
	 141	
 
Therefore, in this section I have discovered and validated a number of novel 
determinants to ATRi resistance in GC, providing with a rationale to study their role in 
carcinogenesis and drug resistance and that can potentially be considered as 
biomarkers or therapy-guiding genes in the clinical practice. 
 
3.2. ATR inhibitor resistant isogenic cells 
With the aim of identifying genetic determinants to ATRi resistance in GC, I created 
eight ATRi resistant isogenic clones from YCC6 tumour cell line and performed 
proteomic analyses to detect significant deregulated proteins that can cause ATRi 
resistance. I observed that five of the clones, all part of the same cluster, according to 
the principal components analysis of the proteome presented a change in the 
micromorphology of the cell (H1, H2, H3, H4 and H6), exhibiting mesenchymal 
attributes, different from the epithelial parental cell line. Epithelial-mesenchymal 
morphology changes have been widely described in tumour cells that undergo genetic 
changes, as mesenchymal morphology has been related to an enhanced capacity of 
cancer cells to invade and metastasise, which can be related to the development of 
drug resistance mechanisms (Lyons, Alizadeh et al. 2016). Metastasis of tumour cells 
requires the following sequence of events: the ability of detachment from the primary 
tumour, migrating to the vascular supply, trespassing of the vessel wall (intravasation), 
transiting in the blood or lymphatics, exiting from the vascular supply (extravasation), 
and finally with the attachment and proliferation at the new site (Chambers, Groom et 
al. 2002). Usually, metastatic cells are associated with deformable shape and a low 
expression of proteins related to cell-cell adhesion or cell-extracellular matrix 
adhesion, which confers to the cell a larger size, mesenchymal-like elongated spindle 
morphology, and changes in the cytoskeleton structure (Cavallaro and Christofori 
2004, Cross, Jin et al. 2007, Cross, Jin et al. 2008, Berx and van Roy 2009). Using 
the REACTOME 2016 pathway database to carry out a pathway analysis in relation to 
the differences in proteome found in the resistant clones in comparison to the parental 
cell line, one of the highest deregulated group of proteins in our resistant clones were 
the cell-cell adhesion proteins (data not shown). These included proteins expressed 
from the following genes: CDH1 (E-Cadherin), n-CAM (Neural Cell Adhesion Molecule 
1), KRT7 (Keratin 7), KRT19 (Keratin 19), SMAD4 (SMAD Family Member 4), PIK3CB 
(Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta), SPTBN1 
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(Spectrin Beta, Non-Erythrocytic 1), ITGB4 (Integrin Subunit Beta 4), PARD6B (Par-6 
Family Cell Polarity Regulator Beta), ROCK2 (Rho Associated Coiled-Coil Containing 
Protein Kinase 2), RHOB (Ras Homolog Family Member B), PAK1(P21 (RAC1) 
Activated Kinase 1), ECM1 (Extracellular matrix protein 1), MLLT4 (Afadin, Adherens 
Junction Formation Factor), EZR (Ezrin), VIM (Vimentin), ARHGAP21(Rho GTPase 
Activating Protein 21) and CD2AP (CD2 Associated Protein), which are known to be 
involved in cell-cell adhesion, cell-extracellular matrix adhesion and the cytoskeletal 
structure in the cell. These changes were seen in the YCC6 ATRi resistant clones that 
had acquired a mesenchymal morphology but were absent in the clones that did not 
undergo morphological changes. This indicates that the changes in the morphology of 
the tumour cells play an important role in the ATRi-resistance mechanism. In contrast, 
some of the resistant clones did not undergo morphological changes, and other 
proteins, not related to cell morphology were detected as significantly deregulated 
proteins, suggesting that this is not the only mechanism mediating resistance. 
 
Apart from the changes in the cell-morphology associated proteins, I detected other 
deregulated proteins in the ATRi resistant clones, compared with the parental cell line. 
This list varied widely when I compared all the clones together to the parental cell lines 
and also when I divided them in two clusters, determined by similarities in the 
proteome (PCA). Several proteins previously related with the carcinogenic process 
were detected. Amongst them, MET/HRAS/PIK3CB have been related to drug 
resistance in cancer (Hah, Zhao et al. 2014, Leiser, Medova et al. 2015, Pietrantonio, 
Fuca et al. 2018). Moreover, NF1 was found to be downregulated in the resistant 
clones. NF1, or Neourofibromatosis type 1 is a tumour suppressor gene that has 
previously been identified as an Cetuximab-resistance conferring factor in EGFR-
amplified colorectal tumours (Mei, Shao et al. 2018). When I cross-referenced the 
results from the proteomic analysis with the GW CRISPR screen data, only 
ARHGAP21 and TYK2 were downregulated in the resistant clones, as well as 
displaying enrichment of sgRNA in the resistant cells. Notably, TYK2 was found in in 
the Top 20 candidates from the screen, and also found to be downregulated in one of 
the resistant colonies (See VX970 positive selection GW CRISPR-Cas9 mutagenesis 
screen section, Figure 20C and Table 8). Additionally, STAT5B was found 
deregulated, also a component of the JAK/STAT pathway, which supports an 
important role of this pathway in the ATRi resistance process. I was especially 
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interested in SMG1, as it validates our hypothesis regarding the role of SMG8/SMG9 
as ATRi resistance mediators. As discussed before, SMG8 and SMG9 form a 
heterodimer in charge of negatively regulating SMG1 (Arias-Palomo, Yamashita et al. 
2011, Fernandez, Yamashita et al. 2011). Therefore, it is reasonable to expect that 
SMG8/SMG9 downregulation could cause an increase in SMG1 expression, which 
could be the mediator of ATRi resistance I have seen in our cells. SMG1 is also 
upregulated in the ATRi resistant clones, which supports our working hypothesis.  
 
In this thesis, I have presented data regarding the proteomic analysis undertaken in 
the resistant clones, although additional mRNA sequencing and exome sequencing of 
the resistant colonies are currently being performed, to achieve a comprehensive view 
of the mechanisms involved in the ATRi resistance process. Integration of sequencing 
results extracted from the different high-throughput techniques, as well as with the GW 
CRISPR screen data will be useful to give us a deeper understanding of the main ATRi 
resistance-causing mechanisms in GC.  
Moreover, for the purposes of this thesis, and due to its interest in relation with the 
GW CRISPR screen data, only SMG1 validation is presented, although more proteins 
will be tested for its part in ATRi resistance mechanisms in the near future. 
 
3.3. Dense Tiling ATR CRISPRx Screen 
With the aim of identifying regions in the ATR protein that are relevant for the 
development of ATRi resistance, I have carried out a dense tiling CRISPRx screen, 
following the principals and methodology described previously (Komor, Kim et al. 
2016, Gaudelli, Komor et al. 2017, Komor, Badran et al. 2017, Komor, Zhao et al. 
2017, Pettitt, Krastev et al. 2018). This approach has allowed me to describe candidate 
mutations in the ATR sequence that cause resistance to the ATRi VX970 in the GC 
tumour cell line YCC6. 
I have detected a cluster of ATRi resistance-conferring mutations affecting residues 
located in the FAT domain (Figure 35A and 35B). The FAT domain has been 
previously described to be crucial for ATR activation through the autophosphorylation 
and stimulation of TopBP1 function, which is crucial for ATR substrate recognition and 
the transmission of the DDR signal (Liu, Shiotani et al. 2011). Apart from its role in 
ATR activation, it has been hypothesised that, due to the fact that FAT and FATC 
domains only occur in combination in the PIKKs, they must structurally interact with 
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each other in a way that ensures the ATR kinase domain function, that is located 
between the two domains (Bosotti, Isacchi et al. 2000, Lempiainen and Halazonetis 
2009). This has also been described to be the case in other PIKKs as ATM, DNA-
PKcs, SMG1 and mTOR, where structural changes in the FAT or the FATC domains 
impair their kinase activity (Stan, McLaughlin et al. 1994, Choi, Chen et al. 1996, 
Bosotti, Isacchi et al. 2000, Peterson, Beal et al. 2000, Takahashi, Hara et al. 2000, 
You, Chahwan et al. 2005, Cavalieri, Funaro et al. 2006, Spagnolo, Rivera-Calzada et 
al. 2006, Morita, Yamashita et al. 2007, Lempiainen and Halazonetis 2009). Lastly, 
mutations in ATR’s FAT domain have been reported to impair ATR-dependent 
responses to DNA damage through the impairment of CHK1 and p53 activation, as 
well as the abrogation of cell cycle arrest (Fang, Tsao et al. 2004, Lewis, Mullany et 
al. 2005, Tanaka, Weinel et al. 2012), which could potentially explain the emergence 
of ATRi resistance mechanisms in our model (Figure 35B). Therefore, I hypothesise 
that mutations in the ATR’s FAT domain are likely to cause ATRi resistance due to the 
impairment of the proper protein folding and kinase function, not allowing ATR to 
ensure the correct repair of DNA damage before cells undergo mitosis.  
The 3D ATR structure has not yet been constructed (due to the technical challenges 
of the large protein size). However, the cryo-electron microscopy structure of the ATR-
ATRIP complex was partially described recently, providing valuable information about 
the complex assembly, and where the ATRi VX970 binds (Rao, Liu et al. 2018). VX970 
is predicted to bind to the catalytic domain of ATR through a deep pocket that is 
thought to accommodate ATP for substrate phosphorylation, preventing the transfer 
of the group phosphate to the substrates (Rao, Liu et al. 2018). Hence, another 
explanation for the observed resistance could be that the aberrant folding of the protein 
impairs the binding of the inhibitor VX970 to bind the ATR catalytic domain, and 
therefore, causing a physical resistance to the drug. The use of other ATRi inhibitors, 
known to bind to other parts of the protein, will reveal if this is the case. 
Following the acquisition of my data, I have designed validation experiments to identify 
the exact effect of a determined mutation in ATR protein activity with respect to ATRi 
response. With this aim, I picked and expanded several resistant clones from the initial 
CRISPRx experiment at the time I retrieved the resistant population for sequencing. 
This will allow us to characterise the clones in terms of ATR mutations and ATRi 
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resistance (to VX970 and other ATRi), and therefore to have a collection of isogenic 
models with mutations located in several areas of the protein. When these models will 
be generated I will create additional isogenic models to represent other areas of the 
protein in this and other cell lines, using the CRISPR/Cas9 technique. This will be 
important to discard model-specific conclusions, thereby removing false positive 
results from our screen. Due to the role of ATR in mediating the DDR cascade through 
its interaction with downstream proteins, it would also be interesting to determine the 
effect of the mutations in a specific region of the protein in other relevant protein-
protein interaction. This could be tested through immunoprecipitation experiments, 
where ATR and its interacting proteins are studied to see changes in the protein 
populations in the ATR mutated cells. At the same time, it would be noteworthy to 
describe the ability of mutated ATR to orchestrate the DDR cascade by carrying out a 
study of the state of phosphorylation of downstream proteins, such as CHK1, TopBP1 
and CDK2. These isogenic models would help to determine whether they are resistant 
to other ATRi that bind to other residues, and whether the resistance I see is due to 
the physical impairment of VX970 accession to ATR catalytic domain.   
 
4. Biological implications of the results and future perspectives 
In this thesis, I have demonstrated that ARID1A deficiency plays an important role in 
ATRi sensitivity, in both, in vitro and in vivo GC models. Although this effect is clear in 
our GC models, the penetrance of this SL (the percentage of models with ARID1A 
deficiency where ATRi enhanced sensitivity is observed) does not seem to be 
complete. To date, only a few highly penetrant SLs have been described, and low 
penetrance SL remains a clinical barrier to exploit genetic dependencies from a 
therapeutic perspective (Ryan, Bajrami et al. 2018). In this study, I have demonstrated 
the ARID1A and ATR SL in GC in vitro and in vivo. More studies, incorporating a larger 
number of models will be necessary to determine the penetrance of this SL in GC or 
across all histologies and thereby, identify robust determinants to ATRi response, in 
the presence or absence of ARID1A deficiency. Therefore, I currently sequencing the 
retrieved resistant tumours from the PDX models to identify other predictive 
biomarkers of ATRi, by comparing them with tumours harvested from the vehicle 
control arm. ARID1A is a gene that is highly mutated across cancer (20%). As a result 
of the data described in this thesis, we are currently negotiating a clinical study 
evaluating response to VX970 in four cohorts of GC: MSI and ARID1A null, MSI and 
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ARID1A WT, MSS and ARID1A null and MSS and ARID1A WT. This will allow us to 
compare responses to ATRi within each genotypic group in a prospective study. 
 
Additionally, I have described and validated several genes involved in the ATRi 
resistance process in GC through undertaking a GW CRISPR screen and the creation 
of ATRi resistant models. Several candidate resistance genes including HUWE1, 
SMG8, SMG9, SMG1, HNRNPF, IRF9, CARD10, CDC25B and STAT2 have been 
robustly validated in orthogonal formats and models. Of note, I have demonstrated 
that SMG1 overexpression mediates ATRi resistance in GC. I am currently creating 
new isogenic models using the CRISPR/Cas9 technique, to generate YCC6 clones 
representing SMG8, SMG9 and SMG1 deficiency in the YCC6 cell line, as well as in 
other mutant gastric cell lines to validate the effect I have described in the YCC6 cells. 
In parallel, I am undertaking knockdown experiments to try to clarify whether this 
resistance is mediated by the regulation of UPF1. The use of orthogonal models will 
allow us to detect ATRi response determinants that are not influenced by the 
genetic/epigenetic profile of a specific model. Additionally, siRNA knockdown and cell 
cycle experiments will be performed to better define the mechanisms by which this 
resistance is occurring.  
 
Furthermore, I have created ATRi resistant models that will allow me to validate 
previous hypotheses generated from the GW CRISPR screen experiment that will be 
useful to further characterise mechanisms of ATRi resistance through DNA whole 
exome sequencing and RNA sequencing. 
 
Finally, I have shown how mutations in the FAT domain of ATR cause resistance to 
ATRi. Going forward, I will create isogenic models that harbour mutations in this 
stretch of the ATR protein, to enable functional validation and to determine whether 
ATRi resistance is caused by an impairment of the inhibitor binding or by the structural 
inability of ATR to carry out its normal function. I will utilise the CRISPRx technique for 
model generation. Mass spectrometry and immunoprecipitation experiments will help 
me to define the changes of ATR-protein interactions in the mutant clones, compared 





In this thesis, I have: 
 
1. Shown that ATR inhibition constitutes an ARID1A synthetically lethal interaction 
in gastric cancer that can be elicited with small molecule inhibitors such as 
VX970, AZD6738 and M4344. These effects have been observed in a panel of 
gastric tumour cell lines, ARID1A isogenic models and gastric cancer human-
derived xenografts. These results provide with a rationale to test these 
compounds in clinical trials recruiting patients with gastric cancer, within the 
context of ARID1A deficiency.  
 
2. Identified and validated HUWE1, HNRNPF, IRF9, SMG8, SMG9, CARD10, 
CDC25B and STAT2 as genetic determinants to ATRi resistance in gastric 
cancer.  
 
3. Described that the overexpression of SMG1 causes resistance to ATRi in 
gastric cancer. 
 
4. Identified potential ATR inhibitors-resistance mediators through the creation of 
ATR inhibition resistance gastric cancer models. 
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Supplementary Table 1. sgRNA and target genes used in the genome-wide screen 
validation experiment. Highlighted in red, the sgRNA used in (Mayor-Ruiz et al., 2016) 
 






























































































































































































ATR-R8 CCTCTCTATGGGCAGTCGGTGATCCTCAGCTAGCGGCAAATGTGGTCAAC  
ATR-F9 GATGCGTCAATTTTACGCAGACTATCTTTCTGGTATGCTCTCACTTCCATG  
ATR-R9 CCTCTCTATGGGCAGTCGGTGATCCTCAGCCACTAACACAACTAGCCCGGATTAC  
ATR-F10 GATGCGTCAATTTTACGCAGACTATCTTTCCCTTGAGTGGAGAACAGCAG  






ATR-R13 CCTCTCTATGGGCAGTCGGTGATCCTCAGCTCTCTCTGGTGAGCCACATCTTG  






ATR-F17 GATGCGTCAATTTTACGCAGACTATCTTTCTCTGTGAGGGTGAAGATGATGAC  
ATR-R17 CCTCTCTATGGGCAGTCGGTGATCCTCAGCCGGCTTTTATCTTTTTTAATTCTGG 























ATR-F29 GATGCGTCAATTTTACGCAGACTATCTTTCATAAGGATGTGACCGCGTGC  
ATR-R29 CCTCTCTATGGGCAGTCGGTGATCCTCAGCTGCTTGTTGAGGATAGGCTAG  
ATR-F30 GATGCGTCAATTTTACGCAGACTATCTTTCCTCGAATTTGTCATTCTCACG 




ATR-R32 CCTCTCTATGGGCAGTCGGTGATCCTCAGCGTCAGAATAGGTCTCAAACCAGCAG  
ATR-F33 GATGCGTCAATTTTACGCAGACTATCTTTCCCACTAAATGATGAATGTGGG 
ATR-R33 CCTCTCTATGGGCAGTCGGTGATCCTCAGCGCAGTGGAACGGCAGTAAGC  
ATR-F34 GATGCGTCAATTTTACGCAGACTATCTTTCCTGAGAACATTCCCTGATCC 
ATR-R34 CCTCTCTATGGGCAGTCGGTGATCCTCAGCCACATGCTCTTCGAAAAAGAC 





























Suplementary Table 3. List of overlapping resistance hits with Z-Score >2 comparing 
our YCC6 CRISPR screen results with the TOV21G screen and the 293A, HCT 116 and 
MCF10A cell lines extracted from Wang et al., 2018. Highlighted in blue are the hits that I 
have validated for our YCC6 CRISPR screen. 
 
YCC6 + 4 CL POLL CDC34 PLBD1 EBLN1 GNB4 
CDC25B SHROOM3 CXCR1 NUDT5 PRR16 GPR161 
TRIT1 UNC45A GALR2 SGMS1 PRKAR1A ALG9 
YCC6 + 3 CL FBXL22 ZSCAN5B CCDC97 ANKRD35 GBE1 
CHCHD1 ATXN3 PPP1R7 INA RRAGA IL22RA1 
C10orf32 CDC26 RBAK-RBAKDN CDH22 SCARF1 PIK3C2B 
CPN1 RXFP3 PSMA1 C12orf56 CTU2 LAMTOR3 
OSGEPL1 FAM69A MXI1 STXBP2 ZNF33A MED7 
URM1 IGF1R GFRA4 NKIRAS2 ADRB1 RGS17 
ATAD1 NDUFS5 PADI2 SNTA1 TLN1 TP53TG5 
ABI3 MRPS18B RDH11 NANP ZNF251 HOXA5 
STYX TFAM CALCRL CDKN1A LAMTOR1 USP31 
GATA5 PIK3CA EDNRA CYP2U1 MAPKAP1 LIPT1 
DARS TTC14 TMIE KIF3C AIP GPIHBP1 
ASIP CEP44 VILL LRRC15 ARHGAP32 JPH4 
RICTOR KRT27 ICAM4 KCNH4 SGOL2 TAF13 
SYNPR PAPOLA LRRC43 SYNGR2 PCTP INSL5 
WFIKKN2 HNRNPF CCDC160 APEH OLA1 AP1G1 
AVEN SMG9 S100P GADD45GIP1 CMIP YCC6 + 1 CL 
SELPLG STAT2 PKN1 HUWE1 MYLPF RIC8A 
TMPRSS11A KIF5B CCRN4L RBP4 ZDHHC7 TRABD 
MRPL50 BLOC1S2 ATP8B1 HNRNPD MTMR4 MSRB2 
CSTA GAP43 TADA2A CUEDC2 MRPS16 GAD2 
FGD6 MIB1 DESI2 AKT2 SEC63 ARL5B 
PLD6 EFCAB11 GABRG1 DERL2 GTPBP10 GNA13 
SMG8 ITIH2 SPATA22 HOGA1 CFHR5 TNRC6A 
CDC25A GLUD1 PLA2G7 INCA1 MFSD9 RGCC 
AEBP2 BTBD7 RGS13 PRPH2 PFDN4 SEMA3G 
YCC6 + 2 CL ERGIC2 NUDT6 NLRP8 MLNR RXFP2 
SYNPO2L IVD FAM96A PDE6G PHPT1 SOX13 
MTOR CST9L SPIN3 KIAA1984 CCDC117 ZNF268 
SUV39H2 C17orf80 PPFIA2 POLR3F CPQ LTA4H 
MOB3A GPR65 CLIP3 HTR7 COX17 CCSER2 
MED12 VWA5A PHF14 ZFYVE28 ASB6 PTPDC1 
CNPY2 CYP46A1 BROX CALHM2 LOXL2 PML 
SCD USP46 VAT1L MEPE CCDC82 RNF5 
ALKBH5 MAGEB5 NEO1 SCGB3A1 MBOAT2 PAK4 
FAM212A ZFP64 TEKT1 C10orf95 ALG5 RERE 
WDR87 RASSF5 LCN9 OTUD4 ENG SLC6A13 
HNRNPA0 ADCYAP1 CSN2 C4orf17 MITD1 MIEF1 
NDUFAF1 SYNPO2 SLC6A14 HSPB6 GTF2E2 DCUN1D5 
CHUK CYP3A43 PRRX2 SUPT6H TNPO1 CEBPA 
FOXM1 HSP90B1 RGS1 KCTD8 VENTX MGMT 
TRAPPC10 RCAN1 GUCY2C ZNF677 FAF1 VPS37B 
ZFP36L1 RRAS FUT8 IFNAR1 SIGLEC8 COMMD7 
CD164 C17orf105 RNF128 RET RSRC2 BCAT2 
TIGD7 SNX13 NEUROD2 LDB1 STK4 MTF1 
BCAS3 ODF3B TBC1D14 DCUN1D1 FCRL2 HSPA8 
KLK5 MED12L INTU FASTK WDR59 ZMAT1 
NFYB TM4SF19 ADIRF USP6NL RWDD1 LIPJ 
TDP1 CA4 CMAS SEPHS1 SLC6A12 CDR2L 
TRIM69 SLBP TIGD2 BOK UBQLN1 SSR2 
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ALDH6A1 KLHDC1 INPP5F TMEM126B SLC5A2 MYO1C 
CCDC34 C14orf79 NUDT13 TRHR ELMOD2 C15orf60 
CCDC63 CCDC137 VNN2 DGCR2 PSPC1 C17orf58 
TEX29 AP3B1 RAD51AP2 CNIH4 ESCO1 DOK3 
CYP4Z1 NANOS1 MRPL1 TFDP3 CXorf61 TAOK1 
IMPG2 WDR83OS MS4A7 ZNF107 DCTN1 LAMP5 
SKIV2L GRM3 APPBP2 LRRN3 SERTM1 GPR174 
LINGO1 ELOVL2 SNX6 SKA1 DSC3 AIPL1 
SPTB HPS1 ZC2HC1B TMPRSS7 IFT81 HDAC5 
UCK1 AFP TACR2 GLRA3 GBX2 BLOC1S1 
DUS2 CHST8 ARHGEF3 RNF31 RNF138 SEC62 
PTBP1 TRDN VPS13A RAB1A HEBP2 ADSSL1 
SAMHD1 CDV3 ANGPTL5 C21orf33 TMEM168 CST9 
TCERG1 RBM12 CNNM2 LRRC16B MLXIPL ORM2 
FAM214A NCAN RAB21 APBA1 CCDC114 LRRC46 
NPAS1 SCN4B ARRB1 TRAF1 MYH3 AGFG1 
MOB3C GZF1 PDE6C RWDD4 KPRP MDM1 
C10orf111 ULBP1 CHAT MAP3K13 PF4V1 DLGAP2 
EFCAB4B TSPAN3 CKLF PROL1 KPNA4 CTSC 
TOR1AIP2 ARSH COMTD1 RABL2B AGBL4 AKAP1 
KLRG2 SLC45A3 C11orf91 MLC1 RAP1A OSBPL8 
SPTY2D1 SUGP2 GLYATL2 ABCB1 PAX4 FUT11 
CYFIP1 STARD10 DCAF10 TMEM26 VPS26A RPUSD3 
BTN3A1 C20orf78 PLXDC2 CCDC152 SAA2 CXCR2 
SNX17 C9orf117 ZNF93 VAX1 GJD2 CACNG4 
ECH1 WDR31 C11orf58 RNFT2 IFNGR1 EXD3 
KLF6 ZNF333 ARFGEF1 DENND2A FBRSL1 NREP 
ZSCAN32 FBXL2 TAS2R40 TCTA RAB33B IL23R 
TEAD1 FAM173A AFAP1L2 OXTR BLOC1S5 RSPH3 
ADO MYOM3 HMOX1 LRRC48 ANKS6 PDE6A 
NGLY1 CDC40 CA2 ATP11C DSN1 PLEKHS1 
HMSD C17orf102 SLC46A3 SPAG11B SFTPD CTNNA1 
A4GNT ILDR1 TMEM180 THAP6 BSND MPHOSPH9 
PXN PCDHA9 LHFPL4 PRR24 KIT OTUD6B 
SERPINB13 STK38L IL1A KCNJ11 FAM189B CAMK2G 
TBC1D24 SMYD4 C12orf79 PCGF6 ARHGAP11A VIM 
E2F8 COMP PRSS1 MTERFD1 TOR2A SKIDA1 
C5orf47 MARK4 NGFRAP1 IKBIP SLC24A5 UNC5B 
LRRC37B TMEM106A OPALIN HSDL2 NKX2-2 STOX1 
KHDC1L HSPB8 TTC18 OMG RPL21 GJD4 
BCL6B POLR2A HIST1H4D ARSK RALGAPB MYPN 
VSTM2B GGT7 LRIF1 KIF20B PKDCC TCEB3 
NEMF SPACA3 CD300LD APOL1 MEIS1 WDFY4 
NUDCD1 CLDN12 NRP1 SDF4 GIN1 PTPLA 
HSD3B2 TLR2 SOCS7 PCSK4 MUC1 RBP3 
CCNB2 MAVS PACSIN3 AMOTL1 NDFIP1 A1CF 
MAD1L1 TBCK LOXL4 ELK4 CD2AP FAM107B 
ZNF75A SLC25A41 LCOR ZBTB33 KPNA6 RAP2B 
ZMYM3 NCR2 TLX1 FAM177A1 OAZ3 PRSS27 
CCNL1 ZNF648 AMN HGSNAT PCK1 FAM13C 
CD274 LRRC8E FAM47A FOXRED2 YAP1 ARHGAP21 
TULP4 CADM2 PDS5A NET1 RDX MAGEH1 
UBQLN4 WEE2 PTER PIK3IP1 LARP1B C10orf11 
VN1R1 UROC1 TAGLN ZNF429 CD47 ANKRD30A 
MDM4 UCMA MNDA ZNF654 PHF19 PPP3CB 
PSMB9 ARL13A SLFN12L TFPI 37316 DTNA 
PPAPDC2 TRPV1 IRF1 STOM PLEKHA1 LRRC20 
HOXA4 ARHGEF26 RASSF7 SMIM19 SLC4A8 APPL1 
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ZZEF1 C20orf197 SCN5A UHRF2 ERLIN1 CTSD 
CHAF1A UGT2A1 CCNYL1 CPEB1 ZNF90 PHF2 
ZNF213 CLDN20 BRAF DYNC2LI1 PSKH1 NPM3 
KLK11 SHISA2 REG1A DOCK5 KERA ASB13 
CCDC37 CNN1 IRS1 GJB7 BCO2 ANK3 
N6AMT1 NAGLU CCL19 CCDC166 C1QTNF8 TMEM72 
DOK4 ERAP2 EVA1B MCCC2 ASTL PTF1A 
HDAC8 SH3GL2 SEC61B FLVCR2 NHLRC3 PARD3 
NSUN3 BRD9 ZBTB6 CCDC179 JAKMIP3 CENPH 
GK5 TMEM40 PSD CCDC121 SPOCK2 ZNF124 
SPIRE2 TJAP1 ZNF732 C6orf211 ZNF639 C12orf75 
TLCD2 MANEAL PAPOLG IDH3G PLEC POLR3G 
TOP1MT KRTDAP LIPA TCTN1 P2RY11 PPP1R42 
TANK APBB2 RPRD1A EPS8L1 APAF1 RLN2 
C16orf71 MST1 SNX10 NT5C3A DTWD1 SRCIN1 
ERBB3 UNC5C P2RY10 ATP5L2 CD302 C11orf30 
EBF2 FOXA1 SCD5 AGTR2 PAPSS2 ATXN2 
SMAD2 ZNF518B CRKL CHDC2 CDA KIF2A 
HPCA RNF7 PHLPP1 RBFOX3 KIF22 LRRC7 
NMT2 RTBDN SPTBN1 TGM3 TSPAN8 WFDC3 
KRT36 MPP2 LTBP3 SNCAIP STX16 GFI1B 
CACNA1E RAI14 TMEM189-UBE2V1 C8orf59 ZNF714 SLC30A10 
SOX8 CBLN3 GPR26 FRA10AC1 FN3K RABGAP1 
TMEM70 SLC7A9 TMPRSS11F GKN2 FCN2 CHRM1 
MPP6 ZNF461 FBXL15 HMGN5 C2orf15 HNRNPUL2 
SPATS2L BLMH C10orf54 UBAC2 SCLT1 MS4A1 
ZBED2 PLCH2 SPIN4 UFM1 FAM229B MGARP 
LYPD3 HYKK DNASE2B TAS2R13 RGS3 L1TD1 
TXNDC2 SLC41A1 IQCK ABLIM1 CENPU IL27 
KIF3A DYNLRB2 UGT2B15 ARNTL NTN3 BTG3 
NRD1 KLF2 HTRA1 MEA1 DPYSL4 BCAS1 
TSC22D2 EOMES RIPK3 SERPINB7 SYNE2 RAI2 
PTN ALDH7A1 CHRNA1 SPANXN2 IFIT5 SH3D19 
HYI ZFP36 NME9 GPR116 GLRA1 C4orf27 
GPR45 GDF15 CAPZA2 TMEM243 CHI3L1 FCRL5 
RTKN2 CYP27C1 RPH3AL CEPT1 FBXO32 ADC 
EXOSC1 QSOX1 RPTOR KIAA1107 SLC43A3 GPR150 
LRRC14 SRMS HAAO DLG5 AP4S1 DAOA 
ZNF766 DKK2 PCDHB13 MAN2A1 DNAJC6 KIAA0319L 
PLAC8L1 ACADSB L3MBTL2 ZBTB41 TMEM42 ZNF831 
RIT2 STC2 CDK15 ASAH1 EIF4E3 GRB14 
POLD2 ATP1B3 YME1L1 RELT CHRM4 BTF3L4 
SUV39H1 TFF2 ANTXRL MEOX2 PCDH18 CLUAP1 
TOMM20L GDF1 NOLC1 CUL7 ZNF69 MCM4 
C16orf93 ARIH2 CHST11 FAM168B DDAH1 URAD 
FAM162A HNRNPH3 CCDC13 IRGQ KIR2DL3 TMEFF1 
RNF6 PTPLB SERPINH1 TES FAM50B PAGE5 
PITRM1 CCDC148 CTNNA3 NUDT3 TSPAN9 IKZF2 
DNAJC7 CDH7 WBP1L HGF SPDYE4 C1orf87 
MAFA TIMM17B PGBD3 TMEM86B TNFRSF13B HAPLN3 
BCDIN3D C14orf166B TLE4 C11orf35 ZNF527 ASZ1 
PRDM15 DMXL1 TROAP GLUD2 C7orf65 ELF1 
FAP C7orf10 NFU1 PDZD11 ZFP14 UPB1 
PHF12 CKAP2 LAMC3 GCNT2 CMTM1 PDZD9 
TOMM70A DCN CCDC132 EBPL TRO MMGT1 
IDI2 FLOT2 PBX3 PDXDC1 ATP4B PPM1B 
GPR18 TNFAIP8 NARF NAA38 CYorf17 TRHDE 
SHC4 EPC2 MAN2B1 TRMT10B MXD1 SMARCA4 
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MVB12A TAF1D ZDHHC21 SDF2 ZNF26 DNAJC19 
TMCO6 DNAH10 EVI2A TMEM154 ALDH1A1 HLA-DQB2 
KLHDC7B SCMH1 ANO10 PHF21B DIRC1 PSAP 
CATSPER3 FAM50A SPRED2 C9orf72 ESAM METTL6 
CD86 FNDC8 C8orf88 LLPH PM20D2 CHPT1 
CENPP PGAM5 ARL6 TTPA CCL18 RBM18 
SLC2A13 C22orf23 ST8SIA6 ECHDC3 RNF39 KLHL24 
CDH15 CMPK2 ANXA11 CENPV KXD1 LY96 
ARHGAP18 CLGN GRM5 GPR123 ZNF836 SPINK1 
LINS SMIM20 OLAH IGSF11 SLC7A6 RPL37 
PLEKHN1 EMC8 FGF4 SLC24A2 C14orf178 ARHGEF12 
IPMK MXRA5 DNAJB12 MBNL1 PLK5 ASIC1 
ATP5F1 ZDHHC17 METAP1 TBX3 ZNF721 DGAT2L6 
FAM120AOS NRG4 NODAL ELMSAN1 CALR3 ICOS 
PCDHB2 ZNF329 WBP5 TIPRL DAD1 MROH2B 
TATDN1 THAP10 NXNL2 FAIM TMEM190 POU3F3 
DIABLO C8orf33 HP1BP3 TDRP SEMA7A UBA7 
COG5 PPM1L C1GALT1C1 C2orf47 PDPN TMEM230 
NDN CLRN3 SEMA4G NRBP1 TSEN15 MKRN1 
HIST1H1C ST3GAL6 SEC11A SAMD12 FAM169B ARHGAP19 
LCMT2 PRKCA DPY19L1 MAGEB17 AP3S1 GNAT1 
CMTM4 MBTPS2 FAM196A IQCB1 GUCY2D USP25 
RNF133 DKK4 C14orf39 PTRHD1 USP51 ZNF224 
TTC33 AHI1 PDLIM5 INSL6 HRH4 CLDN14 
CDK6 PMEPA1 ADAMTS14 CCBE1 TAS2R43 RFX1 
LRRC52 MAP1LC3A KLHL1 R3HCC1 SLC35A3 VCL 
RCOR1 PWWP2B MSMO1 C18orf32 PPP1R2 STAT5A 
MSL2 SLC41A2 RFPL3 WASF3 TDRD3 SEZ6 
TMEM140 HCLS1 SPINK9 IHH IRX2 IFLTD1 
KLHL40 COL9A2 C4A PLEKHF2 CLIC2 FXYD4 
IPO4 CAMK2D RHOA PLCL2 FCAMR SYT15 
SLC17A5 CCDC11 THAP2 SVIP TBL2 RRAGC 
SUCLA2 CDK14 SLC25A16 PPP1R3A TMEM194A USP43 
MX2 SPTSSB HIGD1A SSBP2 WISP3 FA2H 
C3orf14 CDKL5 CCR2 CD3G L3MBTL3 LAMTOR2 
TXLNG TRIML1 TMEM65 GRM8 XKR3 DUSP13 
PLA2G5 NEDD4L FOXC1 CORO2A GMDS VAMP4 
PCDHGC5 ZNF346 CEP104 FMNL3 C1orf54 ZNF33B 
DIRAS2 CD3D PRAM1 TCEB3B REG3A TP53AIP1 
FRS2 RBBP6 C7orf63 TCEAL4 SMARCD1 SORCS3 
ZNF674 KIAA0586 RAB18 AQP11 LRBA PPP1R14A 
STATH ZNF214 PALM2 ANGPTL3 SLC25A34 CYB5B 
HLX WNK3 FCER1A MGAT4A COPS2 PPP3R1 
ACSBG1 ZNF625 ZER1 HYAL3 GLI3 ZCCHC24 
MIS12 HOXB5 ACBD7 MEIG1 PLEKHO1 THEM5 
ITM2C IQCF5 CEP70 ZNF98 USB1 BET1 
C5orf15 HECTD1 CCDC169 CRISPLD1 OPN3 RPGRIP1L 
C21orf58 CDHR1 LYN ENHO FETUB TMEM139 
MINPP1 CPD SERPINA9 ZNF573 RAB28 ATP6V1C1 
GLOD4 LIPE COL13A1 BCL2A1 SCPEP1 ALPI 
MYOZ1 NSG1 NUDT7 NLRP3 AMZ2 SV2B 
ARL14 ZBTB7A CT45A5 C1orf173 PRDX4 PSMC5 
WDR49 SERTAD1 CAAP1 HEPH ABCC2 WWP1 
AGTRAP GRIN3B XPNPEP1 SSTR3 CSRP2BP THTPA 
LYSMD3 ASB8 FOXI2 HSBP1L1 CCNI GKAP1 
KLRC4 RTN2 CCDC136 C10orf88 ZNF432 FAM180A 
TICAM2 ADRA1B MTHFD1L MYOD1 DPP4 ASCL2 
ACTR2 FABP2 PPIC TLR7 CALB1 ADM5 
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KCNF1 NPY1R BBIP1 MFSD4 KDELR3 MUM1L1 
SCRIB LSM14B ODAM GNG8 TRIM8 MGAT5 
VSIG1 EIF4B HS3ST5 ZNF276 AJUBA ELP6 
C5orf48 ZMYND11 DPY19L4 TPP2 KRTAP12-3 SPN 
INS FZD8 HS3ST3A1 PTPN3 IFI35 PRX 
AGAP2 NPTX1 ABCB5 HIST1H3A FZD4 HSPG2 
GFPT2 LRAT ZNF83 C8orf47 ZNF567 C6orf25 
C9orf153 TSNAX ZNF503 MUSTN1 ARL4A SSBP4 
HYAL1 IL31RA DUSP5 SLC44A5 NDRG3 HGS 
DDX19B TRIML2 TCP10 EYA1 ZNF596 CARD10 
PHTF2 RBM11 SKAP2 CREB3L3 MMAB C10orf128 
ASB9 HPSE ZNF586 B3GNT3 DEFB132 GPRIN2 
ATRNL1 SPEN TMEM178B CRELD2 PSMG2 ZNF44 
SEC11C VSIG10L SLC45A2 ARHGEF19 SLC23A1 SCUBE3 
WSB1 AXIN2 ATG3 EAPP MMP20 FAM133A 
GUCA1C GRK5 PHYHIPL TEKT4 METTL23 RRAS2 
LCE3D DUS1L TMEM5 DIRAS1 GLYATL1 CCDC3 
SUB1 EXOC3L2 DRD4 FAM45A POPDC2 ISX 
DOT1L SERPINA11 BEND6 LRRC19 ECHDC2 HCN3 
ROR2 ELAVL2 MCMDC2 USP1 ACHE SCN2B 
NUBP1 CHMP4B ADAM18 BLNK PAPPA HMX2 
CCDC7 PAX2 TUBAL3 MARVELD2 PDGFC RHBDD1 
RASGEF1B SIGLEC5 SWT1 VEGFC TC2N SH3PXD2B 
CSGALNACT2 FAS DHFR RNF186 ZNF781 EPDR1 
DHTKD1 PCDHB10 ADI1 SPG21 CDR1 SELV 
FRMPD2 RFC1 GOT1 LIMD1 FCHO2 ARL14EP 
FRAT2 CNTD1 ZNF208 RCN1 C12orf43 LILRB1 
ZRANB1 RBMS3 DENR ARHGEF2 MTCH2 ZNF563 
AKIRIN1 ARHGAP5 NMU MLANA ALDH4A1 LIPK 
ZNF22 GCN1L1 KLRC3 RASGEF1A BBS5 ZFP42 
MMD ZNF419 C1orf229 AKR7A3 38961 STPG2 
SGCD PHOSPHO1 TXNL1 NFE2L3 TTPAL C1orf65 
PAGE1 RAP1GDS1 FAM21C TMEM68 PCBD2 LRTM1 
SLIT1 HLTF ADAM12 GPR160 MYL9 ITGAV 
ILK GXYLT1 HEG1 SPESP1 GIMAP4 CUTC 
VGLL4 LRPAP1 SLC39A11 AP5Z1 UGP2 NSD1 
FKBP8 NXNL1 KNCN APBB1IP RNLS MAPT 
FAM170B C12orf40 PTCHD3 CETN3 TTC12 CYB5A 
DNAJC1 CSRP2 PPAPDC1B ZNF280A NAB2 OCIAD1 
ZNF830 TAF15 TBR1 COMMD3 NUP35 BNIP2 
GALNT12 PCP2 MPC2 IL20RB CLSTN2 REP15 
CCDC127 PDCD2L C10orf129 METTL18 KRTAP26-1 SMAD1 
GSTO2 NFX1 FAM122A EIF6 SC5D IPCEF1 
LTBR KIAA1239 DLC1 C11orf16 PDZRN3 SLFN13 
ZNF239 ZNF557 SHPK SPINK7 PARD6B ZNF488 
PRF1 APCDD1L ARHGEF39 NECAB1 IRF7 HOXA7 
GALNTL6 NIT2 SNX16 GNPDA1 CSTF2 CST7 
PIP4K2A UTP11L TMEM260 FAM149B1 TPST2 ENTPD1 
VDAC2 CNP RPS27A ZC3H12B GALNT2   
MLLT6 CAP1 PDCL2 SEC31B SEC14L4   





Supplementary Figure 1. Mass spectrometry transcriptomic data reveals common 
differentially expressed proteins in all YCC6 ATRi resistant clones. A. Proteins 
downregulated in the resistant clones, compared with the YCC6 WT population. Red means 
high protein expression while blue means low protein expression. B. Proteins upregulated in 
the resistant clones, compared with the YCC6 WT population. Red means high protein 
expression while blue means low protein expression. Statistical significance means 
differences in protein expression levels with a FDR corrected Whelch’s test p-value <0.01 and 
Log2 fold change differences lower than -0.5 or larger than 0.5. All experiments were 

























































































































































































































































































Supplementary Figure 2. Mass spectrometry transcriptomic data reveals common 
differentially expressed proteins in H1/H2/H3/H4/H6 YCC6 ATRi resistant clones. A. Top 
100 proteins downregulated in the H1/H2/H3/H4/H6 resistant cluster, compared with the 
YCC6 WT population. Red means high protein expression while blue means low protein 
expression. B. Top 100 proteins upregulated in the H1/H2/H3/H4/H6 resistant cluster, 
compared with the YCC6 WT population. Red means high protein expression while blue 
means low protein expression. Statistical significance means differences in protein expression 
levels with a FDR corrected Whelch’s test p-value <0.01 and Log2 fold change differences 





























































































































































































































































































































Supplementary Figure 3. Mass spectrometry transcriptomic data reveals common 
differentially expressed proteins in H5/M1 YCC6 ATRi resistant clones.  
A. Proteins up and down regulated in the H5/M1 resistant cluster, compared with the YCC6 
WT population. Red means high protein expression while blue means low protein expression. 
No protein interactions were detected. Statistical significance means differences in protein 
expression levels with a FDR corrected Whelch’s test p-value <0.05 and Log2 fold change 
differences lower than -0.5 or larger than 0.5. All experiments were performed in two biological 










































































Resumen en castellano 
 
Introducción y objetivos de esta tesis 
El cáncer gástrico (CG) es el quinto cáncer más frecuente a escala mundial y 
constituye la tercera causa de muertes ocasionadas por cáncer, produciendo 
alrededor de 800.000 muertes al año. La etiología del CG es compleja, resultando en 
una combinación de factores genéticos, epigenéticos y ambientales entre los cuales 
se encuentran la obesidad, la infección por la bacteria Helicobacter pylori o el virus 
Epstein-Barr, así como diversos factores dietarios, consumo de alcohol y tabaco. 
A pesar de los avances prometedores en el diagnóstico y tratamiento del CG, la 
supervivencia global de los pacientes diagnosticados con este tipo de neoplasias 
sigue siendo extremamente pobre. El tratamiento actual se plantea como una 
estrategia multimodal en la que se incluyen la cirugía, la quimioterapia y la 
radioterapia, sin tener en cuenta las características moleculares de cada tumor. Con 
ello se ha conseguido mejorar el control local del tumor, así como disminuir la tasa de 
diseminación o metástasis, pero, el pronóstico de la enfermedad avanzada sigue 
siendo poco esperanzador. La biología molecular del CG, particularmente, el 
conocimiento de las vías de señalización implicadas en su patogénesis, y su 
contribución al desarrollo de nuevas modalidades de terapias dirigidas se halla en una 
etapa temprana, en comparación a otros tipos de neoplasias. 
Alrededor del 95% de los CGs diagnosticados son de tipo adenocarcinoma, los cuales 
se han clasificado, tradicionalmente, en CG difuso e intestinal, siguiendo las pautas 
clínico-patológicas propuestas por Lauren en el año 1965. Al igual que la clasificación 
de Lauren, otras categorizaciones del CG basadas en las características histológicas 
del tumor han sido utilizadas, las cuales han demostrado muy poco uso pronóstico o 
clínico hasta la fecha.  
No fue hasta hace unos pocos años, cuando se comenzaron a publicar las primeras 
clasificaciones moleculares en CG, como la del “Cancer Genome Atlas Research”, la 
cual clasifica el CG en cuatro subgrupos: el CG con inestabilidad cromosómica (CIN, 
50%), con inestabilidad de microsatélites (MSI, 22%), genómicamente estable (20%) 
y con infección del virus Epstein-Barr (EVB, 9%). Esta nueva clasificación, junto con 
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otras que se han publicado a posteriori, ofrecen una visión más amplia del GC, 
teniendo en cuenta nuevas características genéticas y moleculares que permitirán el 
descubrimiento de nuevas dianas accionables, que puedan mejorar el pronóstico y 
supervivencia de los pacientes con CG.   
El gen ARID1A forma parte del complejo SWI/SNF, encargado de remodelar la 
cromatina para el control de la expresión génica mediante la remodelación de los 
nucleosomas en los promotores génicos. Dado a su papel regulador de la expresión 
génica, las mutaciones en los diversos componentes del complejo SWI/SNF, 
incluyendo las que ocurren en ARID1A, causan la desregulación de diversas rutas 
metabólicas, muchas de las cuales se han relacionado con el desarrollo del cáncer. 
De todas las mutaciones descritas en las distintas subunidades del complejo, las 
ocurrentes en ARID1A son las más comunes, detectadas en alrededor del 20% de 
los cánceres, y en el 20% de los pacientes con CG.  
Las mutaciones en ARID1A suelen resultar en la pérdida de expresión de la proteína, 
y se asocian con el subgrupo de CG con inestabilidad de microsatélites, mutaciones 
activadoras de la ruta PI3K, así como con un genotipo wild-type (WT) para la proteína 
p53. Diversas funciones, aparte de la regulación de la expresión génica han sido 
atribuidas a ARID1A, incluyendo el mantenimiento de la integridad genética, mediante 
su interacción con diversas proteínas relacionadas con procesos de reparación del 
DNA. Así, ARID1A ha sido descrita como una proteína clave en el proceso de 
decatenación del DNA, facilitando su reparación tras una ruptura de doble cadena 
mediante su interacción con la Topoisomerasa IIA y ATR. En relación con estas 
observaciones, se ha descrito que el silenciamiento simultaneo de otras proteínas 
clave en este proceso de reparación, junto con el de ARID1A conduce a la muerte 
celular por medio de un fenómeno denominado “letalidad sintética”. La letalidad 
sintética, es descrita como un escenario en que la pérdida no simultánea de dos 
genes permite la viabilidad celular, pero la ausencia simultánea de ambos genes 
causa la muerte de la célula. Así, estudios previos han demostrado que genes 
relacionados con la reparación del DNA, como es el caso de EZH2, ARID1B, PARP y 
ATR, son letalmente sintéticos con ARID1A, y por tanto causan la muerte de las 
células cancerígenas deficientes en ARID1A cuando son inhibidos. Estos estudios 
han sido realizados principalmente, por medio del uso de modelos cáncer de ovario, 
en el cual las mutaciones en ARID1A son altamente frecuentes (alrededor del 40% 
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de los casos en el caso de los carcinomas de células claras de ovario). Los fármacos 
que tienen como diana algunos de estos genes, como los inhibidores de PARP están 
siendo actualmente utilizados en la práctica clínica para tratar a los pacientes con 
cáncer de mama, ovario o próstata que presentan mutaciones en los genes BRCA1 y 
BRCA2, los cuales juegan un papel central en las rutas de reparación del DNA. 
Asimismo, los inhibidores de ATR (iATR) están comenzando a ser probados en 
diversos ensayos clínicos, algunos de los cuales pretenden tener cuenta, 
retrospectivamente, la presencia de mutaciones en ARID1A y otros genes que 
puedan conferir sensibilidad a dichos inhibidores.  
Aunque los iATR se han convertido en terapias anticancerígenas prometedoras, los 
mecanismos de resistencia farmacológica son muchas veces inevitables, lo cual 
enfatiza la importancia de identificar biomarcadores de respuesta y resistencia a 
dichos fármacos, con el objetivo de encontrar combinaciones terapéuticas que 
puedan proporcionar una respuesta clínica más eficaz y a largo plazo. 
Es por todo esto, que este proyecto se centra en el estudio de ARID1A como un 
biomarcador potencial de la sensibilidad a los inhibidores de proteínas implicadas en 
las rutas de reparación del daño al DNA en CG, así como en la búsqueda de 
biomarcadores de resistencia a los iATR, lo cual nos permitirá diseñar nuevas 
combinaciones de fármacos que eviten la aparición de mecanismos de resistencia a 
dichos inhibidores en los pacientes con CG. 
 
Por ello, los objetivos del presente proyecto son: 
1. Probar los fármacos inhibidores de proteínas letalmente sintéticas con ARID1A en 
un panel de células tumorales y en modelos isogénicos de cáncer gástrico. 
2. Validar las relaciones de letalidad sintética descritas in vitro por medio de modelos 
murinos de cáncer gástrico o PDXs (patient-derived Xenografts).  
3. Identificar mecanismos de resistencia a los inhibidores de ATR en cáncer gástrico 




Metodología principal utilizada en esta tesis 
Con el ánimo de alcanzar dichos objetivos, se han utilizado múltiples tecnologías 
comunes en biología celular y genética funcional, siguiendo los protocolos 
previamente descritos en la literatura (Western Blot, PCR, cultivos celulares, 
extracción de DNA, RNA y proteínas). A continuación, se describen los materiales y 
modelos utilizados, así como la metodología más novedosa utilizada en esta tesis, 
que se basa en la creación de modelos isogénicos y en los experimentos de cribado 
genético de alto rendimiento. 
Modelos usados en esta tesis 
Los ensayos in vitro se han realizado mediante el uso de un panel de siete líneas 
celulares de CG (SNU 1, SNU 5, SNU 484, SNU 638, NCI N87, AGS y YCC6), así 
como la línea celular de cáncer colorrectal isogénica para el gen ARID1A, HCT 116. 
Todos los modelos han sido caracterizados por medio de la secuenciación del exoma, 
así como por PCR cuantitativa y western blot de los genes y proteínas de interés. 
Adicionalmente, las líneas celulares han sido caracterizadas para su estatus de 
inestabilidad de microsatélites. Para los ensayos in vivo se han utilizado cuatro 
modelos murinos derivados de tumores gástricos humanos (PDX) deficientes para el 
gen ARID1A, y tres modelos ARID1A WT. Dichos modelos han sido caracterizados 
por medio de la secuenciación del exoma (DNA), secuenciación del transcriptoma 
(RNAseq), inmunohistoquimica para la expresión de ARID1A (IHQ), y determinación 
de la inestabilidad de microsatélites (MSI). Los experimentos con ratones han sido 
realizados por la empresa CrownBio.  
 
Experimentos de respuesta a fármacos 
La evaluación de la respuesta de los modelos celulares a los inhibidores probados se 
ha realizado mediante el uso de los siguientes inhibidores: para iATR, los fármacos 
VX970, AZD6738 y M4344; para PARP, olaparib y talazoparib; para la ruta PI3K, 
MK2206 y BKM120; para HDAC6, ACY1215; y para EZH2, GSK126. Así, la eficacia 
de dichos inhibidores en los diversos modelos utilizados se ha evaluado por medio de 
experimentos de proliferación celular, en los que se ha medido la capacidad 
proliferativa de las células tras exponerlas a diversas dosis del inhibidor a lo largo de 
5 días, en placas de 384 pocillos. El número de células vivas tras la exposición al 
fármaco utilizado se ha determinado por medio del uso del reactivo cell titre glo, que 
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emite una señal fluorescente solamente en el caso de que la célula esté viva.  
 
Experimentos de cribado genético (CRISPR screens): 
En el caso de los experimentos de cribado genético se ha utilizado la técnica 
CRISPR/Cas9, que se basa en la habilidad de la endonucleasa Cas9 de cortar el DNA 
en una secuencia determinada, dirigida por un RNA guía (gRNA). Así, una vez el 
enzima Cas9 es dirigido a la secuencia diana, ésta es capaz de cortar ambas hebras 
del DNA, causando mutaciones que pueden dar lugar a la pérdida de función del gen 
escogido. En esta tesis, se ha utilizado dicha técnica, no solo para editar el genoma 
de una manera dirigida (creación de modelos isogénicos para ARID1A y otros genes 
de interés), sino también para la realización de cribados genómicos de alto 
rendimiento y la identificación de dianas moleculares de relaciones de letalidad 
sintética con los iATR (“CRISPR screens”). En este caso, y con el objetivo de 
encontrar biomarcadores de resistencia a los iATR, se han llevado a cabo dos tipos 
de cribado mediante CRISPR. El primero de ellos, denominado CRISPRn screen, se 
ha realizado a escala de todo el genoma (GW CRISPR screen, con gRNAs para 
alrededor de unos 20,000 genes), y consiste en la simultánea producción de 
mutaciones de pérdida de función del gen a lo largo de todo el genoma en una 
población de células, en la que cada célula es mutada en sólo uno de los genes. Ésta 
población es pues sometida a altas dosis del fármaco iATR (VX970 en éste caso), 
bajo las cuales, solamente las células con mutaciones en genes que confieren una 
ventaja selectiva son capaces de sobrevivir y proliferar. La secuenciación del DNA 
extraído de las células resistentes (Next-Generation Sequencing) y el correcto análisis 
de los resultados, permite conocer los gRNAs que se encuentran sobre-
representados en dicha población resistente y, por tanto, los genes que, al ser 
mutados confieren resistencia a los iATR. El otro tipo de CRISPR screen utilizado es 
el llamado CRISPRx, en el cual se utiliza un enzima Cas9 sin capacidad 
endonucleasa, que retiene la habilidad de unión al DNA en una secuencia específica, 
por medio de la dirección del gRNA. Es entonces, cuando la adición de enzimas 
editoras del DNA (desaminasas), capaces de causar sustituciones de bases en la 
secuencia diana (por medio de su unión con la Cas9), son transfectadas al interior de 
la célula. Así, se consiguen realizar sustituciones de aminoácidos en la zona 
circundante a la secuencia complementaria al gRNA, sin realizar roturas de la doble 
hélice de DNA. Esta variante del CRISPR, permite evaluar los efectos que 
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determinadas mutaciones puntuales tienen sobre la funcionalidad de la proteína 
diana. En esta tesis, esta tecnología ha sido utilizada para realizar substituciones de 
aminoácidos del gen ATR a lo largo de toda su secuencia, ya que éste es un gen 
esencial en la célula, y las mutaciones troncales (que eliminan completamente ATR 
de la célula) no pueden ser evaluadas de una manera funcional.  
  
Silenciamiento de genes 
Los experimentos de silenciamiento de genes han sido llevados a cabo por medio de 
la transfección inversa de las células con RNAs silenciadores (siRNAs). 
  
Creación de modelos isogénicos de resistencia a los iATR 
La creación de las líneas celulares resistentes a los iATR se ha realizado por medio 
de la exposición progresiva a dosis ascendientes del fármaco VX970 en un periodo 
de 4-6 meses. Así, se han generado los clones H1, H2, H3, H4, H5, H6 y M1, que han 
sido sometidos a la secuenciación del proteoma por medio de técnicas de 
espectrometría de masas.  
  
Ciclo celular 
La medición del ciclo celular ha sido llevada a cabo por medio de técnicas de 
citometría de flujo, tras la tinción de las células con ioduro de propidio (marcador de 
la cantidad de DNA en cada fase del ciclo) y EdU (marcador de la síntesis del DNA). 
  
Análisis estadístico 
Todos los análisis estadísticos han sido llevados a cabo por medio del 
programa GraphPad Prism, excepto el análisis de los resultados de los CRISPR 
screens, en cuyo caso se ha utilizado el programa R. 
  
Resultados principales de esta tesis 
  
1. ARID1A y ATR son sintéticamente letales in vitro 
En la primera parte de la tesis, se ha llevado a cabo la caracterización de un panel de 
líneas celulares de CG, y se ha probado su sensibilidad a diversos inhibidores que 
han sido previamente definidos como efectivos en modelos deficientes en ARID1A, 
en otros tipos de cáncer (inhibidores de ATR, PARP, PI3K, HDAC6 y EZH2). De todos 
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los inhibidores probados, se ha observado que las líneas celulares con mutaciones 
en ARID1A son especialmente sensibles a los iATR, tanto en el caso del panel de 
líneas celulares de CG, así como en el modelo isogénico HCT 116. Esto se ha 
observado fundamentalmente en los casos en los que las líneas celulares 
presentaban niveles nulos de expresión de ARID1A. Con el objetivo de validar estas 
observaciones, se han realizado tanto experimentos de silenciamiento de ARID1A en 
líneas celulares resistentes para los iATR por medio del uso de siRNAs, así como la 
generación de una línea celular de CG isogénica para ARID1A. En ambos casos, el 
silenciamiento del gen o la represión de la expresión de la proteína ARID1A ha 
causado un incremento en la sensibilidad de las células cancerígenas a los iATR, 
demostrando que ARID1A y ATR son sintéticamente letales en las líneas celulares 
de CG. 
  
2. ARID1A y ATR son sintéticamente letales in vivo 
Para validar las observaciones descritas en las líneas celulares, se han utilizado siete 
modelos murinos derivados de tumores gástricos humanos, en los cuales se 
ha probado la respuesta al iATR M4344 en modelos deficientes para ARID1A, así 
como en modelos WT. Consecuentemente con lo que hemos observado in vitro, los 
ratones con tumores deficientes para ARID1A han demostrado ser exquisitamente 
sensibles a los iATR, comparados con el grupo control. En el caso de dos de los tres 
modelos de PDX ARID1A WT, se ha observado que el tratamiento con M4333 es 
capaz de reducir la proliferación del tumor, a una escala mucho menor que en los 
casos deficientes para ARID1A. Sorprendentemente, uno de los modelos ARID1A WT 
ha resultado ser altamente sensible a M4344, indicando que ARID1A no es el único 
determinante de sensibilidad a iATR en CG. En este último caso, y con el objetivo de 
determinar las causas de la sensibilidad detectada en este modelo, se han recogido 
los tumores resultantes al final del experimento, para su caracterización molecular y 
la determinación de nuevos biomarcadores de sensibilidad a los iATR. 
Adicionalmente, se ha probado el tratamiento combinatorio de M4344 con un inhibidor 
de PARP (talazoparib), con el objetivo de observar si la combinación de ambos 
fármacos es capaz de mejorar la respuesta en los modelos murinos. En este caso, 
hemos observado como la combinación de M4344 y talazoparib tiene un impacto 
incluso mayor en el tamaño del tumor en varios de los modelos usados, pero esto 
parece ser independiente del estatus de expresión de ARID1A en dichos modelos.  
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3. Determinación de biomarcadores de resistencia a los inhibidores de ATR 
Aunque los iATR prometen ser un tratamiento efectivo para los cánceres con defectos 
genéticos en las proteínas reparadoras del DNA, los pacientes que reciben 
tratamientos en monoterapia corren el riesgo de sufrir resistencias terapéuticas a 
largo plazo. Es por ello por lo que las combinaciones de fármacos suelen ser más 
efectivas a la hora de detener el desarrollo de las células tumorales de una forma 
efectiva. Para determinar los fármacos que pueden potenciar el efecto de los iATR y 
evitar la aparición de resistencias, es importante detectar los genes implicados en el 
desarrollo de dichas resistencias. Para ello, hemos seguido tres aproximaciones: 
CRISPR screens de todo el genoma “genome-wide (GW) CRISPR screens”, 
generación de modelos isogénicos resistentes a los iATR y CRISPRx screens.  
  
3.1. GW CRISPR screens: 
La realización de un GW CRISPR screen en la línea de CG YCC6, nos ha permitido 
detectar una larga lista de biomarcadores potenciales de la resistencia a los iATR, por 
medio de la selección de las células resistentes a altas dosis del fármaco, tras producir 
en ellas mutaciones individuales a lo largo de todo el genoma (una mutación por 
célula).  
Al probar una lista de alrededor de 20.000 genes, un análisis riguroso y meticuloso 
de los datos debe ser llevado a cabo para poder descartar los resultados verdaderos 
de los falsos positivos y falsos negativos. Adicionalmente, es necesaria la realización 
de diversos experimentos de validación de los descubrimientos por medio del uso de 
formatos y modelos ortogonales. Con este objetivo, se ha realizado un 
subsecuente mini-CRISPR screen, en el que se ha probado un número reducido de 
genes seleccionados, escogiendo los que resultaron tener una mayor significatividad 
estadística en el estudio inicial. De esta forma, hemos podido validar el papel de los 
genes CDC25B, HUWE1, HNRNPF CARD10, SMG8, SMG9, IRF9, STAT1 y STAT2 
en la resistencia a los iATR. Además, se han creado modelos isogénicos de algunos 
de los genes validados, con el objetivo de llevar a cabo experimentos funcionales que 





3.2. Los modelos isogénicos resistentes a los iATR han permitido definir una lista de 
determinantes de resistencia terapéutica 
Con el objetivo de obtener los modelos relevantes, que nos permitan determinar 
nuevos biomarcadores de resistencia a los iATR, se han generado diversos clones 
de células resistentes a los iATR a partir de la línea celular de CG, YCC6. Estos clones 
han sido caracterizados para la expresión del proteoma (por medio de la medición de 
la expresión más de 9.000 proteínas), a través de técnicas de espectrometría de 
masas. Así, se han podido evaluar los cambios significativos de expresión de 
proteínas, potencialmente ligados a la aparición de la resistencia terapéutica. 
Sorprendentemente, varios de los clones resistentes presentan un cambio en la 
morfología celular, pasando de ser células originalmente epiteliales, a células con una 
morfología más mesenquimal, indicativa de un elevado potencial metastático de las 
células cancerígenas. Esto se ha correlacionado con el hecho de que diversas 
proteínas, implicadas en la adhesión celular, adhesión a la matriz extracelular y en la 
definición del citoesqueleto se encuentran desreguladas en dichos clones resistentes. 
Entre estas proteínas se encuentran las codificadas por los genes CDH1, n-CAM, 
KRT7, KRT19, SMAD4, PIK3CB, SPTBN1, ITGB4, PARD6B, ROCK2, RHOB, PAK1, 
ECM1, MLLT4, EZR, VIM, ARHGAP21 y CD2AP.  
Aparte de la desregulación de las proteínas implicadas en la determinación de la 
morfología celular, otras proteínas, también potencialmente relevantes en los 
fenómenos de resistencia a los iATR han sido detectadas. Éstas incluyen proteínas 
ampliamente relacionadas con cáncer como son MET, HRAS, PIK3CB, NF1, TYK2 y 
STAT5B.  
Llamativamente, la proteína SMG1 se encuentra sobreexpresada en los clones 
resistentes, cuando son comparados con las células parentales. SMG1 es una 
proteína quinasa central en el mantenimiento de la estabilidad genómica de la célula, 
por medio de la degradación de los RNAs mensajeros defectuosos. SMG1 es 
negativamente regulada por el heterodímero formado por las proteínas SMG8 y 
SMG9, las cuales han sido definidas en la sección anterior como causantes 
de resistencia a los iATR. Es por esto por lo que, tras validar que la proteína SMG1 
esta sobreexpresada en los clones resistentes por medio de western blot, hemos 
realizado experimentos de silenciamiento de SMG1 utilizando siRNAs. Estos 
experimentos han demostrado que al silenciar SMG1, las células resistentes vuelven 
a ser sensibles a los iATR. Esto nos indica el interés de probar la combinación de 
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los iATR con los inhibidores de SMG1 en ensayos clínicos, con el objetivo de evitar 
resistencias a los iATR en CG.  
  
3.3. Las mutaciones en el dominio FAT de ATR causan resistencia a los iATR 
(CRIPRx screens) 
Finalmente, con el mismo objetivo de determinar los procesos genéticos por los 
cuales las células cancerígenas pueden resultar resistentes a los iATR, hemos 
modificado genéticamente la línea celular YCC6, causando mutaciones a lo largo de 
toda la secuencia del gen ATR. Esto nos ha permitido determinar qué zonas de la 
proteína son relevantes a la hora causar resistencias a su inhibición en nuestros 
modelos. Tras el evento de mutagénesis, se han seleccionado las células resistentes 
por medio del tratamiento con altas dosis de los iATR y secuenciado el gen ATR, para 
determinar cuáles son las mutaciones causales de dicha resistencia. Así, hemos 
detectado que las mutaciones en el dominio FAT de ATR son capaces de transformar 
las células cancerígenas, previamente sensibles, en células resistentes a los iATR. 
Con el objetivo de validar estas observaciones, se pretende crear modelos isogénicos 
mutados para esta zona del gen ATR, en los que podamos determinar si las causas 
de esta resistencia son estructurales (debidas al bloqueo de la unión del inhibidor a 
la molécula de ATR) o funcionales (por la función anormal de ATR en la célula). 
  
Implicaciones biológicas e importancia de los resultados presentados en esta 
tesis  
En este estudio, se ha demostrado por primera vez que ARID1A es un candidato 
valioso como biomarcador de sensibilidad a los iATR en CG, tanto por medio de 
modelos celulares (en el panel de células y en modelos isogénicos de CG) como en 
modelos animales (PDXs). Debido al hecho de que ARID1A se encuentra mutado en 
alrededor del 20% de los CGs, se plantea el interés del diseño de ensayos clínicos 
que permitan probar los iATR en pacientes con CG deficiente para ARID1A. Esto 
podría mejorar el pronóstico y la supervivencia de dichos pacientes. Asimismo, se 
abre la puerta a la valoración del uso de dichos inhibidores en cánceres provenientes 
de otras histologías, ya que las mutaciones en ARID1A son comunes en muchos otros 
tipos de cánceres.  
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Por otro lado, en esta tesis se han identificado y validado una lista de biomarcadores 
de resistencia a ATRi, lo cual abre la posibilidad a probar nuevas combinaciones de 
fármacos que puedan incrementar el éxito del uso de los iATR por medio del 
detenimiento de la aparición de metástasis, la mejora de la supervivencia y calidad 
de vida de los pacientes con CG.  
  
Finalmente, se resalta la importancia de evaluar a los pacientes seleccionados para 
su tratamiento con los iATR en ensayos clínicos, para las mutaciones en el 
gen ATR, ya que estas pueden evitar una respuesta farmacológica completa al 
tratamiento, por medio del bloqueo de la unión del inhibidor a la proteína o, por medio 
de la alteración de la función de ATR en la maquinaria celular. De esta forma, será 
posible mejorar la selección del inhibidor a utilizar y la prevención de posibles 
resistencias al tratamiento. 
  
Conclusiones  
Como parte de las conclusiones de la tesis presentada, se ha: 
  
1. Demostrado que la inhibición de ATR causa letalidad sintética en los cánceres 
gástricos con deficiencias en el gen ARID1A. Esto se ha evaluado por medio del uso 
de un panel de líneas celulares, modelos isogénicos celulares y modelos murinos 
derivados de tumores humanos. 
  
2. Propuesto que los genes HUWE1, HNRNPF, IRF9, SMG8, SMG9, CARD10, 
CDC25B y STAT2, deben ser evaluados como potenciales biomarcadores de la 
resistencia a los inhibidores de ATR en pacientes con cáncer gástrico.  
  
3. Descrito que la sobreexpresión del gen SMG1, consecuencia de la pérdida de 
expresión de sus reguladores SMG8 y SMG9 conduce a la resistencia a los 
inhibidores de ATR en cáncer gástrico. 
  
4. Identificado una lista de potenciales biomarcadores de resistencia a los inhibidores 
de ATR en cáncer gástrico por el medio de la creación de modelos isogénicos 
terapéuticamente resistentes.  
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5. Descrito que mutaciones en el dominio FAT del gen ATR causan resistencia a los 
inhibidores de ATR y por tanto debe considerarse su evaluación a la hora de someter 
a los pacientes de cáncer gástrico a dicho tratamiento en los ensayos clínicos. 
  
	
 
 
 
  
	
 
